Author: cpatches

Noble Capital Markets Research Report Friday, February 21, 2025

Companies contained in today’s report:

ACCO Brands (ACCO)/OUTPERFORM – A Peak Into 4Q24 Results
Aurania Resources (AUIAF)/OUTPERFORM – Take-Aways from the Kuri-Yawi IP Geophysical Survey
Codere Online (CDRO)/OUTPERFORM – Favorable Underlying Revenue Trends
InPlay Oil (IPOOF)/OUTPERFORM – Transformative Acquisition of Pembina Cardium Oil Assets
Unicycive Therapeutics (UNCY)/OUTPERFORM – OLC Shows Synergy With Alternative Potassium Binder

ACCO Brands (ACCO/$5.52 | Price Target: $12)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Peak Into 4Q24 Results
Rating: OUTPERFORM

4Q24. Fourth quarter sales and EPS were in line with expectations, excluding greater than anticipated foreign currency headwinds. ACCO experienced ongoing softer demand for certain office-related products and lower demand for back-to-school products in Brazil, partially offset by growth in the technology accessories categories. ACCO further increased its multi-year cost reduction program to $100 million of cumulative savings.

Details. Revenue of $448.1 million was down 8.3% y-o-y, with comp sales down 5.9% and adverse foreign exchange reducing sales by 2.4%. Adjusted operating income was $64.2 million versus $68.3 million last year. Adjusted net income was $37.5 million, and adjusted EPS was $0.39 for both 4Q24 and 4Q23.

Get the Full Report

Aurania Resources (AUIAF/$0.33 | Price Target: $0.55)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Take-Aways from the Kuri-Yawi IP Geophysical Survey
Rating: OUTPERFORM

Kuri-Yawi epithermal gold target. In late 2024,Aurania commenced an induced polarization (IP) geophysical survey over its Kuri-Yawi epithermal gold target at the company’s Lost Cities-Cutucu project in Ecuador. Kuri-Yawi is a geochemical anomaly with enrichments in epithermal pathfinder elements. The IP survey was designed to identify deep conductors that could correspond to gold mineralization and to target drill holes for a future drilling program.

Survey results. Data collected from the survey was used to generate a three-dimensional model of the ground’s resistivity and chargeability. Conductive and chargeability anomalies are geophysical signatures that can indicate the presence of gold mineralization. The survey returned two main chargeability vertical structures. Resistivity results highlighted different bodies of rock, or lithologic units, with a conductive sedimentary unit to the east and a resistive volcanic unit overlaying another conductive unit at depth.

Get the Full Report

Codere Online (CDRO/$8.44 | Price Target: $14)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Favorable Underlying Revenue Trends
Rating: OUTPERFORM

Currency exchange impact. Q4 revenue of €52.6 million was roughly in line with our estimate of €55.0 million in spite of currency headwinds. Adj. EBITDA of €1.9 million was better than our estimate of €1.5 million, as illustrated in Figure #1 Q4 Results. Revenues would have been stronger if not for the depreciation of the Mexican Peso, down roughly 13.5% against the Euro. On a constant currency basis, revenue was up a strong 15% compared to reported growth of 5%.

NASDAQ extends deadline. The company’s auditor, Marcum, resigned unexpectedly in December, quickly replaced by MaloneBailey. Importantly, the company was able to present a plan to NASDAQ in its hearing on January 16 and was granted an extension until May 12 to file its 2023 annual report, the maximum extension allowed. The company intends to file within the extension deadline.

Get the Full Report

InPlay Oil (IPOOF/$1.17 | Price Target: $3.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Transformative Acquisition of Pembina Cardium Oil Assets
Rating: OUTPERFORM

Strategic acquisition. InPlay Oil Corp. executed a definitive agreement to acquire light oil-focused assets from Obsidian Energy Ltd. (TSX: OBE, NYSE American: OBE) in the Pembina area of Alberta. The assets have a current production rate of approximately 10,000 barrels of oil equivalent per day (boe/d), with 68% consisting of oil and natural gas liquids (NGLs). The total purchase price is C$309 million and will consist of C$220 million in cash, C$85 million in InPlay common shares priced at C$1.55 per share, and the inclusion of InPlay’s non-operated 34.6% working interest in the Willesden Green Cardium Unit #2 oil field, which has a year-end 2023 Proved Developed Producing (PDP) value of about C$4.4 million.

Transaction highlights. The acquisition appears to offer significant synergies and benefits to InPlay’s operations. InPlay’s production is expected to more than double to 18,750 boe/d from previous guidance of 8,650-9,150. Additionally, on a per share basis, 2025 adjusted funds flow (AFF) is expected to increase to C$204 million from previous guidance of C$69-75 million. Furthermore, the nature of the assets acquired is expected to enhance operational efficiencies to InPlay’s existing Pembina asset base by increasing the scale and contributing to lower decline, higher oil-weighting, and less capital-intensive production.

Get the Full Report

Unicycive Therapeutics (UNCY/$0.61 | Price Target: $7)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
OLC Shows Synergy With Alternative Potassium Binder
Rating: OUTPERFORM

Pre-Clinical Study Shows Synergy With Tenapanor. Unicycive Therapeutics announced the results of an animal model study that tested its phosphate binder, OLC, or oxylanthanum carbonate, and tenapanor, a phosphate-control drug that works through a different mechanism than the phosphate binding drugs. The results showed OLC had a greater reduction than tenapanor, and the combination of both drugs given together had synergistic effects that were better than either drug given alone.

Study Design. Tenapanor (Xphozah, from Ardelyx) is a sodium/hydrogen exchanger 3 (NHE3) inhibitor that works through paracellular absorption. It is used in patients that do not respond to phosphate binders or do not tolerate them. The study, “Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats,” was published in the American Nephrology Society’s journal Kidney360. It compared the two drugs against a control (delivery vehicle alone) in rats receiving a high phosphorus diet.

Get the Full Report

Noble Capital Markets Research Report Wednesday, February 19, 2025

Companies contained in today’s report:

FreightCar America (RAIL)/OUTPERFORM – New $35 Million ABL Credit Facility; Adjusting Our Forward Estimates
Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Strong End to the Year

FreightCar America (RAIL/$10.38 | Price Target: $13.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
New $35 Million ABL Credit Facility; Adjusting Our Forward Estimates
Rating: OUTPERFORM

New asset-based lending credit facility. FreightCar America executed a new $35 million asset-based lending (ABL) credit agreement with Bank of America consisting of revolving loans and a sub-facility for letters of credit. Compared to the company’s previous ABL credit agreement, the new revolving credit facility offers a lower interest rate that is based on the secured overnight financing rate (SOFR) plus 175 basis points with a term ending on February 12, 2030.

Greater financial flexibility. The new facility is expected to provide the company with greater financial flexibility to support its growth and strategic objectives. Because the borrowing base requirements include eligible parts inventory and railcar inventory, we think the ability to borrow against its inventory could also provide the company with greater flexibility with respect to how it manages its production schedule.

Get the Full Report

Great Lakes Dredge & Dock (GLDD/$8.98 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Strong End to the Year
Rating: OUTPERFORM

4Q24. Revenue of $202.8 million was up from $181.7 million a year ago but modestly below our $215 million estimate. Gross margin came in at 24.1%, up from 21.3% in 4Q23 and above our 20.9% estimate. Adjusted EBITDA improved to $40.2 million, flat with $40.8 million a year ago. We had forecasted $37 million. Net income was $19.7 million, or $0.29/sh, versus $21.6 million, or $0.32/sh, last year, which benefitted from a one time $7.4 million gain. We were at $15 million and $0.22/sh.

Backlog. Great Lakes ended the year with $1.19 billion of dredging backlog and $1.24 billion of total backlog. The Company had an additional $282.1 million of low bids and options pending award at year’s end. Approximately 94% of the backlog was in higher margin capital and coastal protection work. This provides solid visibility into 2026.

Get the Full Report

Noble Capital Markets Research Report Tuesday, February 18, 2025

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Shareholders Approve Reverse Stock Split

Comstock (LODE/$0.35)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Shareholders Approve Reverse Stock Split
Rating: MARKET PERFORM

Reverse split. Following shareholder approval on February 14, Comstock Inc. announced a reverse split of its common stock at a ratio of 1-for-10, resulting in ~23,767,578 shares outstanding. The reverse split, effective on February 24, will not alter any stockholder’s percentage interest in the company except to the extent that it results in a shareowner owning a fractional share. Fractional shares resulting from the reverse split will be rounded up to the nearest whole share. Comstock’s authorized number of shares of common stock remains 245,000,000. LODE shares will begin trading on a split-adjusted basis when the market opens on February 25.

Greater financial flexibility. The reverse split will increase the number of shares available for issuance should the company need to raise additional capital. We think the company is making significant progress toward commercializing its Comstock Metals and Comstock Fuels businesses. Key elements are coming together for Comstock Fuels to secure project financing to build its first commercial demonstration facility. Comstock Metals currently operates a commercial demonstration facility in Silver Springs, Nevada, and is working toward an industry-scale expansion that will position the company to serve the rapidly expanding solar industry in the western United States.

Get the Full Report

Noble Capital Markets Research Report Friday, February 14, 2025

Companies contained in today’s report:

Kelly Services (KELYA)/OUTPERFORM – Solid Fourth Quarter Results
Nutriband (NTRB)/OUTPERFORM – Nutriband Extends Partnership Agreement To Include Post-Approval Financial Terms

Kelly Services (KELYA/$14.25 | Price Target: $27)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Solid Fourth Quarter Results
Rating: OUTPERFORM

4Q24. Kelly’s top line of $1.19 billion was in-line with our estimates and consensus estimates and was up 4.4% on an organic basis. Adjusted EBITDA came in at $43.5 million, with margin up 110 basis points to 3.7%. We had forecasted $40 million. Due to a non-cash impairment charge, Kelly reported a net loss of $0.90/sh. On an adjusted basis, EPS was $0.82, compared to $0.93/sh last year. We were at $0.32.

Solid Results. In the fourth quarter, Kelly delivered both top and bottom-line growth on a year-over-year basis, increasing organic revenue by more than 4% and adjusted EBITDA by 34%. This reflects strong profitability for the quarter, as the Company delivered 110 basis points of margin expansion through targeted organic and inorganic initiatives.

Get the Full Report

Nutriband (NTRB/$7.57 | Price Target: $13)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Nutriband Extends Partnership Agreement To Include Post-Approval Financial Terms
Rating: OUTPERFORM

Previous Agreements Have Been Extended. Nutriband and its partner, Kindeva, have amended their development and commercialization agreement covering AVERSA Fentanyl, the abuse-deterrent transdermal fentanyl patch in development. The amendments include cost sharing and royalties on product sales. We see this as a sign that both parties are optimistic for the future of the product.

Agreement Provides For Development Cost Sharing and Royalty Payments. Nutriband and Kindeva first collaborated on a feasibility study to determine the efficacy of the AVERSA abuse-deterrent technology and its manufacturing requirements. The next agreement covered the development of manufacturing processes for commercial-scale production. The new revisions cover sharing of development costs and royalty payments on sales.

Get the Full Report

Noble Capital Markets Research Report Thursday, February 13, 2025

Companies contained in today’s report:

Conduent (CNDT)/OUTPERFORM – Improved Financials; Operational Execution Comes into Focus
Euroseas (ESEA)/OUTPERFORM – Favorable Time Charter Contract for the M/V EM Hydra
Ocugen (OCGN)/OUTPERFORM – Phase 2 OCU410 Trial Completes Patient Enrollment Ahead Of Schedule

Conduent (CNDT/$4.12 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Improved Financials; Operational Execution Comes into Focus
Rating: OUTPERFORM

Q4 results in line. The company reported Q4 revenue of $800 million, largely in line with our estimate of $808 million. Adj. EBITDA in the quarter was $32 million, better than our estimate of $27 million. Notably, adj. revenue (ex-divestitures) improved sequentially, as the company continued to sign new business, which resulted in new business annual contract value in Q4 exceeding Q3.

Commercial segment momentum. Although Commercial segment adj. revenue was down 3.7% in Q4, management noted that the gap is narrowing between lost and expiring business and new business signings. Importantly, the segment, which is the largest by revenue, is expected to swing towards positive revenue growth near the end of 2025.

Get the Full Report

Euroseas (ESEA/$34.96 | Price Target: $65)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Favorable Time Charter Contract for the M/V EM Hydra
Rating: OUTPERFORM

New time charter contract. Euroseas Ltd. executed a time charter contract for the M/V EM Hydra at a gross daily rate of $19,000 for a minimum period of 24 months to a maximum of 26 months at the charterer’s option. The M/V EM Hydra is a 1,740 twenty-foot equivalent unit (TEU) feeder container ship. The new charter will commence on May 1, 2025, in continuation of its current charter.

Attractive rate and improved charter coverage.  The new time charter is an improvement over the previous contract rate of $13,000 per day and is expected to contribute EBITDA of $7.3 million during the minimum contracted period. We had previously assumed the vessel would be re-contracted at a rate of $16,000 per day. The new time charter enhances Euroseas’ charter coverage for the remainder of 2025 and 2026 to ~85% and ~50%, respectively.

Get the Full Report

Ocugen (OCGN/$0.66 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Phase 2 OCU410 Trial Completes Patient Enrollment Ahead Of Schedule
Rating: OUTPERFORM

Ocugen Announced Completion of OCU410 Phase 2 Enrollment. The Phase 2 trial testing OCU410 for Geographic Atrophy in Dry Age-Related Macular Degeneration (GA/dAMD) has completed patient enrollment ahead of schedule. The trial is expected to announce interim data around YE2025 with top-line data in 1H26. We anticipate a Phase 3 trial starting in late 2026, which could allow for a BLA application in 2028. This could become Ocugen’s third BLA in three years.

Trial Design Has Two Stages. The Phase 1/2 ArMaDa trial is treating patients with geographic atrophy (GA), a symptom of advanced dry AMD. The trial completed a Phase 1 dose-escalation stage to determine basic safety. The current Phase 2 is a randomized, dose expansion stage with two doses tested against a control. The study has 17 patients in each arm (21 patients total).

Get the Full Report

Noble Capital Markets Research Report Wednesday, February 12, 2025

Companies contained in today’s report:

CoreCivic, Inc. (CXW)/OUTPERFORM – Raising to Outperform with $25 PT
MustGrow Biologics Corp. (MGROF)/MARKET PERFORM – Exclusive Distribution Agreement Signed

CoreCivic, Inc. (CXW/$18.04 | Price Target: $25)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Raising to Outperform with $25 PT
Rating: OUTPERFORM

Opportunity, Opportunity, Opportunity. With the change in Administration and new Congress, CoreCivic is anticipating significant growth opportunities, possibly the most significant growth in the Company’s history, over the next several years. We believe the Company is exceptionally well positioned operationally and financially to meet this expected sharp increase in demand for its services.

Potential. Management has put forth a proposal to ICE for 28,000 beds. If accepted, such a proposal could be worth about $1.5 billion in revenue. Just adding in approximately 15,000 beds from existing idle facilities and the South Texas facility could add $750-$800 million of revenue and some $200-$275 million of adjusted EBITDA. Current proposals by the Administration and Congress support such growth, although funding will be key.

Get the Full Report

MustGrow Biologics Corp. (MGROF/$0.935)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Exclusive Distribution Agreement Signed
Rating: MARKET PERFORM

New Distribution. Yesterday, MustGrow announced the signing of a five-year exclusive distribution agreement with Adjuvants Plus Inc., in which MustGrow will distribute Adjuvants’ product line across Canada through NexusBioAg. In addition, MustGrow has a First Right of Refusal for the distribution of Adjuvants’ product line in the U.S. market.

Complementing Products. Four key products are being introduced by Adjuvants in the agreement, with a particular focus on EndoFine and EndoGuard. Adjuvants’ patented Clonostachys rosea, a fungus that provides plant health and protection benefits, is in both products, offering an abundance of advantages for various crops in North America, such as corn, soybeans, pulses, canola, and fruits and vegetables. In our view, products such as EndoFine and EndoGuard complement MustGrow’s product line, as both lines target similar crops while offering health and protection benefits.

Get the Full Report

Noble Capital Markets Research Report Tuesday, February 11, 2025

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – New Colocation Agreement
CoreCivic, Inc. (CXW)/MARKET PERFORM – A Solid End to 2024
Graham (GHM)/OUTPERFORM – Third Quarter Results and Updated Models
SelectQuote (SLQT)/OUTPERFORM – Poised for a Balance Sheet Improvement

Bit Digital (BTBT/$3.06 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
New Colocation Agreement
Rating: OUTPERFORM

Agreement in Place. Yesterday, Bit Digital announced it secured a colocation contract through WhiteFiber, its newly rebranded HPC business, and an unnamed client. Under the agreement, the Company will provide 5MW of built-to-suit data center infrastructure for a period of five years. The Company anticipates the contract to commence in mid-2025. No financial terms of the agreement were disclosed.

Potential Financial Impact. While no financial terms were given in the announcement, based on Enovum’s current 4MW colocation data center producing $7.2 million in revenue annually, the new agreement could generate roughly $9 million in additional revenue if the terms are similar. We expect a $5-$5.6 million impact for annualized EBITDA based on the $4-$4.5 million from the initial data center.

Get the Full Report

CoreCivic, Inc. (CXW/$18.84)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Solid End to 2024
Rating: MARKET PERFORM

A Solid End to the Year. CoreCivic posted solid 4Q24 results, especially given the facility closures from earlier in the year. Results for the quarter surpassed internal as well as consensus estimates, resulting from both cost management initiatives and increased occupancy, which reached 75.5% of available capacity, the Company’s highest level since the first quarter of 2020.

4Q24 Results. Revenue of $479.3 million compared to $491.2 million in 4Q24. We were at $463 million, and the consensus was $465 million. Adjusted EBITDA totaled $74.2 million compared to $90 million in 4Q24. We were at $65.2 million, and the consensus was $66.3 million. Adjusted diluted EPS of $0.16, versus $0.23 last year. We and consensus were at $0.10.

Get the Full Report

Graham (GHM/$39.04 | Price Target: $52)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Third Quarter Results and Updated Models
Rating: OUTPERFORM

3Q25 Results. Revenue increased 7.3% to $47.0 million, driven by continued strength in key end-markets. We had forecast $48 million in revenue. Gross margin rose 260 basis points y-o-y to 24.8% of sales. Graham reported adjusted EBITDA of $4.0 million in the quarter, an 8.6% margin, compared to $3.0 million and 6.8% in the year ago period. Net income was $1.6 million, or $0.14/sh, with adjusted EPS of $0.18/sh. In the same period last year, net income totaled $165,000, or $0.02/sh, and adjusted EPS was $0.13. We had projected an adjusted EPS of $0.13.

Orders. As expected, orders for 3Q25 declined to $24.8 million, given the higher level of orders earlier in the fiscal year. Book-to-bill for the first nine months of the year was 1.0. Backlog at quarter end was $384.7 million, down 3.6% over the prior-year period and down 5.5% sequentially.

Get the Full Report

SelectQuote (SLQT/$4.38 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Poised for a Balance Sheet Improvement
Rating: OUTPERFORM

Q2 beat. The company reported fiscal year Q2 revenue of $481.1 million and adj. EBITDA of $87.5 million, better than our estimates of $416.7 million and $50.0 million, respectively. Strong agent close rates during the Medicare Advantage Annual Enrollment Period (AEP) were an important contributor to the impressive results. Notably, the Senior segment generated an impressive 39% adj. EBITDA margins in the quarter, 700 basis points year over year.

Raising guidance. Management guided fiscal 2025 revenue and adj. EBITDA to $1.5 billion – $1.575 billion, and $115 million – $140 million, respectively. Management’s previous guided ranges were $1.425 billion – $1.525 billion and $100 million – $130 million. We are raising our revenue and adj. EBITDA forecasts for fiscal 2025 and fiscal 2026, detailed later in this report.

Get the Full Report

Noble Capital Markets Research Report Monday, February 10, 2025

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – January Production
Comstock (LODE)/MARKET PERFORM – Taking Shape: A Funding Plan for Comstock Fuels
Eledon Pharmaceuticals (ELDN)/OUTPERFORM – Tegoprubart Used In Pig Kidney Transplant Patient

Bit Digital (BTBT/$3.09 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
January Production
Rating: OUTPERFORM

GPU Cloud Business. The Company earned approximately $4.4 million in revenue from AI contracts during the month of January 2025. Bit Digital had 268 servers (2,144 GPUs) actively generating revenue from its Bit Digital AI contracts. In addition, the Company received $131,000 in cash payments from its equipment leasing contract with Boosteroid during the month.

Colocation Services Business. Bit Digital’s HPC data center colocation revenue was approximately CAD $757.8k (approximately USD $522.9k) in January. The Company had 14 customers actively generating revenue at its Tier-3 Enovum Data Center as of month’s end. Bit Digital has rebranded its HPC business as WhiteFiber, Inc., encompassing the Company’s GPU Cloud business and its HPC data center business.

Get the Full Report

Comstock (LODE/$0.39)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Taking Shape: A Funding Plan for Comstock Fuels
Rating: MARKET PERFORM

Term sheet with Marathon Petroleum. Comstock Fuels executed a non-binding term sheet with a subsidiary of Marathon Petroleum Corporation (NYSE, MPC) to negotiate a series of agreements, including: 1) an agreement under which MPC will contribute a combination of assets and cash to Comstock Fuels for conversion into equity on the same terms as Comstock Fuels’ planned Series A financing, 2) an offtake agreement for Marathon to purchase advanced biomass-based intermediates and fuels from Comstock Fuels’ planned commercial demonstration facility, and 3) a joint development agreement for Marathon to provide support services to Comstock Fuels in exchange for a warrant providing Marathon with an option to purchase additional equity in Comstock Fuels.

Oklahoma private activity bond allocation. Separately, Comstock Fuels was approved by the Oklahoma State Treasurer’s Office to issue up to $152 million in qualified private activity bonds to finance its first commercial demonstration biorefining facility in Oklahoma. The bonds are a key component of Comstock Fuels’ capital and financing plans, including funding each of its planned Bioleum refineries in the U.S. with dedicated project financing.

Get the Full Report

Eledon Pharmaceuticals (ELDN/$4.7 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Tegoprubart Used In Pig Kidney Transplant Patient
Rating: OUTPERFORM

Tegoprubart Used For Immunosuppression In Another Transplantation Surgery. A transplant patient that received a genetically engineered pig kidney has been given tegoprubart as part of their drug regimen to prevent organ rejection. The genetically engineered pig kidney was produced by Eledon’s partner, eGenesis, with the surgery performed at Massachusetts General Hospital (MGH). We see the continued use of tegoprubart instead of tacrolimus, the standard of care, as a positive sign from the transplant community.

Tegoprubart Was Chosen Over Tacrolimus. Tegoprubart is an anti-CD40 ligand antibody that modulates the immune system and avoids the long-term toxic side effects of tacrolimus. It is currently in two human clinical trials for kidney transplantation and has been used in several recent xenotransplantation procedures. We see this choice as a sign that doctors see its clinical data as an improvement over tacrolimus.

Get the Full Report

Noble Capital Markets Research Report Friday, February 7, 2025

Companies contained in today’s report:

DLH Holdings (DLHC)/OUTPERFORM – Transition Ongoing
EuroDry (EDRY)/MARKET PERFORM – Rating Lowered to Market Perform, Awaiting an Improvement in Time Charter Rates
Graham (GHM)/OUTPERFORM – A Transition At The Top
Zomedica (ZOM)/OUTPERFORM – New TRUFORMA Assay Improves Diagnostic Offering

DLH Holdings (DLHC/$6.33 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Transition Ongoing
Rating: OUTPERFORM

Revenue Decline. 1Q25 y-o-y lower revenue was driven by the unbundling of contracts to small business set-asides, which negatively impacted revenue by $3.5 million, $1.5 million from the winding down of acquired small business contracts, another $1.5 million from winding down of international business, and roughly $2 million of HHS revenue that was pushed out into the second quarter of 2025.

Strong Pipeline. DLH’s pipeline remains strong with over $4.0 billion of new business opportunities. For fiscal year 2025, management identified 13 opportunities worth a total of $700 million. The Company is focused on opportunities that leverage DLH’s digital transformation, cyber security, research and development, and systems engineering capabilities.

Get the Full Report

EuroDry (EDRY/$10.93)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Rating Lowered to Market Perform, Awaiting an Improvement in Time Charter Rates
Rating: MARKET PERFORM

Sale of M/V Tasos. EuroDry Ltd. recently agreed to sell the M/V Tasos, a vessel built in 2000, for ~$5 million. The vessel is expected to be scrapped and recycled and will be delivered to its buyer between mid-February and mid-March 2025. Eurodry expects to book a gain of approximately $2.1 million. Following the sale of the M/V Tasos, Eurodry will have a fleet of 12 vessels with total cargo capacity of 843,402 dwt. Upon delivery of two Ultramax vessels in 2027, the fleet will consist of 14 vessels with total cargo capacity of 970,402 dwt.

Market environment. Charter rates have continued to decline due, in part, to a weak outlook for the economy in China, which accounts for a large portion of dry bulk trade, and previous route disruptions that have largely abated. The Panama Canal has returned to full capacity, further undermining dry bulk rates. Recent U.S. tariffs imposed on imports from China could also weigh on its economy. While higher scrapping rates and more stringent environmental regulations could constrain the available bulker fleet, we are not optimistic that rates will make a significant recovery in 2025 despite a historically low industry order book.

Get the Full Report

Graham (GHM/$47.28 | Price Target: $52)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Transition At The Top
Rating: OUTPERFORM

A Transition. Yesterday, Graham Corporation announced its current President and CEO, Daniel Thoren, will transition to the role of Executive Chairman, effective June 10, 2025. Matthew J. Malone, current Vice President and General Manager for Graham subsidiary Barber-Nichols, will be appointed to President & COO effective February 2025 and is expected to assume the CEO role of Graham Corporation in June 2025. The transition is part of an established succession plan.

Malone Background. Mr. Malone brings over 15 years of engineering and executive experience to his new role as President and Chief Operating Officer. Mr. Malone joined Barber-Nichols in 2015 as a Project Engineer focused on rocket engine turbopump design and development. He was promoted to Navy Program Manager in 2018, overseeing key U.S. Navy programs, and was appointed Vice President of Operations at Barber-Nichols in 2020 and then General Manager in 2021.

Get the Full Report

Zomedica (ZOM/$0.12 | Price Target: $0.25)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
New TRUFORMA Assay Improves Diagnostic Offering
Rating: OUTPERFORM

Zomedica Launches New ACTH Assay For Equine PPID. Zomedica has launched an updated TRUFORMA assay for diagnosis of Equine PPID, Pituitary Pars Intermedia Dysfunction, an endocrine disorder in horses also known as Equine Cushing’s Disease. The new assay measures ACTH and one of its breakdown products, CLIP, then calculates a value that can be compared with established standard levels. The measures in this assay allow for better, faster diagnosis at the point-of-care.

PPID Is A Common Condition In Older Horses. An estimated 20% of the horses over 15 years of age are affected by PPID. Benign tumors or enlargement of the pituitary gland leads to overproduction of endocrine hormones and dysregulation of metabolism. ACTH is one of the hormones affected, causing a variety of symptoms that may lead to muscle wasting, thirst, urination, behavior, immune suppression, and metabolic changes. This affects the horse’s overall health, quality of life, and value to the owner.

Get the Full Report

Noble Capital Markets Research Report Thursday, February 6, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – AZZ Provides Fiscal Year 2026 Guidance, No Change to Our Estimates
DLH Holdings (DLHC)/OUTPERFORM – A Peek into the First Quarter Results
InPlay Oil (IPOOF)/OUTPERFORM – Updating Estimates Based on New Guidance for 2024 and 2025
Lucky Strike Entertainment (LUCK)/OUTPERFORM – Expecting a Stronger Finish

AZZ (AZZ/$92.55 | Price Target: $110)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
AZZ Provides Fiscal Year 2026 Guidance, No Change to Our Estimates
Rating: OUTPERFORM

A market leader with a strong growth profile. AZZ is the leading independent provider of hot dip galvanizing and coil coating solutions to a broad range of end markets. We expect AZZ Precoat Metals’ new manufacturing facility in Washington, Missouri to contribute to top-line growth in fiscal year 2026 while capital expenditures decline. Approximately 75% of the facility’s production is already committed and could generate roughly $50 million to $60 million in revenue on an annualized basis once production is fully ramped.

Fiscal 2026 corporate guidance. AZZ Inc. released financial guidance for fiscal year 2026 and expects sales in the range of $1.625 billion to $1.725 billion, adjusted EBITDA in the range of $360 million to $400 million, and adjusted diluted EPS of $5.50 to $6.10. Fiscal year 2026 guidance includes an increase in the Metal Coatings EBITDA margin expectations to a range of 27% to 32% from 25% to 30%, while Precoat Metals EBITDA margin expectations are unchanged at 17% to 22%.

Get the Full Report

DLH Holdings (DLHC/$7.22 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Peek into the First Quarter Results
Rating: OUTPERFORM

1Q Results. Revenue for the quarter was $90.8 million, below our estimate of $97 million and last year’s revenue of $97.9 million. Net income totaled $1.1 million, or diluted EPS of $0.08, compared to $2.2 million or $0.15 in the prior year. EBITDA was $9.9 million compared to $11.1 million last year and is in line with our estimate of $10 million.

Year-Over-Year Impact. Management indicated several factors impacted the year-over-year comparison of its TPS platform. For example, during the first quarter, one of the Company’s recompetes was awarded to a small business. This resulted from the prior administration’s Executive Order to unbundle contracts during the recompete cycle and reserve portions for small businesses. Additionally, acquired contracts that were won as a small business transitioned in the latter quarters of 2024, and other small, non-strategic projects were winding down or fully completed.

Get the Full Report

InPlay Oil (IPOOF/$1.16 | Price Target: $3.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Updating Estimates Based on New Guidance for 2024 and 2025
Rating: OUTPERFORM

Updated 2024 guidance. Inplay Oil modestly lowered its 2024 production guidance to 8,700 to 8,750 boe/d from 8,700 to 9,000. Additionally, the company lowered its expectations for crude oil prices and slightly raised expense guidance. Due to these changes, the adjusted funds flow (AFF) is expected to range from C$68 million to C$70 million compared to prior guidance of C$70 million to C$73 million. Capital expenditures for 2024 are expected to come in at around C$63 million compared to original expectations of C$64-67 million. The savings are mainly due to cost efficiencies from the Pembina Cardium Unit #7 (PCU7) drilling program.

Outlook for 2025. Management has planned a capital-efficient program in 2025. The company expects to increase production by 2%, in the range of 8,650 to 9,150 boe/d, compared to 2024, while spending around C$20 million less. The total capital budget for 2025 is C$41 million to C$44 million and will primarily be directed toward the Pembina Cardium Unit #7 property. Management expects adjusted funds flow (AFF) to benefit from lower capital expenditures and anticipates 2025 AFF to be between C$69 million and C$75 million.

Get the Full Report

Lucky Strike Entertainment (LUCK/$10.89 | Price Target: $17.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Expecting a Stronger Finish
Rating: OUTPERFORM

Q2 Results.  The company reported Q2 revenue and adj. EBITDA of $300.7 million and $98.8 million, both of which were modestly lower than our estimates of $321.0 million and $104.5 million, respectively. Notably, operating results were impacted by reduced corporate events that were attributed to election outcome concerns, a shortened holiday event window, and New Year’s Eve falling in Q3 this year. Importantly, we anticipate the company will offset the softness in the second half.

Strategic initiatives. With consumers cautious over the macroeconomic environment and some uncertainty around revenue, management is focused on optimizing labor costs, and offering more promotional items to attract value conscious consumers. Furthermore, the company is focused on rebranding locations to Lucky Strike from Bowlero, and pursuing acquisitions in the bowling and broader entertainment space.

Get the Full Report

Noble Capital Markets Research Report Wednesday, February 5, 2025

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – Lowering Expectations for 2025; Growth Outlook Remains Favorable
MAIA Biotechnology (MAIA)/OUTPERFORM – THIO-101 Interim Update Shows Increasing Survival
The ODP Corporation (ODP)/OUTPERFORM – Participation in Another New Award

Alliance Resource Partners (ARLP/$27.98 | Price Target: $32)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Lowering Expectations for 2025; Growth Outlook Remains Favorable
Rating: OUTPERFORM

Full year and fourth quarter 2024 financial results. On a full year basis, Alliance generated 2024 adjusted EBITDA of $714.2 million and earnings per unit (EPU) of $2.77, respectively, compared to $933.1 million and $4.81 in 2023. Fourth quarter adjusted EBITDA was $124.0 million, and EPU amounted to $0.12, respectively, compared to $185.4 million and $0.88 during the prior year period. Fourth quarter and full year results were impacted by lower coal volumes, operational challenges within ARLP’s coal operations in Appalachia, and a $30.1 million non-cash asset impairment charge which had a negative impact of ~$0.24 per unit.

Management guidance for 2025. Coal sales are expected to be in the range of 32.25 million to 34.25 million tons, while the sales price of coal per ton is expected to be in the range of $57.00 to $61.00. Segmented adjusted EBITDA expense per ton sold is expected to be $40.00 to $44.00. The company has committed and priced 26.0 million tons of its 2025 sales volume, including 23.5 million for the domestic market and 2.5 million tons for the export market.

Get the Full Report

MAIA Biotechnology (MAIA/$2 | Price Target: $14)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
THIO-101 Interim Update Shows Increasing Survival
Rating: OUTPERFORM

MAIA Provides Phase 2 Interim Data Update In NSCLC. The Phase 2 THIO-101 trial is testing the combination of THIO with cemiplimab (Libtayo), a PD-1 checkpoint inhibitor from Regeneron, in patients with advanced non-small lung cancer (NSCLC). Median overall survival was 16.9 months, compared with expected survival of 5.8 months. Importantly, the lower limit of the statistical confidence intervals for the trial shows a 99% chance of surviving 10.8 months, a statistically significant result.

Combination Uses Two Mechanisms Of Action. The THIO-101 trial combines the killing effects from THIO with the PD-1 inhibition from cemiplimab. THIO uses its telomere targeting to damage cancer cell DNA, causing cell death. This also stimulates an immune response in the tumor through the cGAS/STING pathway and T-cell responses. Cemiplimab provides a second mechanism, allowing the immune cells to recognize and kill the cancer cells.

Get the Full Report

The ODP Corporation (ODP/$21.96 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Participation in Another New Award
Rating: OUTPERFORM

New Award. Another in a string of new business, ODP Corporation announced its Business Solutions segment is participating in a new award for a multi-year furniture contract with Region 4 Education Service Center (ESC) that brings the potential of up to $500 million in total annual revenue. After a challenging 2024 for Business Solutions, the new year has started positively with the recent contract awards that have the potential to drive top line growth for the segment.

Details. The new contract enables the ODP Business Solutions Workspace Interiors team to offer compliant cooperative purchasing solutions through OMNIA Partners, providing furniture, installation, and related services to K-12 schools, higher education institutions, and cities and counties across the U.S. The new contract grants OMNIA Partners members access to a comprehensive range of products.

Get the Full Report

Noble Capital Markets Research Report Tuesday, February 4, 2025

Companies contained in today’s report:

Euroseas (ESEA)/OUTPERFORM – Updating Estimates Due to Two New Time Charters

Euroseas (ESEA/$30.77 | Price Target: $56)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Updating Estimates Due to Two New Time Charters
Rating: OUTPERFORM

New time charter contracts. Euroseas executed two new time charter contracts for M/V Synergy Antwerp and M/V Synergy Keelung. The charter contracts are at gross daily rates of $35,500 for a minimum period of 36 months and a maximum period of 39 months at the charterer’s option. Both contracts will take effect at the completion of the vessels’ respective current charters; M/V Synergy Antwerp’s new charter is expected to commence in May 2025, and M/V Synergy Keelung’s new charter is expected to commence in June 2025.

Favorable rates and improved coverage. The new time charters are expected to contribute roughly $57.0 million in EBITDA during the minimum contracted period. The new charters improve the company’s 2025 and 2026 charter coverage to 82% and 45%, respectively. Additionally, Euroseas announced that M/V Synergy Keelung will be retrofitted with energy-saving devices (ESDs) and the upgrade costs will be shared with the charterer.

Get the Full Report

Noble Capital Markets Research Report Monday, February 3, 2025

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Comstock Fuels Completes Definitive Agreement with SACL Pte. Ltd.
FreightCar America (RAIL)/OUTPERFORM – Taking the Long View

Comstock (LODE/$0.381)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Comstock Fuels Completes Definitive Agreement with SACL Pte. Ltd.
Rating: MARKET PERFORM

Agreement with SACL. Comstock Fuels executed definitive agreements with SACL Pte. Limited (SACL), a Singapore-based renewable fuel project developer with plans to develop renewable energy projects in Australia, New Zealand, Vietnam, Cambodia, and Malaysia. SACL has been granted a master non-exclusive license to Comstock Fuel’s intellectual property to develop, finance, build, and manage renewable fuel production facilities. The agreement provides exclusive rights to market projects subject to SACL’s satisfaction of certain milestones, including completion of engineering and financing for SACL’s first licensed facility in 2025 followed by commissioning and production in 2027.

Favorable terms. Comstock will contribute site-specific technology rights in exchange for a 20% equity stake in each refinery and provide engineering support in exchange for 3% of each facility’s capital and construction costs. This will increase to 6% for facilities with a capacity of 250,000 metric tons per year (MTPY) or more. Additionally, an upfront payment of $2.5 million will be required upon the execution of a site license agreement. Comstock Fuels will receive a royalty fee equal to 3% of the total sales from licensed products produced by each facility, which will rise to 6% for facilities with a capacity of 250,000 metric tons per year or greater.

Get the Full Report

FreightCar America (RAIL/$12.21 | Price Target: $14.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Taking the Long View
Rating: OUTPERFORM

Tariffs. Pursuant to the International Emergency Economic Powers Act, the Trump Administration is implementing a 25% additional tariff on imports from Canada and Mexico and a 10% additional tariff on imports from China. The tariffs are effective on February 4. Energy resources from Canada will have a lower 10% tariff. The action is intended to hold Mexico, Canada, and Mexico accountable for their promises of halting illegal immigration and preventing fentanyl and other drugs from entering the United States. The ad valorem duties do not appear to consider the origin of raw materials or to be subject to exemption.

Exposure. In 2021, FreightCar moved its manufacturing activities in the United States to a new state-of-the-art facility in Castanos, Mexico. It steadily grew production capacity to 5,000 rail cars per year with the addition of a fourth production line during the fourth quarter of 2023. Importantly, the company’s competitors, Greenbrier Companies (NYSE-GBX) and Trinity Industries (NYSE-TRN), also have significant manufacturing operations in Mexico that serve the U.S. market.

Get the Full Report

Noble Capital Markets Research Report Friday, January 31, 2025

Companies contained in today’s report:

1-800-Flowers.com (FLWS)/OUTPERFORM – A Largely Self Inflicted Miss
FAT Brands (FAT)/OUTPERFORM – Distribution of Twin Hospitality Shares Completed

1-800-Flowers.com (FLWS/$8.09 | Price Target: $12)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
A Largely Self Inflicted Miss
Rating: OUTPERFORM

Fiscal Q2 Results. The company reported fiscal Q2 revenue and adj. EBITDA of $775.5 million and $116.3 million, both of which were lower than our estimates of $801.1 million and $124.7 million, respectively. Notably, an order management system (OMS) that was implemented in Q2 for Harry & David faced issues with complicated orders during periods of high volume. The OMS issue, which was resolved in the quarter, resulted in roughly $20 million of lost revenue and is largely to blame for the downside variance.

Strategic initiatives. Importantly, the company remains focused on reducing costs through increased automation, increasing investments in sales and marketing, and broadening its product offerings for its price-sensitive customers. Notably, management highlighted that the savings from its cost reduction efforts will largely fund its increased investment in sales and marketing in an effort to broaden its customer base.

Get the Full Report

FAT Brands (FAT/$3.81 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Distribution of Twin Hospitality Shares Completed
Rating: OUTPERFORM

Distribution. FAT Brands has completed the previously announced distribution of approximately 5.0% of the fully diluted shares of Class A common stock of Twin Hospitality Group Inc. to holders of Class A common stock and Class B common stock of FAT Brands. We believe the distribution of Twin Hospitality will begin to highlight the value of the assets FAT Brands has assembled.

Details. FAT Brands common stockholders received 0.1520207 shares of Twin Hospitality common stock for each share of Class A common stock or Class B common stock of the Company held. In total, FAT Brands distributed 2,659,412 shares of the Twin Hospitality Class A common stock. FAT Brands continues to hold 44,638,859 Class A Twin Hospitality shares and 2,870,000 Class B shares (or 100% of the outstanding B shares).

Get the Full Report

Noble Capital Markets Research Report Thursday, January 30, 2025

Companies contained in today’s report:

Hemisphere Energy (HMENF)/OUTPERFORM – Favorable 2025 Growth Outlook

Hemisphere Energy (HMENF/$1.28 | Price Target: $2.35)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Favorable 2025 Growth Outlook
Rating: OUTPERFORM

Outlook for 2025. Hemisphere Energy expects 2025 capital expenditures of approximately C$17 million which are expected to support ~15% growth in annual average production to 3,900 barrels of oil equivalent per day (boe/d) compared to 2024. Expenditures will be funded entirely from adjusted funds flow. Most of the capital will be allocated to drilling, optimization, and facility work, with approximately 10% allotted to exploration and land acquisition. Most planned expenditures are scheduled for the third quarter of 2025, providing the company with the flexibility to adjust plans based on changes in commodity prices.

Updating estimates. We have increased our 2024 adjusted funds flow (AFF) and EPS estimates to C$45.4 million and $0.32, respectively, from C$43.5 million and $0.31 to reflect modestly higher operating earnings. AFF and EPS in the fourth quarter are estimated to be C$10.0 million and $0.06, respectively. We have also increased our 2025 AFF and EPS estimates to C$50.6 million and $0.37, respectively, from C$38.0 million and $0.27 to reflect higher average annual production of 3,900 boe/d compared to our prior estimate of 3,625 boe/d. Additionally, we increased our WTI crude oil price assumption to US$72.00 per barrel versus our prior estimate of US$70.00.

Get the Full Report

Noble Capital Markets Research Report Wednesday, January 29, 2025

Companies contained in today’s report:

Seanergy Maritime (SHIP)/OUTPERFORM – Definitive Agreements to Acquire Two New Vessels

Seanergy Maritime (SHIP/$6.89 | Price Target: $10)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Definitive Agreements to Acquire Two New Vessels
Rating: OUTPERFORM

Fleet expansion. Seanergy entered into two definitive agreements, one for purchasing a Newcastlemax vessel and the other for a bareboat charter with a purchase obligation for a Capesize vessel. The total acquisition cost is approximately $69.0 million and will be funded with cash and proceeds from credit facilities. Following the purchases, Seanergy’s fleet will consist of 21 vessels with an aggregate cargo-carrying capacity of 3,803,918 deadweight tons (dwt). Both vessels are expected to be delivered within the first quarter of 2025.

Vessel details. The Newcastlemax vessel, to be named “Meiship”, was built in 2013 and has cargo capacity of 207,851 dwt. The Capesize vessel, to be named “Blueship”, was built in 2011 and has a capacity of 178,459 dwt. Pursuant to a six-month bareboat charter, Seanergy advanced a down payment of $4.0 million and will pay an additional $4.0 million upon delivery of the vessel. Seanergy will pay the owner a daily rate of $9,750 per day during the six-month charter period and earn revenue based on the Baltic Capesize Index (BCI). At the end of the six-month charter period, Seanergy is obligated to purchase the vessel for $22.5 million.

Get the Full Report

Noble Capital Markets Research Report Tuesday, January 28, 2025

Companies contained in today’s report:

Kratos Defense & Security (KTOS)/OUTPERFORM – Raising Price Target
The ODP Corporation (ODP)/OUTPERFORM – Expanding the Addressable Market

Kratos Defense & Security (KTOS/$33.48 | Price Target: $38)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Raising Price Target
Rating: OUTPERFORM

Raising Price Target. We are maintaining our Outperform rating but raising our price target on KTOS shares to $38 from a prior $30. KTOS shares have performed well since we raised our price target to $30 in mid-November and have spent the last two weeks above our old target. We remain positive on the growth potential for Kratos, both on the defense and commercial sides.

Drivers. We continue to believe KTOS shares benefit from investor belief in the Trump Administration’s determination to increase defense spending and allocate more dollars to areas in Kratos’ wheelhouse, such as unmanned systems, hypersonics, and space. We also expect less friction from a drawn-out continuing resolution.

Get the Full Report

The ODP Corporation (ODP/$23.67 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Expanding the Addressable Market
Rating: OUTPERFORM

A Hospitality Agreement. The ODP Corporation’s Business Solutions segment entered into a key new partnership with one of the world’s largest hotel management organizations, becoming a preferred provider for operating supplies and equipment. We believe expansion into the hospitality market is a strategic step forward for ODP which leverages the Company’s expertise and represents a major inflection point for the Company. In our view, ODP is well positioned to pursue growth in new and growing industry segments.

Details. Under the new agreement, ODP will provide high-quality textiles for bed and bath products. It will also distribute liquid beauty products and lodging kits, all uniquely packaged to accommodate the needs of every client and guest. The expansion of their product portfolio also includes hotel room technology and in-room amenities.

Get the Full Report

Noble Capital Markets Research Report Monday, January 27, 2025

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – Secures New HPC Contract with Anchor Customer

Bit Digital (BTBT/$3.69 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Secures New HPC Contract with Anchor Customer
Rating: OUTPERFORM

New Contract. Last Friday, Bit Digital announced a new agreement with its anchor customer in the GPU Cloud portion of its HPC business. The new 464 Nvidia B200 GPUs contract replaces a prior agreement to provide 2,048 H100 GPUs. The contract represents approximately $15 million of annualized revenue and features a two-month prepayment from the customer. While the new agreement reduces annualized revenue from what the Company anticipated last year (roughly $50 million), management is exploring additional contracts with the customer, which we are hopeful, when combined, will at least rise to the originally expected contract level.

Additional Terms. Under the new agreement, Bit Digital will provide the customer with 58 B200 servers (464 GPUs) for 18 months. Furthermore, the customer may deduct 100% of the service fees from the previously paid $30 million non-refundable deposit.

Get the Full Report

Noble Capital Markets Research Report Thursday, January 23, 2025

Companies contained in today’s report:

Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Options for the Acadia, if Needed
NN (NNBR)/OUTPERFORM – A First Look at 2025
Vince Holding Corp. (VNCE)/OUTPERFORM – Hoffman Returns; Sowing Seeds For Growth
Maple Gold Mines (MGMLF)/OUTPERFORM – Maple Gold Commences Drilling at the Douay Gold Project

Great Lakes Dredge & Dock (GLDD/$12.17 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Options for the Acadia, if Needed
Rating: OUTPERFORM

Executive Order. Monday, President Trump signed an Executive Order for the temporary withdrawal of all areas on the Outer Continental Shelf (OCS) from offshore wind leasing as well as a review of the federal government’s leasing and permitting practices for wind projects. This withdrawal temporarily prevents consideration of any area in the OCS for any new or renewed wind energy leasing for the purposes of generation of electricity or any other such use derived from the use of wind.

Impact on GLDD. Notably, nothing in the withdrawal affects rights under existing leases in the withdrawn areas. However, the President has directed the Secretary of the Interior to comprehensively review the ecological, economic, and environmental necessity of terminating or amending any existing wind energy leases. Great Lakes’ two existing projects, Empire Wind and Sunrise Wind, have already undergone extensive governmental review and, presumably, should go forward.

Get the Full Report

NN (NNBR/$2.76 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A First Look at 2025
Rating: OUTPERFORM

Corporate Presentation. Yesterday, NN management presented at an investment conference. Among the topics discussed were the enterprise transformation, tariffs, balance sheet transformation, M&A, and the five-year growth plan. Management also introduced 2025 guidance.

Transformation Plan and Tariffs. The transformation plan continues to move forward. Notably, management indicated that all plants will be profitable in 2025, with a new focus on improving below average performing plants. Management does not expect the proposed Trump tariffs to impact business negatively as the vast majority of products are consumed in the country in which they are produced. Management did note recent inquiries from potential customers seeking capacity to produce products in the U.S. that customers had previously purchased overseas.

Get the Full Report

Vince Holding Corp. (VNCE/$2.35 | Price Target: $7)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Hoffman Returns; Sowing Seeds For Growth
Rating: OUTPERFORM

Well timed move. P-180, a venture between Christine Hunsicker and former CEO of Vince, Brendan Hoffman, purchased Sun Capital’s 65% majority stake, or 8.4 million shares, for $19.8 million in cash. The transaction also included significant debt paydown and debt forgiveness, highlighted later in this report. We believe that the transaction puts the company into friendly hands and with a stronger balance sheet.

Management shuffle. Brendan Hoffman will reassume his role as CEO on February 3. David Stefko will step down as interim CEO but will continue to serve on the board of directors. Additionally, Matthew Garff, who represented Sun Capital Partners on the board of directors, resigned.

Get the Full Report

Maple Gold Mines (MGMLF/$0.04 | Price Target: $0.25)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Maple Gold Commences Drilling at the Douay Gold Project
Rating: OUTPERFORM

Phase I Drilling at Douay. Maple Gold Mines commenced a Phase I diamond drilling program at the Douay Gold project that is expected to last three to four months. The company’s drilling program will entail a minimum of 10,000 meters of diamond drilling, with ~70% dedicated to derisking and expanding the Douay mineral resource and 30% for testing new regional geological and geophysical targets. At the Douay gold project, the goal is to expand and upgrade the current three-million-ounce gold resource to five million ounces. The first phase will target shallow portions of the Douay system at a vertical depth of less than 500 meters, while the second phase will test vertical depths greater than 500 meters.

Drilling at Joutel is planned in 2H 2025. An additional 3,000 meters of diamond drilling is planned at Joutel in the second half of 2025 to extend the known high-grade gold mineralization along the past-producing Eagle-Telbel mine trend.

Get the Full Report

Noble Capital Markets Research Report Wednesday, January 22, 2025

Companies contained in today’s report:

Century Lithium Corp. (CYDVF)/OUTPERFORM – Setting the Stage for an Anchor Sodium Hydroxide Off-take Agreement
Comstock (LODE)/MARKET PERFORM – Strategic Agreement with Hexas Biomass Supports Liquid Fuels Innovation and Commercialization
Nutriband (NTRB)/OUTPERFORM – Initiating Coverage With An Outperform Rating And $13 Price Target
Townsquare Media (TSQ)/OUTPERFORM – Preliminary Q4 Results Appear Promising

Century Lithium Corp. (CYDVF/$0.22 | Price Target: $2.3)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Setting the Stage for an Anchor Sodium Hydroxide Off-take Agreement
Rating: OUTPERFORM

Paving the way for an off-take agreement. Century Lithium recently executed a non-binding memorandum of understanding (MOU) to formalize a multi-year off-take agreement with Orica Specialty Chemicals to purchase sodium hydroxide from Century Lithium’s wholly owned Angel Island project. Orica is a leading mining and infrastructure solutions provider, the largest producer of sodium cyanide, and a supplier of specialty mining chemicals to Nevada’s mining industry.

Initial term of five years. The contemplated off-take agreement will have an initial term of five years and a right of first offer for an additional five years. It would account for a large portion of the surplus sodium hydroxide produced during the early years of the Angel Island project’s operation. A definitive agreement will contain pricing terms.

Get the Full Report

Comstock (LODE/$0.333)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Strategic Agreement with Hexas Biomass Supports Liquid Fuels Innovation and Commercialization
Rating: MARKET PERFORM

Agreement with Hexas Biomass. Comstock Fuels executed an agreement with Hexas Biomass Inc. to acquire an exclusive worldwide license to Hexas’ intellectual properties in liquid fuels applications, subject to certain pre-existing agreements and relationships. Moreover, Hexas will provide development services in connection with Comstock Fuels’ site development and innovation activities. Comstock Fuels will invest $500,000 in Hexas to be paid in four tranches on January 15, January 31, February 28, and March 31, 2025.

High yield energy crops. Hexas has developed a portfolio of proprietary intellectual properties supporting the propagation, production, harvesting, and processing of purpose-grown energy crops with yields exceeding 25 to 30 dry metric tons per acre per year, or about 4 to 7 times the yields of traditional forestry species. 

Get the Full Report

Nutriband (NTRB/$5.21 | Price Target: $13)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Initiating Coverage With An Outperform Rating And $13 Price Target
Rating: OUTPERFORM

We Are Initiating Coverage With An Outperform Rating. Nutriband, Inc. is a pharmaceutical company developing transdermal patch technologies for drug delivery. Its proprietary technology, known as AVERSA, has abuse-deterrent features with important differences from other transdermal patches on the market. The lead product is AVERSA Fentanyl, an abuse-deterrent transdermal patch for delivering fentanyl that improves safety, compliance, and patient comfort.

Only One Clinical Trial Is Required For the 505 (b)(2) New Drug Application. AVERSA Fentanyl can follow the 505(b)(2) regulatory pathway with only a single Phase 1 clinical abuse potential study required to support the new label claims. We expect this study to begin in 1H25, announce results in 2H25, and file an NDA around YE2025 to early 2026.

Get the Full Report

Townsquare Media (TSQ/$9.02 | Price Target: $21)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Preliminary Q4 Results Appear Promising
Rating: OUTPERFORM

Preliminary Q4 results. The company announced preliminary Q4 results that were in-line with previously issued guidance. The company expects Q4 revenue to be in the range of $117 million – $119 million and adj. EBITDA to be approximately $31 million. Notably, the company’s digital segment is expected to increase revenue by 11% over the comparable year-earlier period.

in line with previously issued guidance. The company expects Q4 revenue to be in the range of $117 million—$119

In line results. The Q4 preliminary results exceed our revenue estimate of $115.0 million, and our adj. EBITDA estimate of $30.4 million. Preliminary results and our Q4 and full year 2024 forecasts are illustrated in Figure #1 & Figure #2, respectively.

Get the Full Report

Noble Capital Markets Research Report Tuesday, January 21, 2025

Companies contained in today’s report:

Euroseas (ESEA)/OUTPERFORM – Vessel Sale Adds a New Wrinkle to the Proposed Euroholdings Ltd. Spin-Off
GeoVax Labs (GOVX)/OUTPERFORM – Gedeptin To Begin Phase 2 Clinical Trial

Euroseas (ESEA/$33.01 | Price Target: $52)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Vessel Sale Adds a New Wrinkle to the Proposed Euroholdings Ltd. Spin-Off
Rating: OUTPERFORM

Sale of the M/V Diamantis P. A wholly owned subsidiary of Euroseas sold the M/V Diamantis P for ~$13.2 million and delivered the vessel to its new owners on January 15. Recall that the Diamantis P is a feeder containership that was built in 1998. The transaction is expected to result in a gain on sale of ~$10.2 million. 

Spin-off transaction. Recall that Euroseas announced its intention to spin off three of its subsidiaries, two owning the M/V Aegean Express and M/V Joanna, and one that owned the M/V Diamantis P (prior to its sale) into Euroholdings Ltd. In exchange, Euroseas will receive 100% of the shares of Euroholdings Ltd., which will then be distributed to its shareholders (please refer to our note dated January 3 for transaction details).

Get the Full Report

GeoVax Labs (GOVX/$2.22 | Price Target: $12)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Gedeptin To Begin Phase 2 Clinical Trial
Rating: OUTPERFORM

GeoVax Starts The Year By Announcing Phase 2 Trial For Gedeptin. GeoVax has announced that a Phase 2 trial for Gedeptin, its gene therapy for delivering cytotoxic cancer drugs, is planned to start in 1H25. As we expected, the trial will test Gedeptin with a checkpoint inhibitor in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).

Gedeptin Delivers A Gene To Activate The Cancer Drug In The Tumor. Gedeptin is based on the Gene-Directed Enzyme Prodrug Therapy (GDEPT) technology platform. It uses an adenovirus vector to deliver the E. coli PNP gene to cancer cells. Once inside the cells, the gene produces an enzyme that converts an inactive prodrug (fludarabine) into an active cytotoxic drug. This increases the drug’s potency inside the cancer cells while avoiding healthy tissue. Gedeptin has completed Phase 1/2 trials in advanced head and neck cancer and has been granted Orphan Drug Designation for oral and pharyngeal cancers.

Get the Full Report

Noble Capital Markets Research Report Thursday, January 15, 2025

Companies contained in today’s report:

SKYX Platforms (SKYX)/OUTPERFORM – A Step Forward for Its Commercial Distribution Channel

SKYX Platforms (SKYX/$1.28 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
A Step Forward for Its Commercial Distribution Channel
Rating: OUTPERFORM

Commercial expansion. On January 15th, the company announced that it will begin supplying its products to real estate developer Jeremiah Baron Companies. The developer has mixed-use residential and commercial projects underway in Florida. The partnership is expected to encompass approximately 1,000 units, which we believe equates to roughly 30,000 receptacles.

Seeding for the future. The company will initially supply receptacles to the developer, followed by plug-in products in the later stages of development, such as chandeliers, ceiling fans, and others. Importantly, the company’s fixtures, which plug into the receptacles, sell at higher prices. As such, we expect initial revenue impacts from the partnership to be modest, followed by a more meaningful impact when the units are ready for the installation of plug-in products. We anticipate that the development of the mixed-use project will extend into 2026. 

Get the Full Report

Noble Capital Markets Research Report Wednesday, January 15, 2025

Companies contained in today’s report:

NN (NNBR)/OUTPERFORM – Another Year of Record-Setting New Business Wins

NN (NNBR/$2.69 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Another Year of Record-Setting New Business Wins
Rating: OUTPERFORM

New Business Wins. NN reported full-year 2024 new business wins of $73 million, exceeding the high end of the Company’s guidance. This is the second consecutive year of record annualized new business wins, up from the previous record of $63 million in 2023. The new wins were in key focus areas such as vehicle control, energy efficiency, electrical grid components, and medical components.

Driving to the Five-Year Goal. With another record year of new business wins, NN remains on track to meet its five-year goal of $325 million in new business wins, which will, in turn, be a key driver in the Company’s organic growth to $600 million in sales. Notably, we expect management to also seek inorganic growth opportunities, especially in the medical and electrical segments, to drive the five-year revenue goal even higher.

Get the Full Report

Noble Capital Markets Research Report Tuesday, January 14, 2025

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Taking Steps to Enhance Financial Flexibility and Close Strategic and Financial Partnerships
Comtech Telecommunications (CMTL)/MARKET PERFORM – Reports First Quarter Results
Saga Communications (SGA)/OUTPERFORM – Recent Stock Price Drop Is Gaining Investor Attention

Comstock (LODE/$0.28)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Taking Steps to Enhance Financial Flexibility and Close Strategic and Financial Partnerships
Rating: MARKET PERFORM

Special meeting of stockholders. Comstock will host a virtual special meeting of stockholders on February 14 at 9:00 a.m. PT. Stockholders of record, as of January 2, are asked to vote to authorize a reverse stock split of the company’s issued and outstanding common stock at a ratio ranging from one-for-five to one-for-twenty, with the timing and ratio to be determined by the Board. There will be no reduction or change to Comstock’s 245,000,000 authorized share count. The primary goal of the reverse split is to increase the number of shares available for issuance should the company need to raise additional capital.

Convertible promissory note financing. Comstock recently executed a 6.0% convertible promissory note agreement with a principal amount of $10,638,298 to Kips Bay Select, LP. The note is due on April 10, 2026. On the initial closing date, Kips Bay will fund $5,000,000 which will result in an aggregate principal amount of $5,319,149, including the original issue discount. Following and contingent on the reverse split, Comstock could receive additional funding of $5,000,000 in a second tranche, likely next month, on the same terms. Kips Bay could also receive restricted shares equal to 2% of the principal amount of the convertible note and registered shares equal to 3% of the principal amount.

Get the Full Report

Comtech Telecommunications (CMTL/$2.34)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Reports First Quarter Results
Rating: MARKET PERFORM

1Q25 Results. Revenue came in at $115.8 million, down 23.8% y-o-y. Revenue was below our estimate, consensus estimate, and management’s 4Q24 commentary. Adjusted EBITDA loss totaled $19.4 million, again below our estimate, consensus estimate, and management’s 4Q24 commentary. Comtech reported a GAAP net loss of $5.29/sh versus a loss of $0.11/sh in 1Q24. Adjusted net loss was $1.27/sh compared to EPS of $0.26/sh last year.

Segments. Terrestrial &Wireless revenue of $56.9 million rose 14.9% y-o-y. Adjusted EBITDA was $11 million, up 14% y-o-y. Book-to-bill was 1.22x. Satellite & Space segment revenue of $58.9 million declined 42.5% y-o-y, driven by a combination of divestitures and suboptimal performance. Segment adjusted EBITDA was a negative $21.1 million, while book-to-bill was 0.99x.

Get the Full Report

Saga Communications (SGA/$11.4 | Price Target: $24)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Recent Stock Price Drop Is Gaining Investor Attention
Rating: OUTPERFORM

Recent weak stock performance. The SGA shares are down roughly 24% over the past six months and nearly 50% over the past year to near current levels. The performance is in line with its peer group, which is down approximately 45% over the past year. We believe that investors have thrown the baby out with the bath water, given that SGA has virtually no debt, unlike its highly debt levered peers, and has better revenue and cash flow growth potential.

Increased stake. Given the recent stock performance, Gate City Capital Management, LLC, a micro-cap focused investment firm, announced on January 8 that it nearly doubled its position during December 2024. Gate City Capital Management, LLC now owns 863,845 shares or approximately 13.8% of the total outstanding shares.

Get the Full Report

Noble Capital Markets Research Report Monday, January 13, 2025

Companies contained in today’s report:

Aurania Resources (AUIAF)/OUTPERFORM – Priorities for 2025
FAT Brands (FAT)/OUTPERFORM – More Details on Twin Hospitality Distribution

Aurania Resources (AUIAF/$0.25 | Price Target: $0.55)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Priorities for 2025
Rating: OUTPERFORM

Private placement financing. In December, Aurania closed the second and final tranche of its private placement financing. A total of 3,747,243 units were sold at C$0.45 per unit for gross proceeds of C$1,686,259.35. Each unit is comprised of one common share and one common share purchase warrant, which entitles the holder to purchase one common share at an exercise price of C$0.75 for a period of 24 months following the closing date of the applicable tranche of the offering. Aurania expects to allocate most of the net proceeds to fund exploration activities in France.

Kuri-Yawi epithermal gold target. In November, Aurania commenced an induced polarization (IP) geophysical survey over its Kuri-Yawi epithermal gold target at the company’s Lost Cities-Cutucu project in Ecuador. The IP survey is designed to identify deep conductors that could correspond to gold mineralization and to target drill holes for a drilling program in 2025. In his recent shareholder letter, Dr. Keith Barron, Aurania’s Chairman and CEO, mentioned that while he is awaiting the Geophysicist’s report on the IP survey at Kuri-Yawi, the preliminary reports look great. Some epithermal veins were discovered during the survey and samples are being assayed.

Get the Full Report

FAT Brands (FAT/$5.22 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
More Details on Twin Hospitality Distribution
Rating: OUTPERFORM

Twin Hospitality Transaction. On Friday after the market closed, Twin Hospitality Group filed an amended Form 10 providing additional detail regarding the distribution of Twin Hospitality shares to existing FAT Brands shareholders. We believe the distribution and subsequent potential actions will highlight the value of Twin Hospitality and, by extension, FAT Brands shares.

Details. Initially, FAT Brands will own 100% of the equity of Twin Hospitality, consisting of 47,298,271 Class A shares and 2,870,000 Class B shares. Just like at FAT Brands, the B shares are super-voting with 50 votes per share. Class A shares have one vote. 

Get the Full Report

Noble Capital Markets Research Report Friday, January 10, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Well-Positioned for Sales Growth and Margin Expansion; Increasing Estimates
Bit Digital (BTBT)/OUTPERFORM – December Production Numbers Released
Bitcoin Depot (BTM)/OUTPERFORM – Scores Another Retail Partnership
DLH Holdings (DLHC)/OUTPERFORM – A New Award
Kratos Defense & Security (KTOS)/OUTPERFORM – Award Momentum Continues

AZZ (AZZ/$83.11 | Price Target: $110)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Well-Positioned for Sales Growth and Margin Expansion; Increasing Estimates
Rating: OUTPERFORM

Third quarter financial results. For the fiscal year (FY) 2025, AZZ reported third quarter adjusted net income of $41.9 million or $1.39 per share compared to $34.8 million or $1.19 per share during the prior year period and our estimate of $37.7 million or $1.25 per share. Compared to the prior year period, sales increased 5.8% to $403.6 and exceeded our estimate of $398.5 million. AZZ generated a 24.2% gross margin as a percentage of sales compared to 23.1% during the prior year period and our estimate of 23.3%. Adjusted EBITDA increased 5.0% to $90.7 million, above our estimate of $86.1 million, representing 22.5% of sales versus 22.6% of sales during the third quarter of FY 2024.

Updating estimates. We have increased our 2025 EBITDA and EPS estimates to $351.6 million and $5.23, respectively, from $346.8 million and $5.05. Our 2026 EBITDA and EPS estimates have been raised to $372.6 million and $5.77, respectively, from $371.5 million and $5.70. Our revised estimates are largely due to changes in sales growth and gross margin assumptions. The company is expected to provide guidance for FY 2026 in early February. 

Get the Full Report

Bit Digital (BTBT/$3.36 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
December Production Numbers Released
Rating: OUTPERFORM

HPC/AI Side. At year-end, Bit Digital had 266 servers actively generating revenue from its Bit Digital AI contracts and earned approximately USD $4.5 million of total unaudited GPU Cloud revenue during the month of December. In addition, $177k in revenue from the Boosteroid contract was recognized. The Company’s HPC data center colocation revenue was approximately CAD $757.8k (approximately USD $528.1k) and had 14 customers generating revenue at the Enovum Data Center facility as of December 31, 2024.

Mining. The Company produced 32.4 BTC in December, a 27.8% decrease from 44.9 BTC last month due to changes in the Company’s hosting portfolio, ongoing redeployment of mining assets to new sites, and the retirement of older generation miners. The active hash rate was roughly 1.8 EH/s, a decline from 2.51 EH/s last month due to the reasons mentioned earlier. During the month, 941 S21 miners were purchased for $3.2 million, with the Company selling 4,506 S19 mining units for approximately $836.6k. We expect the hash rate to climb back up as the Company redeploys its new and current miners to new sites.

Get the Full Report

Bitcoin Depot (BTM/$1.57 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Scores Another Retail Partnership
Rating: OUTPERFORM

Adding 50 kiosks. On December 8, the company announced the deployment of 50 additional kiosks through a new partnership with a convenience store operator. The newly deployed kiosks are in the Texas Panhandle and surrounding region, including multiple states.

Executing its kiosk expansion strategy. In our view, the recent development illustrates the company’s favorable execution of its kiosk expansion strategy. Importantly, the company owns over 10,000 kiosks, of which roughly 8,300 were deployed as of September 30, 2024. As such, we believe the company is well positioned to aggressively deploy additional kiosks and seed future revenue growth.

Get the Full Report

DLH Holdings (DLHC/$7.86 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A New Award
Rating: OUTPERFORM

New Contract. On Monday, DLH was awarded a new Governmentwide Acquisition Indefinite Delivery/Indefinite Quantity contract through the One Acquisition Solution for Integrated Services (OASIS+). OASIS+ is a multi-billion dollar expansive suite program used by various federal agencies such as the Defense Health Agency, CDC, and the DoD, and is expected to grow in usage over the next few years.

Details. Through the contract, DLH will deliver complex professional services and advanced capabilities to various federal agencies. DLH won all five domains for which the Company submitted a bid, including Research and Development Services, Technical and Engineering Services, Intelligence Services and Solutions, Logistics Services and Solutions, and Management and Advisory Services. As a prime awardee of the contract, the base period is five years, with one option for an additional five. 

Get the Full Report

Kratos Defense & Security (KTOS/$28.94 | Price Target: $30)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Award Momentum Continues
Rating: OUTPERFORM

Award Momentum. Hot on the heels of announcing the largest award in Company history, Kratos Defense & Security received two more awards totaling over $107 million. The two new awards continue the award momentum for Kratos, in our view, and suggest a solid growth opportunity for the Company in 2025.

Geolocation Services. Kratos was awarded a Geolocation Global Support Services (GGSS) contract in the amount of $48 million. The Company will provide support services to Space Forces Space electromagnetic interference managers and supporting elements with EMI resolution services. Notably, this award takes advantage of Kratos’ internally funded and constructed, one-of-a-kind, worldwide Space Domain Awareness network.

Get the Full Report

Noble Capital Markets Research Report Wednesday, January 8, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Third Quarter Financial Results Exceed Expectations
Euroseas (ESEA)/OUTPERFORM – Thoughts on Euroseas Planned Spin-Off
MAIA Biotechnology (MAIA)/OUTPERFORM – MAIA Announces Supply Agreement For Second Phase 2 Trial With Three New Indications
V2X (VVX)/OUTPERFORM – Term Loan Repriced; Shares Attractive

AZZ (AZZ/$82.9 | Price Target: $110)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Third Quarter Financial Results Exceed Expectations
Rating: OUTPERFORM

Third quarter financial results. For the fiscal year (FY) 2025, AZZ reported third quarter adjusted net income of $41.9 million or $1.39 per share compared to $34.8 million or $1.19 per share during the prior year period and our estimate of $37.7 million or $1.25 per share. Compared to the prior year period, sales increased 5.8% to $403.6 and exceeded our estimate of $398.5 million. AZZ generated a 24.2% gross margin as a percentage of sales compared to 23.1% during the prior year period and our estimate of 23.3%. Adjusted EBITDA increased 5.0% to $90.7 million, above our estimate of $86.1 million, representing 22.5% of sales versus 22.6% of sales during the third quarter of FY 2024. AZZ narrowed the range of its FY 2025 sales guidance range to $1.550 billion to $1.600 billion, lifted the lower end of adjusted EBITDA to a range of $340 million (from $320 million) to $360 million, and increased adjusted diluted EPS expectations to a range of $5.00 to $5.30 from $4.70 to $5.10.

Debt reduction. During the first nine months of FY 2025, AZZ generated operating cash flow of $185.6 million and reduced debt by $80 million and expects full year debt reduction to exceed $100 million. At quarter end, the company’s net leverage was 2.6 times trailing twelve months EBITDA, and cash and cash equivalents amounted to $1.5 million.

Get the Full Report

Euroseas (ESEA/$35.95 | Price Target: $60)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Thoughts on Euroseas Planned Spin-Off
Rating: OUTPERFORM

Planned spin-off of older vessels. On January 7, Euroseas held an investor call to discuss its planned spin off the company’s three older vessels into a separate company, Euroholdings Ltd., which has applied for a listing on the NASDAQ Capital Market. The three unlevered vessels include M/V Aegean Express, M/V Diamantis P, and M/V Joanna. In exchange for contributing the three vessels, Euroseas will receive 100% of the shares of Euroholdings, which will then be distributed to its shareholders.

Euroseas to modernize its fleet. Following the spin-off, Euroseas will own 22 vessels, including 15 feeder and 7 intermediate containerships with 2 under construction. Euroseas will be positioned to expand its fleet of modern, eco-friendly containerships, with the goal of becoming a significant competitor in the feeder/intermediate containership segment. A modern and fuel-efficient fleet should command premium rates and longer contracts resulting in greater profitability and earnings visibility.

Get the Full Report

MAIA Biotechnology (MAIA/$2.38 | Price Target: $14)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
MAIA Announces Supply Agreement For Second Phase 2 Trial With Three New Indications
Rating: OUTPERFORM

Agreement With BeiGene Covers THIO-102 In 3 Indications. MAIA announced a clinical supply agreement with BeiGene to use its checkpoint inhibitor, Tevimbra (tislelizumab) in combination with THIO in the upcoming Phase 2 THIO-102 trial. The trial will test THIO with tislelizumab in three tumor types. MAIA will avoid the expense of the drug while BeiGene will see clinical data from its PD-1 inhibitor, a recent entry to the market.

The Phase 2 THIO-101 Is On Schedule As THIO-101 Preparations Begin. The Phase 2 THIO-101 trial testing the combination of THIO with Libtayo (cemiplimab, an anti-PD-1 checkpoint inhibitor from Regeneron) in non-small cell lung cancer (NSCLC) is in its final stages. Interim results over the past year have shown meaningful improvements in overall survival (OS) and several other clinical measures of efficacy. Long term patient data is expected in 2H25.

Get the Full Report

V2X (VVX/$46.94 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Term Loan Repriced; Shares Attractive
Rating: OUTPERFORM

Term Loan. V2X successfully repriced its $900 million First Lien Term Loan at 2.25%, a 50 basis point reduction in the interest margin. The interest margin reduction represents approximately $4.5 million of annual interest expense savings. The repricing continues a series of actions that have reduced the cost and outstanding debt. We would remind investors that the Company’s goal was to achieve a net leverage ratio of 3.0x or below by the end of 2024.

Shares Attractive. With VVX shares down from the $68 level just prior to the November 12th stock sale by AIP, we believe the current price represents an attractive risk/reward opportunity. The shares have been pressured by the AIP sale, as well as concerns about the future growth rate of Defense spending, especially given the DOGE focus. We believe these concerns are overblown.

Get the Full Report

Noble Capital Markets Research Report Tuesday, January 7, 2025

Companies contained in today’s report:

FreightCar America (RAIL)/OUTPERFORM – FreightCar America Lowers its Cost of Capital
Graham (GHM)/OUTPERFORM – Raising Price Target
Kratos Defense & Security (KTOS)/OUTPERFORM – Awarded Largest Contract in Company History

FreightCar America (RAIL/$10.24 | Price Target: $14.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
FreightCar America Lowers its Cost of Capital
Rating: OUTPERFORM

Redemption of preferred stock. FreightCar America closed a $115 million four-year term loan on December 31, 2024. The loan is priced at the secured overnight financing rate (SOFR) plus 600 basis points. Proceeds from the term loan were used to redeem all 85,412 shares of Series C preferred stock for a total redemption price of $113,274,739, including accrued dividends of $27,862,739. Recall that the dividends accrued at a rate of 17.5% per annum on the initial stated value of the preferred stock.

Lower cost of capital. The completion of the term loan financing, along with the retirement of the Series C preferred stock, enhances the company’s financial flexibility, cash flow profile, and lowers borrowing costs. Most recently, the secured overnight financing rate was ~4.40%.

Get the Full Report

Graham (GHM/$45.38 | Price Target: $52)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Raising Price Target
Rating: OUTPERFORM

Strong Performance. Since the beginning of November, GHM shares have risen from approximately $30 to over $45, exceeding our $45 price target, which we had raised on November 8th. We believe the positive stock performance reflects investors’ increased awareness of Graham’s current operating performance and future potential.

Defense Opportunity. Graham already has a significant billion dollar plus opportunity with the U.S. Navy. The incoming Trump Administration is likely to drive defense spending at an increased pace, potentially targeting areas in which Graham specializes for even faster growth.

Get the Full Report

Kratos Defense & Security (KTOS/$29.53 | Price Target: $30)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Awarded Largest Contract in Company History
Rating: OUTPERFORM

Award. Kratos announced yesterday that it was awarded a five-year OTA contract for the Multi-Service Advanced Capability Hypersonic Test Bed (MACH-TB) 2.0 under Task Area 1. The total value of this award, if all options are exercised over the five-year period, is  $1.45 billion, which would be the largest contract in the Company’s history.

Tasks. Kratos was awarded the prime role in Task Area 1 Systems Engineering, Integration, and Testing (SEIT), to include integrated subscale, full-scale, and air launch services to address the need to affordably increase hypersonic flight test cadence. Kratos will lead a team of subcontractors that will provide systems engineering, assembly, integration, and test (AI&T), mission planning and execution, and launch services.

Get the Full Report

Noble Capital Markets Research Report Monday, January 6, 2025

Companies contained in today’s report:

Cocrystal Pharma (COCP)/OUTPERFORM – Influenza Trial To Extend Enrollment, Norovirus Trial Data Expected in 1H25
E.W. Scripps (SSP)/OUTPERFORM – Executing on Its Asset Monetization Strategy
Euroseas (ESEA)/OUTPERFORM – Intention to Spin Off Older Vessels into a Separate Company
MustGrow Biologics Corp. (MGROF)/MARKET PERFORM – Completes Acquistion of NexusBioAg
NN (NNBR)/OUTPERFORM – New ABL Facility
Resources Connection (RGP)/OUTPERFORM – Reports 2Q25 Results

Cocrystal Pharma (COCP/$2.35 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Influenza Trial To Extend Enrollment, Norovirus Trial Data Expected in 1H25
Rating: OUTPERFORM

Phase 2a Trial Enrollment To Be Extended. Cocrystal announced plans to extend enrollment for the Phase 2a clinical trial testing its influenza drug, CC-42344. The trial was designed to infect healthy volunteers with a pharmaceutically prepared H3N2 strain of influenza and then test the drug’s effects against the infection. However, the rate of infection was lower than anticipated, so the effects could not be tested.

Volunteers Did Not Develop Robust Influenza Infections. The trial administered influenza virus to healthy volunteers as planned, but there was an unexpectedly low infection rate. The subjects did not have the influenza measures needed to test CC-42344 efficacy. Cocrystal plans to submit a protocol amendment to the UK’s MHPA to extend the enrollment in the study.

Get the Full Report

E.W. Scripps (SSP/$2.5 | Price Target: $10)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Executing on Its Asset Monetization Strategy
Rating: OUTPERFORM

Asset Sale. On December 30, the company completed the sale of its San Diego Tower sites to K2 Towers for $20 million and entered into tower space leases with the buyer for $1 million annually. We view the sale as a favorable step toward the company’s asset monetization strategy. The proceeds from the sales is expected to be used to pare down debt.

Asset monetization. Prior to the asset sale announcement, management highlighted that it had letters of intent for roughly $60 million in real estate transactions and is still shopping Bounce, a leading Over The Air (OTA) broadcast network. Notably, we believe Bounce could be worth more than $150 million. We believe that a sale of Bounce could be announced in the first half 2025. 

Get the Full Report

Euroseas (ESEA/$35.98 | Price Target: $62)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Intention to Spin Off Older Vessels into a Separate Company
Rating: OUTPERFORM

Spin-off of older vessels into a new entity. Euroseas announced that it intends to spin off the company’s three older vessels into a separate company, Euroholdings Ltd., which has applied for a listing on the NASDAQ Capital Market. The three unlevered vessels include M/V Aegean Express, M/V Diamantis P, and the M/V Joanna. In exchange for contributing the three vessels, Euroseas will receive 100% of the shares of Euroholdings, which will then be distributed to its shareholders.

Investor conference call. Euroseas does not expect the spin-off to have any impact on its growth strategy or dividend policy and expects to continue modernizing its fleet. Management believes Euroholding’s valuation will be supported by the company’s fleet profile, capital structure, and higher intended dividend distribution policy. Euroseas management will host a conference call and webcast to discuss the spin-off on January 7 at 9:00 a.m. ET.

Get the Full Report

MustGrow Biologics Corp. (MGROF/$1.25)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Completes Acquistion of NexusBioAg
Rating: MARKET PERFORM

Acquisition Finalized. MustGrow announced the execution and closing of an Asset Purchase Agreement of assets representing NexusBioAg. The purchase price consists of (i) a deferred cash payment of approximately CAD$1,662,000, subject to adjustment in accordance with the terms of the APA; and (ii) earn-out payments equal to a specified percentage amount of gross margin on certain itemized products sold by MGRO in 2025 and 2026.

Financial Impact. Based on historical sales figures, management noted that NexusBioAg brings roughly CAD$15-$20 million of revenue annually to MustGrow and expects this to continue into 2025 and 2026. While no comment was made about the NexusBioAg’s margins, the expectation is that the Nexus side will be cashflow breakeven for 2025 as revenue stays the course. EBITDA is expected to be positive by 2026.

Get the Full Report

NN (NNBR/$3.3 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
New ABL Facility
Rating: OUTPERFORM

New Facility. As part of the ongoing strategic transformation, NN entered into a new ABL facility. The new agreement provides NN with a $50 million revolving credit facility, with proceeds used to repay amounts outstanding under the previous ABL. The new agreement eliminates liquidity covenants under the previous ABL. We view the new ABL as a positive.

Improved Terms. The new ABL comes with improved terms, an indicator of the markets growing confidence in NN. The maturity date has been pushed out until December 2029, assuming the term loan is refinanced. The fee structure is lower across the board. And, most significantly, the interest rate should be lower. Based on the current one-month SOFR rate, the interest rate would be approximately 6%, down from approximately 7.2% at the end of September.

Get the Full Report

Resources Connection (RGP/$9.08 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Reports 2Q25 Results
Rating: OUTPERFORM

2Q25 Results. RGP exceeded expectations in 2Q25 with sequential improvement in revenue, gross margin, run rate SG&A, and adjusted EBITDA. Revenue totaled $145.6 million, up 6.3% sequentially (up 5% on a constant currency basis), but fell 10.7% (down 13.2% constant currency) y-o-y. Gross margin of 38.5% was up 200 bp sequentially, and nearly flat with the prior year’s 38.9%. RGP reported adjusted EPS of $0.18 in 2Q25 compared to $0.25 a year ago.

Green Shoots. RGP is seeing early signs of success in its new strategy, although the market remains choppy. Management highlighted cross selling opportunities and success on pipeline activities and client dialogue this quarter. Management is cautiously optimistic the new calendar year will bring a stronger demand environment.

Get the Full Report

Noble Capital Markets Research Report Friday, January 3, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Favorable Outlook Through FY 2026; Increasing Estimates

AZZ (AZZ/$82.9 | Price Target: $110)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Favorable Outlook Through FY 2026; Increasing Estimates
Rating: OUTPERFORM

Corporate guidance for fiscal year 2025. Following AZZ’s strong second quarter earnings report for fiscal year 2025, the company maintained its FY 2025 sales guidance range of $1.525 billion to $1.625 billion, lifted the lower end of adjusted EBITDA to a range of $320 million to $360 million, and increased adjusted diluted EPS expectations to a range of $4.70 to $5.10. During the company’s second quarter investor conference call, management indicated that AZZ had experienced a strong start to the third quarter of fiscal year 2025. Moreover, the tone seemed to indicate that the company’s fiscal year 2025 guidance was grounded in conservative assumptions knowing that the latter half of the fiscal year is generally weaker than the first half due to seasonality. 

Updating estimates. We have increased our FY 2025 EBITDA and EPS estimates to $346.8 million and $5.05, respectively, from $344.8 million and $5.00. The revisions are driven mostly by higher third quarter margin expectations. Our estimates for FY 2026 revenue, EBITDA, and EPS have been increased to $1.675 billion, $371.5 million, and $5.70, respectively, from $1.673 billion, $367.4 million, and $5.60. We think the incoming Trump administration could support pro-growth economic policies that could favorably impact AZZ’s business.

Get the Full Report

Noble Capital Markets Research Report Thursday, January 2, 2025

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – Executes an MSA with a New Client
FAT Brands (FAT)/OUTPERFORM – New Locations

Bit Digital (BTBT/$2.93 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Executes an MSA with a New Client
Rating: OUTPERFORM

MSA Underway. On Tuesday, Bit Digital announced the execution of an MSA with an AI Compute Fund managed by DNA Holdings Venture Inc., a new client. The MSA execution builds on the term sheet signed and disclosed on November 20, 2024. The contract provides for 576 Nvidia H200 GPUs over a two-year term and represents an aggregate revenue opportunity of roughly $20.2 million, or $10.1 million annually, and is expected to commence February 2025.

GPUs Ordered. To fulfill the contract, Bit Digital will use GPUs that are currently on order and awaiting delivery to a third-party data center in Iceland. Earlier in December, the Company ordered 130 H200 servers (or 1,040 GPUs) for approximately $30 million. Of those servers, 72 of them will be supplied to the customer, and management expects to deploy the remainder of the servers to separate customer contracts.

Get the Full Report

FAT Brands (FAT/$5.32 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
New Locations
Rating: OUTPERFORM

Business Update. With 2024 coming to a close and the focus on the Twin Hospitality distribution, we wanted to review the ongoing business in terms of new openings for additional expansion. As we have emphasized in the past, the continuing expansion of the overall operating units provides a “cost free” means of improving overall adjusted EBITDA for FAT Brands.

New Openings. Since the beginning of November, or since FAT Brands reported third quarter results, the Company has announced the opening of a number of new locations, including a Hurricane Grill & Wings location in a Six Flags Great Escape Lodge in upstate NY, a Johnny Rockets in the Soaring Eagle Casino Resort in MI, a Pretzelmaker location in Clear Lake, IA, the fifth Round Table Pizza in Reno, NV, and five new locations for Great American Cookies and Marble Slab Creamery in Texas.

Get the Full Report

Noble Capital Markets Research Report Tuesday, December 31, 2024

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – A Tier-3 Data Center Site Acquired
Comstock (LODE)/MARKET PERFORM – Comstock Plants a Flag in Pakistan

Bit Digital (BTBT/$3 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Tier-3 Data Center Site Acquired
Rating: OUTPERFORM

New Site. Yesterday, Bit Digital announced the acquisition of real estate and a building for a “build-to-suit” 5MW Tier-3 data center in Montreal, Canada. The 160,000 square feet site was purchased for CAD $33.5 million (or $23.3 million assuming a CAD/USD exchange rate of 0.70) and closed on December 27, 2024. The Company funded the purchase with cash on hand and is in the process of securing mortgage financing for the site acquisition and subsequent infrastructure capex. A new customer is expected to fill the capacity with new-generation Nvidia GPUs.

Building the Site Up. Bit Digital expects to spend roughly CAD $27.6 million (or $19.3 million) to develop the site to meet Tier-3 standards. The initial gross load for the site is at 5MW, which has the potential to expand, allowing scalability by market demand. In our view, the potential allows for the expansion of an owned site with an average cost per MW of $8 million, below market rates. Development is expected to be completed and operational by May 2025.

Get the Full Report

Comstock (LODE/$0.88)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Comstock Plants a Flag in Pakistan
Rating: MARKET PERFORM

License agreement with Gresham’s Eastern Ltd. Comstock Inc. announced the execution of an agreement between Comstock Fuels and Gresham’s Eastern (Pvt) Ltd., a sustainable energy engineering, equipment, and construction company based in Pakistan, pursuant to which Comstock Fuels will grant Gresham’s exclusive project and site development rights in Pakistan. The agreement will allow Gresham’s to utilize Comstock Fuels’ proprietary and patented lignocellulosic biomass refining technologies to produce sustainable aviation fuel and other renewable fuels in Pakistan.

Demonstration facility in Pakistan. Gresham’s will lead the development, financing, construction, and management of renewable fuel production facilities based on Comstock Fuel’s proprietary Bioleum refining technologies. Gresham’s will develop an initial demonstration facility in Lahore, Pakistan capable of processing 75,000 metric tons of biomass annually with the potential to scale up to a 1,000,000 metric ton per year facility. Site-specific license agreements associated with each Bioleum refinery will help ensure compliance with Comstock Fuels’ performance and quality standards.

Get the Full Report

Noble Capital Markets Research Report Monday, December 30, 2024

Companies contained in today’s report:

Commercial Vehicle Group (CVGI)/OUTPERFORM – CVG Amends its Credit Agreement

Commercial Vehicle Group (CVGI/$2.34 | Price Target: $8)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
CVG Amends its Credit Agreement
Rating: OUTPERFORM

New Amendment. As CVG continues to implement strategic portfolio actions, including paying down debt to create a more streamlined, lower cost entity, the Company amended its credit agreement. In the amendment, CVG’s existing term loan facility is reduced to $85 million from $175 million, while the revolving credit facility is reduced to $125 million from $150 million. At the end of September, CVG had approximately $115 million outstanding under the term loan and $14 million outstanding under the revolver. The maturity date of the credit facilities remains May 12, 2027.

Rate Changes. The new amendment altered the rate and leverage table. If the leverage ratio is 4:1 or above, the maximum SOFR loan rate is now at SOFR +3.25%, and the base rate loan is now at base rate +2.25%. Previously, the maximum rates of  SOFR +2.75% and base +1.75% were hit at a leverage ratio of 3.5:1.

Get the Full Report

Noble Capital Markets Research Report Friday, December 27, 2024

Companies contained in today’s report:

Comtech Telecommunications (CMTL)/MARKET PERFORM – What’s Up With CMTL Shares?
Xcel Brands (XELB)/OUTPERFORM – A Noisy Quarter, But In Line With Expectations

Comtech Telecommunications (CMTL/$4.37)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
What’s Up With CMTL Shares?
Rating: MARKET PERFORM

Share Price and Volume Action. CMTL shares have experienced some unusual price and volume action recently. With the share price rising each day over the past week, someone is feeling positive about CMTL. Could the recent action suggest a deal for the sale of the Terrestrial and Wireless segment is closer? Business conditions are improving? Something else? While the answer is unknown at this point, CMTL shares bear watching, in our view.

Recent Action. CMTL shares closed at $3.01 on December 19th. The next day, the shares rose to $3.69 on a volume of 2,132,200 shares, about five times ADV. On December 23rd, another 1,074,900 shares were traded, with the stock closing at $3.89. Yesterday, 866,278 shares were traded, with CMTL closing at $4.37, with an intraday high of $4.57, meaning CMTL shares have appreciated over 45% over the past week.

Get the Full Report

Xcel Brands (XELB/$0.52 | Price Target: $1.75)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
A Noisy Quarter, But In Line With Expectations
Rating: OUTPERFORM

Q3 Results. The company reported Q3 revenue and adj. EBITDA of $1.9 million and a loss of $1.0 million, respectively, both of which were largely in line with our forecast, as illustrated in Figure #1 Q3 Results. Notably, the quarter was impacted by Hurricanes, which led to canceled shows and delayed sales, resulting in roughly $500,000 of lost revenue. Importantly, we believe the company’s long term growth outlook remains favorable.

Looking past the Noise. In Q3, the company recorded a non-cash charge of $6.3 million, which is related to its equity interest in Isaac Mizrahi. The write-down anticipates that the company may not meet the minimum royalty threshold in 2025, which would result in a decrease in its ownership interest in Isaac Mizrahi from 30% to 17.5%.

Get the Full Report

Noble Capital Markets Research Report Thursday, December 26, 2024

Companies contained in today’s report:

Perfect (PERF)/OUTPERFORM – Turning on the Acquisition Engine

Perfect (PERF/$2.22 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Turning on the Acquisition Engine
Rating: OUTPERFORM

Acquisition of Wannaby. On December 24, the company announced that it has entered into an agreement to acquire Wannaby from Fartech, a British e-commerce company. Wannaby is a virtual try-on technology operation that focuses on shoes and accessories, such as handbags. The addition of Wannaby’s technology is set to expand Perfect’s suite of virtual try-on capabilities. 

Expanding service offering. The addition of Wannaby’s virtual try-on capabilities should open new revenue verticals. It also allows the company to provide a more all-encompassing suite of virtual try-on services to existing and perspective brand clients. We believe this will bolster the company’s competitive position and could lead to higher B2B contract values and enhanced revenue growth. 

Get the Full Report

Noble Capital Markets Research Report Tuesday, December 24, 2024

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Partnership Seeks to Enhance Low Carbon Renewable Fuel Yields

Comstock (LODE/$0.39)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Partnership Seeks to Enhance Low Carbon Renewable Fuel Yields
Rating: MARKET PERFORM

Partnership with Emerging Fuels Technology, Inc. (EFT). Under terms of a Technology Cooperation Agreement, Comstock will enter into a Master License Agreement with Emerging Fuels Technology, Inc. (EFT) to integrate EFT’s gas-to-liquids (GTL) process into Comstock’s renewable fuel solutions to capture and convert carbon emissions into emissions derived renewable fuels. Commercialization of existing and future Comstock Fuels Corporation’s renewable fuel technologies, including those developed through its partnership with EFT, will be managed exclusively by Comstock Fuels.

The goal. Integrating EFT’s GTL process to convert process emissions offers the potential to increase Comstock’s bulk biomass conversion yields to more than 140 gasoline gallon equivalents (GGE) and greater than 70% of the maximum yield from most forms of woody biomass. Because up to 20% of feedstock value could otherwise be lost to process emissions, converting a portion of the losses into additional yield with EFT’s commercial solution could enhance market adoption of the companies’ combined offering.

Get the Full Report

Noble Capital Markets Research Report Monday, December 23, 2024

Companies contained in today’s report:

Maple Gold Mines (MGMLF)/OUTPERFORM – Setting Up for an Eventful 2025

Maple Gold Mines (MGMLF/$0.04 | Price Target: $0.25)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Setting Up for an Eventful 2025
Rating: OUTPERFORM

Completion of the restructuring transaction. As expected, Maple Gold Mines recently completed its joint venture restructuring transaction with Agnico Eagle Mines Ltd. (NYSE, AEM). Maple has legal title to and a 100% ownership interest in the Douay Gold Project with gold mineral resources exceeding 3.0 million ounces and the past-producing, high-grade Joutel Gold Project. Both projects are located along the Casa Berardi-Douay Gold Trend in the renowned Abitibi Greenstone Gold Belt in Quebec, Canada.

Upcoming drilling program. Maple Gold’s fully funded drilling program is expected to commence shortly and run through March. The company is using a data-driven approach toward exploration that is focused on expanding the company’s gold mineral resource from approximately three million ounces to five million ounces across the combined Douay/Joutel projects, along with making new discoveries. An updated resource estimate and scoping study is expected to be completed within the next 12 to 18 months (Refer to our research note dated December 12 for more details).

Get the Full Report

Noble Capital Markets Research Report Friday, December 20, 2024

Companies contained in today’s report:

Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – $182 Million of Awarded Work
Steelcase (SCS)/OUTPERFORM – Reports Third Quarter Results

Great Lakes Dredge & Dock (GLDD/$11.55 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
$182 Million of Awarded Work
Rating: OUTPERFORM

Awarded Work. Great Lakes announced an additional $182 million of awarded work across four projects. The new projects were part of the $465 million of low bids and options pending as of the end of the third quarter. The new awards will add to a record backlog of work for 2025 and are likely to keep Great Lakes’ fleet fully engaged during the year. The projects are all for coastal protection.

Projects. Ocean City Beach Renourishment in New Jersey is valued at $73.6 million. This project also includes an additional $41.4 million in open options pending award. This project will start in 1Q25 and is expected to be completed in 3Q25. Myrtle Beach Renourishment in South Carolina is valued at $72.3 million. Work is expected to start in 4Q25 and be completed in 1Q26. Both projects were awarded by the U.S. Army Corps of Engineers.

Get the Full Report

Steelcase (SCS/$12.32 | Price Target: $16)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Reports Third Quarter Results
Rating: OUTPERFORM

3Q25 Results. Revenue was $794.9 million, up 2.1% y-o-y, with higher revenue from government, large corporate, healthcare, and education customers as the drivers. Organic revenue was up 3%, with Americas up 7% and International off 8%. Gross margin came in at 33.4%, up 100 bp y-o-y. GAAP EPS totaled $0.16 versus $0.26, while adjusted EPS was $0.30 versus $0.29.

Green Shoots. Orders in the first three weeks of 4Q25 grew 15% y-o-y. Internationally, Steelcase is seeing higher project activity levels, with recent wins related to large opportunities with national accounts in France, Germany, and the Middle East. Continuation of such trends would bode well for future performance.

Get the Full Report

Noble Capital Markets Research Report Wednesday, December 18, 2024

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Investment Rating Lowered to Market Perform
Cumulus Media (CMLS)/MARKET PERFORM – Highlights From NobleCon20
MAIA Biotechnology (MAIA)/OUTPERFORM – Pediatric Designation Qualifies THIO For A Priority Review Voucher
Tonix Pharmaceuticals (TNXP)/OUTPERFORM – Tonix Announces FDA Acceptance Of NDA For Review

Comstock (LODE/$0.37)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Investment Rating Lowered to Market Perform
Rating: MARKET PERFORM

Reassessing the path to commercialization. We are lowering our investment rating to a Market Perform from Outperform. While Comstock has made significant progress advancing its business unit plans, we think the path toward commercializing its Fuels and Metals businesses could take longer than we previously expected and is subject to a number of risk factors, including execution and financing. Based on the company’s liquidity, anticipated capital requirements, risk and reward profile, and lead time associated with commercializing its businesses, we think a Market Perform is appropriate.

SBC Commerce transaction. In August, Comstock announced a significant and promising transaction with SBC Commerce LLC (SBCC), a U.S. based private equity group, to directly invest in each of Comstock’s businesses and acquire Comstock’s properties in Silver Springs, Nevada. Our previous valuation and price target were based in part on the implied value of the transaction. To date, no definitive agreement has been announced with SBC Commerce, and it is unclear to us whether the transaction will close as contemplated. We look forward to an update and will wait to assess any final agreement(s).

Get the Full Report

Cumulus Media (CMLS/$0.75)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From NobleCon20
Rating: MARKET PERFORM

NobleCon20. On December 4, Frank Lopez-Balboa, CFO, presented at NobleCon20 at Florida Atlantic University (FAU) in Boca Raton, Florida, to the investment community. A replay of the presentation can be viewed here. Notably, the presentation highlighted the prospect of digital revenue growth, a national advertising recovery, which accounts for roughly 50% of revenue, and its sizeable cost reduction efforts.

Digital Outlook. Notably, digital revenue has been a bright spot for the company throughout 2024, given that revenue growth has been positive every quarter. Mr. Frank Lopez-Balboa highlighted his optimism about the company’s digital growth prospects, stating it could generate north of $200 million in revenue a few years from now. Moreever, digital offers healthy contribution margins. 

Get the Full Report

MAIA Biotechnology (MAIA/$2.2 | Price Target: $14)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Pediatric Designation Qualifies THIO For A Priority Review Voucher
Rating: OUTPERFORM

Successful Development Could Qualify For A Valuable Asset. Maia announced that THIO has received FDA designation as a drug for a rare pediatric disease (RPD) when used to treat pediatric-type diffuse high-grade gliomas (PDHGG). This designation makes MAIA eligible to receive a Priority Review Voucher (PRV) upon approval. The PRV can be redeemed for priority review for a different new drug application or sold to another company. During 2024, PRVs have been sold for between $100 million and $158 million.

Data In Pediatric Brain Cancer Was Presented In April 2024. MAIA presented clinical data testing THIO in the PDHGG indication at the American Association for Cancer Research (AACR) Annual Meeting in April 2024. Patients with a highly aggressive subtype of PDHGG known as diffuse intrinsic pontine glioma (DIPG) were treated with ionizing radiation and THIO. The results showed significant decreases in cell proliferation and anti-cancer effects.

Get the Full Report

Tonix Pharmaceuticals (TNXP/$0.33 | Price Target: $4)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Tonix Announces FDA Acceptance Of NDA For Review
Rating: OUTPERFORM

New Drug Application For Tonmya Accepted For Review. Tonix announced that the FDA has accepted the filing of the Tonmya NDA, showing that the application met the requirements for a full review. Tonmya received Fast Track designation, and an application for Priority Review was filed. Next, notification of the assigned PDUFA date (the statutory date for completing a review under the Prescription Drug User Fee Act) and Priority Review status are expected in about 14 days.

We Believe Tonmya Can Have A Significant Impact On Fibromyalgia Treatment. Symptoms of fibromyalgia include chronic pain, insomnia, depression, brain fog, fatigue, and abdominal cramps with varying severity. This variety of physical and cognitive symptoms has been treated with a combination of pain medications, anti-depressants, insomnia drugs, and neurological drugs. Tonmya is the first drug that was developed for fibromyalgia. Its clinical trials showed strong statistical significance in its primary endpoint (pain reduction) and all six secondary endpoints. No other single drug has shown this broad effect on multiple fibromyalgia symptoms.

Get the Full Report

Noble Capital Markets Research Report Tuesday, December 17, 2024

Companies contained in today’s report:

Comtech Telecommunications (CMTL)/MARKET PERFORM – Late 1Q25 Financials
Lucky Strike Entertainment (LUCK)/OUTPERFORM – A New Chapter as Lucky Strike
The GEO Group (GEO)/MARKET PERFORM – An Investment and a Leadership Change
Townsquare Media (TSQ)/OUTPERFORM – Timeliness Appears To Have Improved

Comtech Telecommunications (CMTL/$3.3)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Late 1Q25 Financials
Rating: MARKET PERFORM

A NT10-Q. Comtech missed the deadline for filing its 10-Q for the period ended October 31, 2024, the first quarter of the Company’s fiscal 2025. Unfortunately, this is another late filing, following an NT10-K for the 2024 fiscal year and an NT10-Q for the fiscal third quarter of 2024. We are hopeful the Company will be able to file the required documents shortly.

Reasons. According to the 12b-25 filing, Comtech is unable to file on a timely basis due to “the Company’s ongoing efforts to finalize its condensed consolidated financial statements, which include: (i) its recoverability assessments of (x) receivables and contract assets related to a certain international reseller of our troposcatter technologies, and (y) goodwill and certain long-lived assets due to the Company’s ongoing evaluation of its strategic transformation plans; and (ii) the accounting for and presentation of certain debt instruments and exchanges of convertible preferred shares.”

Get the Full Report

Lucky Strike Entertainment (LUCK/$10.52 | Price Target: $17.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
A New Chapter as Lucky Strike
Rating: OUTPERFORM

Complete rebrand to Lucky Strike. On December 12, the company announced that it had completed its recently announced rebranding to Lucky Strike Entertainment, which was effective on December 16th. The newly branded company will trade on the NYSE under the symbol “LUCK” as of today.

An acquired brand. The company acquired Lucky Strike Entertainment in September of last year. At that time, management noted that the company would test the brand strength of Lucky Strike in comparison with the Bowlero brand. We believe that Lucky Strike has a strong brand presence and is a compelling change for the company. 

Get the Full Report

The GEO Group (GEO/$27.73)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
An Investment and a Leadership Change
Rating: MARKET PERFORM

Ramping Up. The GEO Group announced a $70 million investment to expand the Company’s detention capacity, secure transportation, and electronic monitoring services to U.S. Immigration and Customs Enforcement (“ICE”). Already the largest services provider to ICE, GEO is currently providing approximately 21,000 detention beds (with a present census of 14,000) at 16 ICE Processing Centers with the ability to expand to a minimum of 32,000 beds at 23 facilities.

Financing. To help offset the $70 million investment in capital expenditures and further reduce debt, GEO intends to pursue the possible sale of several underperforming company-owned state correctional facilities. Any potential sale of facilities will depend, at least partially, on valuation, but we view this positively.

Get the Full Report

Townsquare Media (TSQ/$10.08 | Price Target: $21)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Timeliness Appears To Have Improved
Rating: OUTPERFORM

Digital revenue trends are improving. On December 4, Stu Rosenstein, CFO, presented at NobleCon20 at Florida Atlantic University (FAU) in Boca Raton, Florida, to the investment community. A replay of the presentation can be viewed here. Notably, we believe the company’s digital businesses are gaining momentum, and we anticipate an acceleration of revenue growth for Ignite and a swing towards positive growth for Interactive.

Townsquare Interactive posed to turn the corner toward revenue growth. Notably, the company’s Interactive business has been experiencing improving revenue trends and net subscriber growth throughout 2024. Furthermore, we believe the interactive business has turned the corner in Q3 and will swing towards positive revenue growth in Q4.

Get the Full Report

Noble Capital Markets Research Report Monday, December 16, 2024

Companies contained in today’s report:

Aurania Resources (AUIAF)/OUTPERFORM – Looking Ahead to a Catalyst-Rich 2025
Vince Holding Corp. (VNCE)/OUTPERFORM – A Closer Look At The Recent Quarter

Aurania Resources (AUIAF/$0.313 | Price Target: $0.6)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Looking Ahead to a Catalyst-Rich 2025
Rating: OUTPERFORM

Private placement financing. Aurania announced the closing of the first tranche of its recently announced private placement of up to 8,888,888 units at a price of C$0.45 per unit to raise gross proceeds of up to C$4,000,000. In the first tranche, a total of 2,726,499 units were sold for gross proceeds of C$1,226,924.55. Each unit is comprised of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at an exercise price of C$0.75 for a period of 24 months following the closing of the first tranche. The net proceeds will be used to fund exploration in France including impact studies, exploration programs at key targets in Ecuador, and working capital.

Preparing for 2025. In November, Aurania commenced an induced polarization (IP) geophysical survey over its Kuri-Yawi epithermal gold target at the company’s Lost Cities-Cutucu project in southeastern Ecuador. The IP survey is designed to identify deep conductors that could correspond to gold mineralization and to target drill holes for the planned program in 2025. The IP survey is expected to be completed this month with results expected in early 2025 following a review and interpretation of the data.

Get the Full Report

Vince Holding Corp. (VNCE/$1.57 | Price Target: $3)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
A Closer Look At The Recent Quarter
Rating: OUTPERFORM

Solid Q3 Results. The company reported favorable Q3 revenue of $80.2 million and adj. EBITDA of $7.1 million, both of which were in line with our estimates of $81.5 million and $7.0 million, respectively. Furthermore, gross margin improved by 580 basis points from the prior year period. In our view, the solid results demonstrate the efficacy of the company’s initiatives to enhance its expense structure and improve gross margins.

Improved gross margin. The company’s strong gross margin improvement was largely driven by a 480bp improvement in product costs and reduced freight costs, with an 80bp contribution from lower promotional activity and discounting in its Direct To Consumer (DTC) segment. 

Get the Full Report

Noble Capital Markets Research Report Friday, December 12, 2024

Companies contained in today’s report:

1-800-Flowers.com (FLWS)/OUTPERFORM – Highlights From NobleCon20
Conduent (CNDT)/OUTPERFORM – Highlights from NobleCon20
Snail (SNAL)/OUTPERFORM – Highlights From NobleCon20

1-800-Flowers.com (FLWS/$7.94 | Price Target: $14)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From NobleCon20
Rating: OUTPERFORM

NobleCon20. On December 3rd, management presented at NobleCon20 at Florida Atlantic University (FAU) in Boca Raton, Florida, to the investment community. The presentation conducted by Bill Shea, CFO, highlights the company’s strategic initiatives to grow revenue and return to a normalized gross margin. A replay of the presentation can be viewed here.

A transitional year. Revenue guidance is flat to down mid single digits, but should start to grow again next year. The key growth drivers are expected to be led by its innovation initiatives, introduction of new products (ie. most recently, Cheryl’s Ice Cream, Wolferman’s New York Style Bagels, and Greeting Cards), bundling products (ie. Harry & David’s baskets with Shari’s Berries), products with new price points, and driving repeat customers. Plus, the company believes there is more to do with its 1.1 million Passport Loyalty customers, which is 10% of its customer base but accounts for over 20% of its revenues.

Get the Full Report

Conduent (CNDT/$4.32 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Highlights from NobleCon20
Rating: OUTPERFORM

NobleCon20. On December 3, management presented at NobleCon20 at Florida Atlantic University (FAU) in Boca Raton, Florida. Giles Goodburn, Global Head of FP&A and Investor Relations, highlighted the company’s ongoing transformation to a leaner, more focused organization. A replay of the presentation can be found here.

Business transformation underway. Since the start of 2024, the company has completed several divestitures totaling roughly $780 million in net proceeds. This has allowed the company to make significant balance sheet improvements. The company is also in the process of cutting corporate overhead and various stranded costs following the recent divestitures. Moreover, with an infusion of new business leaders across its three segments we believe the company is positioning itself for future revenue growth as a more focused and efficient organization.  

Get the Full Report

Snail (SNAL/$1.4 | Price Target: $4)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From NobleCon20
Rating: OUTPERFORM

NobleCon20. On December 3rd, management presented at NobleCon20 at Florida Atlantic University (FAU) in Boca Raton, Florida, to the investment community. The presentation conducted by Tony Tian, CEO, and Heidy Chow, CFO, highlighted the company’s release roadmap, strategy, and unique offerings. A replay of the presentation can be viewed here.

Release roadmap. There are five free Downloadable Content (DLC) packages that are included in the sale of  Ark: Survival Ascended (ASA), three of which have not been released yet. The next DLC is expected in Q4, and two more are expected in 2025. Importantly, as DLC packages included in ASA are released, the company will defer less revenue from ASA sales, which should provide investors with a clearer picture of company operating results. 

Get the Full Report

Noble Capital Markets Research Report Thursday, December 12, 2024

Companies contained in today’s report:

Maple Gold Mines (MGMLF)/OUTPERFORM – Thoughts on the Winter 2024/2025 Exploration and Drilling Program
Resources Connection (RGP)/OUTPERFORM – Workforce Reduction Initiated; Confirms 2Q25 Guidance
The GEO Group (GEO)/MARKET PERFORM – NobleCon20 Highlights
The ODP Corporation (ODP)/OUTPERFORM – Presentation Highlights from NobleCon20

Maple Gold Mines (MGMLF/$0.04 | Price Target: $0.25)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Thoughts on the Winter 2024/2025 Exploration and Drilling Program
Rating: OUTPERFORM

NobleCon20 presentation. During Noble’s recent NobleCon20 Annual Emerging Growth Equity Conference, Mr. Kiran Patankar, Maple Gold’s CEO, provided some additional details regarding the company’s upcoming exploration and drilling program. A link to Maple Gold’s NobleCon20 presentation is here. Recall that Maple Gold has a 400 square kilometer district-scale property in Quebec’s Abitibi Greenstone Gold Belt, including gold mineral resources of approximately three million ounces at Douay with significant expansion potential and the past producing Telbel and Eagle West mines at Joutel.

Upcoming drilling program. Maple Gold’s fully funded drilling program is expected to commence shortly and run through March. The company is using a data-driven approach toward exploration that is focused on expanding the company’s gold mineral resource from approximately three million ounces to five million ounces across the combined Douay/Joutel projects, along with making new discoveries. An updated resource estimate and scoping study is expected to be completed within the next 12 to 18 months.

Get the Full Report

Resources Connection (RGP/$8.81 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Workforce Reduction Initiated; Confirms 2Q25 Guidance
Rating: OUTPERFORM

Workforce Reduction. We had an opportunity to speak with management about the December 6th 8-k filing in which Resources Connection announced a reduction in the global management and administrative workforce intended to enhance efficiencies through reduced costs and streamlined operations. The RIF impacts about 8% of the management and administrative workforce. Cost savings are expected to range from $4-$5 million in 2H25, or $8-$10 million annually on a go-forward basis. Restructuring charges of $2.5-$3.0 million are expected to be recognized in the third quarter of fiscal 2025.

But Reaffirming 2Q25 Guidance. Management re-confirmed guidance for 2Q25 (ended November 23, 2024). For 2Q25, the Company expects full quarter revenue to be in the range of $135-$140 million and expects gross margin to be in the range of 36% to 37%. The Company’s run rate SG&A for the quarter is expected to be in the range of $48-$50 million.

Get the Full Report

The GEO Group (GEO/$27.8)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
NobleCon20 Highlights
Rating: MARKET PERFORM

NobleCon20. The GEO Group CEO Brian Evans presented at NobleCon20. Highlights included potentially improving segment trends, an aging prison infrastructure, and reducing debt to be more flexible. A rebroadcast is available at https://www.channelchek.com/videos/the-geo-group-noblecon20-replay.

Segment Trends. With the new Trump administration approaching in January, management notes the administration’s immigration enforcement policies may positively impact its detention capacity, electronic monitoring, and secure transportation businesses. GEO remains poised to capitalize on any increase in detention and/or enhanced supervision with roughly 8,000 beds at existing facilities and 10,000 beds at six company-owned currently idle facilities. In addition, ISAP populations were roughly double today’s level two years ago.

Get the Full Report

The ODP Corporation (ODP/$28.29 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Presentation Highlights from NobleCon20
Rating: OUTPERFORM

NobleCon20. The ODP Corporation Co-CFO Adam Haggard and VP of IR Tim Perrott presented at NobleCon20. Highlights included are the Company’s pivot towards B2B, targeting new markets, and the return of value to shareholders. 

B2B Pivot. Noted in our previous report, ODP is accelerating its B2B pivot through leveraging its nationwide supply chain, extensive B2B customer base, compelling value proposition, and strong balance sheet. A recent B2B win involves the Company’s ODP Business Solutions with a recent key contract win that is worth up to $1.5 billion over 10 years. Another involves Veyer with a major contract with one of the world’s largest social media focused e-commerce companies to deliver warehouse and fulfillment services for their online sales. In our view, both contracts represent management’s focus on its efforts within the space.

Get the Full Report

Noble Capital Markets Research Report Wednesday, December 11, 2024

Companies contained in today’s report:

FAT Brands (FAT)/OUTPERFORM – Highlights from NobleCon20
Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – NobleCon20 Highlights
V2X (VVX)/OUTPERFORM – A New JV
Vince Holding Corp. (VNCE)/OUTPERFORM – Q3 Is Illustrative Of Its Improving Margin Story

FAT Brands (FAT/$5.53 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Highlights from NobleCon20
Rating: OUTPERFORM

NobleCon20. FAT Brands Chairman Andy Wiederhorn presented at NobleCon20. Highlights included FAT Brands’ acquisition strategy, Twin Peaks spin-off, and focus for 2025. A rebroadcast is available at https://www.channelchek.com/videos/fat-brands-inc-noblecon20-replay

Acquisition Strategy. Management noted the Company utilizes a near-term focus on brands that will accelerate growth for its Twin Peaks brand as well as drive revenue and profit at its cookie and pretzel factory. Smokey Bones is an example of accelerating Twin Peaks growth as select Smokey Bones are being converted into Twin Peaks due to having a similar format, providing more efficient conversions. The Nestle Toll House Café by Chip acquisition drove unit growth of Great American Cookies while also getting cookie dough business for its manufacturing facility.

Get the Full Report

Great Lakes Dredge & Dock (GLDD/$12.66 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
NobleCon20 Highlights
Rating: OUTPERFORM

NobleCon20. Great Lakes CFO Scott Kornblau presented at NobleCon20. Highlights included the strong dredging market, expanding into the offshore wind market in the U.S., and having a record backlog. A rebroadcast is available at https://www.channelchek.com/videos/great-lakes-dredge-dock-corporation-noblecon20-replay.

Dredging Market. The outlook for the dredging market remains robust, in our view. The Army Corps of Engineers budget in fiscal 2024 was a record $8.7 billion, a record that likely will be surpassed in fiscal 2025 as both the House and Senate appropriations committees submitted proposed fiscal 2025 budgets with Army Corp funding at or above the $10 billion level. We expect Great Lakes’ bid opportunity pipeline to remain strong, leading towards potential backlog and revenue growth.

Get the Full Report

V2X (VVX/$59.49 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A New JV
Rating: OUTPERFORM

JV. Yesterday, V2X, Inc. announced a strategic joint venture with Parsons Corporation (NYSE: PSN) in pursuit of the National Science Foundation Antarctica Science and Engineering Support Contract (ASESC) with an $8 billion ceiling value. The newly formed joint venture, named Polar Science Alliance (PSA), is a wholly dedicated entity that will enable world class scientific research support services for the United States Antarctic Program (USAP) over the next two decades.

Strengths. V2X brings over a decade of experience in large-scale polar operations and logistics expertise and was recently awarded the follow-on option for a ten year period supporting the multibillion-dollar U.S. Space Force, Pituffik Space Base in Greenland. V2X boasts decades of expertise in science support services. Parsons has 55 years of successful and proven polar operations experience, beginning in 1970 on the North Slope of Alaska. Parsons’ capabilities span program and construction management, engineering and planning, and logistics.

Get the Full Report

Vince Holding Corp. (VNCE/$1.69 | Price Target: $3)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Q3 Is Illustrative Of Its Improving Margin Story
Rating: OUTPERFORM

Q3 Results. The company reported Q3 revenue of $80.2 million, which was in line with our estimate of $81.5 million. Notably, gross margin improved by 580 basis points from the prior year period. We believe the solid results demonstrate the efficacy of the company’s initiatives to enhance its expense structure andimprove gross margin.

Improved gross margin. The company’s strong gross margin improvement was largely driven by a 480bp improvement in product costs and reduced freight costs, with an 80bp contribution from lower promotional activity and discounting in its Direct To Consumer (DTC) segment. 

Get the Full Report

Noble Capital Markets Research Report Tuesday, December 10, 2024

Companies contained in today’s report:

E.W. Scripps (SSP)/OUTPERFORM – Highlights From NobleCon20
GDEV (GDEV)/OUTPERFORM – Highlights From NobleCon20: Geared For Growth
GeoVax Labs (GOVX)/OUTPERFORM – GeoVax Receives Allowance For New Patent Covering Vaccine Platform Technologies
Graham (GHM)/OUTPERFORM – NobleCon20 Presentation Highlights
Information Services Group (III)/OUTPERFORM – Highlights from NobleCon20
NN (NNBR)/OUTPERFORM – Presentation Highlights from NobleCon20

E.W. Scripps (SSP/$2.36 | Price Target: $10)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From NobleCon20
Rating: OUTPERFORM

NobleCon20. On December 3rd, management presented to the investment community at NobleCon20, held at Florida Atlantic University (FAU) in Boca Raton, Florida. The fireside chat presentation with Jason Combs, Chief Financial Officer, highlighted the company’s strategy regarding Scripps Sports, retransmission revenue, political revenue and debt reduction. A replay of the presentation can be viewed by clicking here.

Favorable sports model. Scripps Sports employs a unique model that offers sports teams wider viewership than the traditional Regional Sports Networks (RSNs) model, which is failing. Notably, the company has local broadcasting rights for the Las Vegas Golden Knights, Florida Panthers, and the Arizona Coyotes. Furthermore, the company has the national broadcast rights for the WNBA, which has seen a significant increase in viewership this season.

Get the Full Report

GDEV (GDEV/$23 | Price Target: $70)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Highlights From NobleCon20: Geared For Growth
Rating: OUTPERFORM

NobleCon20. On December 3rd, management presented to the investment community at NobleCon20, held at Florida Atlantic University (FAU) in Boca Raton, Florida. The presentation was conducted by Alexander Karavaev, chief financial officer, and Roman Safiyulin, chief corporate development officer. The duo highlighted the company’s dynamic growth prospects and the prospective swing toward growth in bookings. A replay of the presentation can be viewed by clicking here.

Dynamic business model. The company focuses on live-service games, meaning that the games have a continuous lifespan and are updated on an ongoing basis. This allows for a stable revenue base that grows over time, unlike many gaming companies with a “lumpier” revenue profile that oscillates based on game release schedules. 

Get the Full Report

GeoVax Labs (GOVX/$2.6 | Price Target: $12)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
GeoVax Receives Allowance For New Patent Covering Vaccine Platform Technologies
Rating: OUTPERFORM

Intellectual Property Estate Is Expanding. GeoVax announced that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application covering the expression of antigens in virus-like particles delivered with a viral vector. This is a mechanism used to stimulate an immune response from the GeoVax MVA-based vaccines. The patent allowance is the final step in the USPTO application process, and the patent will be issued after payment of fees.

The Application Covers Expression Of Immune Stimulation Antigens. The patent titled “Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles” includes claims for expressing a tumor associated antigen (TAA) in virus-like particles (VLPs) from a recombinant Modified Vaccinia Ankara (MVA) viral vector. This covers vaccines that use the MVA as a vector to deliver DNA that assembles into non-infectious virus-like constructs to simulate an immune response against the targeted virus. This mechanism is used in the MVA MUC-1 (cancer) and infectious disease vaccines. A detailed description of the MVA platform and VLPs begins on page 7 of our Initiation of Coverage report.

Get the Full Report

Graham (GHM/$43.25 | Price Target: $45)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
NobleCon20 Presentation Highlights
Rating: OUTPERFORM

NobleCon20. Graham CFO Chris Thome and Vice President Matt Malone presented at NobleCon20. Highlights included the growth potential in U.S. Navy contracts, revenue diversification in the Space Segment, and M&A strategy. A rebroadcast is available at https://www.channelchek.com/videos/graham-corporation-noblecon20-replay.

Potential in U.S. Navy. The Navy’s Ford Class Carrier and Virginia and Columbia Class Submarines represent $1.2 to $1.4 billion in revenue potential based on planned projects. These project build timelines are expected to be completed as early as 2035 to as late as 2058, providing visibility and recurring revenue. With investments from defense customers to expand capacity and 80% of its defense revenue sole sourced, we believe Graham is uniquely positioned to expand its relationship with the Navy and other defense customers.

Get the Full Report

Information Services Group (III/$3.68 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Highlights from NobleCon20
Rating: OUTPERFORM

NobleCon20. Information Services Group CEO Michael Connors and CFO Michael Sherrick presented at NobleCon20. Management highlighted the opportunity in AI, including ISG Tango, and driving recurring revenue. A rebroadcast is available at https://www.channelchek.com/videos/information-services-group-noblecon20-replay.

Growth in AI. The opportunity in AI for ISG is prevalent, as management noted that 55% of large enterprises are focused on developing an AI roadmap today. This focus translates into a roughly 3 times increase in projected enterprise AI spending through 2025. ISG has two services in AI Advisory and Research that companies can utilize for the application of AI and to be informed on the best use cases. In our view, ISG is well-equipped to handle increased demand through its services.

Get the Full Report

NN (NNBR/$3.9 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Presentation Highlights from NobleCon20
Rating: OUTPERFORM

NobleCon20. NN CFO Chris Bohnert presented at NobleCon20. Highlights included tariffs being a benefit to the Company, NN’s transformation plan, and its five-year growth plan. A rebroadcast is available at https://www.channelchek.com/videos/nn-inc-noblecon20-replay.

Tariffs Good for NN? The Trump administration is seeking protection for U.S. based production through the use of tariffs, potentially increasing costs for companies. However, NN has roughly $120 million of tariff-protected U.S.-produced auto parts and does not import from China. For its China operations, the Company produces auto parts in China for use in the local market there. As a result, we believe the Company can protect its margins through not paying tariffs and can potentially have pricing power over parts produced in the U.S. compared to other companies that import.

Get the Full Report

Noble Capital Markets Research Report Monday, December 9, 2024

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – November Production Numbers Are In
DLH Holdings (DLHC)/OUTPERFORM – New Administration Brings More Opportunity
Kelly Services (KELYA)/OUTPERFORM – Another $50 Million Share Repurchase Authorized
Schwazze (SHWZ)/OUTPERFORM – Update on Accounting

Bit Digital (BTBT/$4.88 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
November Production Numbers Are In
Rating: OUTPERFORM

HPC and AI. As of November 30, 2024, Bit Digital had 266 servers actively generating revenue and earned approximately $4.3 million of total unaudited GPU Cloud revenue during the month. At Enovum’s data center, the Company had 13 customers actively generating revenue with colocation revenue of approximately $503,500. We believe the Boosteroid agreement, along with the two MSAs signed in the third quarter should expand revenue in the coming months.

Mining Side. The Company produced 44.9 BTC in the month, a 14.0% decrease from 52.2 BTC in October. The active hash rate was 2.51 EH/s, a slight increase from 2.43 EH/s last month. Bit Digital’s hosting provider, Coinmint, being acquired resulted in the termination of hosting contracts. Management has signed term sheets for the lost hosting capacity and is replacing energy inefficient miners, with a 3.0 EH/s active hash rate expected by the first half of 2025.

Get the Full Report

DLH Holdings (DLHC/$8.08 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
New Administration Brings More Opportunity
Rating: OUTPERFORM

4Q Results. Reported revenue was $96.4 million compared to $101.5 million from last year and below our $101 million estimate. Net income for the quarter was $2.3 million, or $0.16/sh, compared to a net loss of $2.6 million, or $0.18/sh, last year. Adjusted EBITDA was $10.7 million, down from $12.1 million last year but above our estimate of $10.5 million.

CMOP. Management noted that the Company’s CMOP portfolio is under new task orders that go into the second quarter of 2025. Significantly, the Company has not continued its joint venture bids for specific locations, citing performance dilution. We expect DLH to bid on fewer CMOP contracts, resulting in lower CMOP revenue, likely once past the current extension.

Get the Full Report

Kelly Services (KELYA/$14.33 | Price Target: $27)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Another $50 Million Share Repurchase Authorized
Rating: OUTPERFORM

New Authorization. Kelly’s Board of Directors approved a new share repurchase program, authorizing the Company to purchase up to $50 million of its Class A common stock. The authorization expires on December 2, 2026. Shares under the authorization may be purchased from time to time in the open market, in privately negotiated transactions, or by other means.

Size. The $50 million authorization represents approximately 10% of Kelly’s current Class A market capitalization. We believe any potential share repurchases will be balanced against continued paydown of debt, additional M&A opportunities, and re-investment in the business to drive organic growth.

Get the Full Report

Schwazze (SHWZ/$0.06 | Price Target: $4)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Update on Accounting
Rating: OUTPERFORM

Update. Schwazze, in conjunction with its new auditors, has determined that its financial statements for the two fiscal years ended December 31, 2023, will be restated due to the identification of certain accounting adjustments needed primarily relating to technical accounting areas. The Company filed an 8-k describing the necessary adjustments.

Impact. Although mostly related to technical accounting areas, the Company has concluded that the impact of these corrections is material and, therefore, worthy of restatement. However, Schwazze does not currently believe that the foregoing corrections will have any negative material impact on the Company’s revenue, adjusted EBITDA, cash from operations, or cash position.

Get the Full Report

Noble Capital Markets Research Report Monday, November 27, 2024

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Increasing Our FY2025 and FY2026 Estimates and Price Target
Codere Online (CDRO)/OUTPERFORM – Q3 Beat Despite Exchange Rate Headwinds
MustGrow Biologics Corp. (MGROF)/MARKET PERFORM – A Potential Game Changer

AZZ (AZZ/$93.14 | Price Target: $110)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Increasing Our FY2025 and FY2026 Estimates and Price Target
Rating: OUTPERFORM

A market leader with a strong growth profile. AZZ is the leading independent provider of hot dip galvanizing and coil coating solutions to a broad range of end markets. With AZZ Precoat Metals’ new manufacturing facility in Washington, Missouri expected to be completed in fiscal year 2025, we expect the facility to contribute to top-line growth in fiscal year 2026 while capital expenditures decline. Approximately 75% of the facility’s production is already committed and could generate approximately $50 million to $60 million in revenue on an annualized basis once production is fully ramped.

Updating estimates. We have increased our FY 2025 revenue, EBITDA, and EPS estimates to $1.598 billion, $344.8 million and $5.00, respectively, from $1.584 billion, $343.0 million, and $4.95. Our estimates reflect stronger sales growth during the remainder of the year and into 2026. Our FY 2026 revenue, EBITDA, and EPS estimates have been increased to $1.673 billion, $367.4 million, and $5.60, respectively, from $1.650 billion, $361.2 million, and $5.45. We think the incoming Trump administration could support pro-growth economic policies that could favorably impact AZZ’s business. While we have not assumed any gross margin expansion during the remainder of FY 2025, gross margin increases modestly in FY 2026 to 23.8% versus our prior estimate of 23.5%.

Get the Full Report

Codere Online (CDRO/$7.75 | Price Target: $14)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Q3 Beat Despite Exchange Rate Headwinds
Rating: OUTPERFORM

Strong Q3 results. The company reported 20% year-over-year revenue growth in Q3 to €51.7 million. Q3 was also the company’s third consecutive quarter with positive adj. EBITDA generation, which was €1.5 million. Revenue and adj. EBITDA exceeded our estimates of €50.0 million and €0.4 million, respectively.

Exchange rate headwinds in Mexico. Revenue in Mexico grew 27%, year-over-year, despite weakness in the Mexican Peso. Notably, on a constant currency basis, revenue in Mexico was up 43%, as the company continued its focus in the country.

Get the Full Report

MustGrow Biologics Corp. (MGROF/$1.23)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Potential Game Changer
Rating: MARKET PERFORM

Proposed Acquisition. Last week, MustGrow signed a non-binding term sheet with Univar Solutions Canada Ltd. for the proposed acquisition of NexusBioAg. The acquisition is subject to certain conditions, including due diligence, the negotiation and execution of a definitive asset purchase agreement, and approval by the TSX Venture Exchange.

Light on Details.  Terms of the proposed acquisition were not disclosed. Nor was any detail regarding sales or net income for NexusBioAg. MustGrow also would need to obtain financing for the proposed deal. The purchase consideration for the proposed acquisition is anticipated to include (i) a deferred cash payment and (ii) contingent payments made in 2025 and 2026. The parties are targeting a closing by yearend.

Get the Full Report

Noble Capital Markets Research Report Wednesday, November 27, 2024

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – Increasing Longer-Term Oil and Gas Royalty Volume Expectations; Price Target Increased
MustGrow Biologics Corp. (MGROF)/MARKET PERFORM – Sales are Trickling In
Travelzoo (TZOO)/OUTPERFORM – Raising Price Target
Traws Pharma (TRAW)/OUTPERFORM – Antiviral Pipeline Makes Progress and Moves Forward

Alliance Resource Partners (ARLP/$28.17 | Price Target: $33)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Increasing Longer-Term Oil and Gas Royalty Volume Expectations; Price Target Increased
Rating: OUTPERFORM

Adjusting estimates. While our 2024 and 2025 estimates are unchanged, we have increased our 2026 through 2030 EBITDA and EPU estimates to reflect higher year-over-year growth in oil and gas royalty volumes of 12.5% compared to our previous estimate of 2.0% which we think is too conservative based on the partnership’s record. Our commodity price deck is unchanged. We have assumed an average of $75 million per year in oil and gas reserve acquisitions in 2026 through 2030. Based on our higher forward estimates and a modest 100-basis point reduction in our discount rate to 9.5%, we have increased our price target to $33 per share from $28.

Hail to the incoming chief. We expect industries associated with the fossil fuels to benefit from the upcoming change in U.S. Presidential administrations. It is our belief that the Trump Administration may seek to roll back the EPA’s carbon emissions rule which could extend the life of existing coal-fired power plants. Moreover, we think the business climate could improve based on a move toward market-based energy policies and a reduction in regulatory burden.

Get the Full Report

MustGrow Biologics Corp. (MGROF/$1.23)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Sales are Trickling In
Rating: MARKET PERFORM

3Q Results. Revenue for the quarter totaled CAD$279,182, including the Company’s CAD$272,500 in deferred revenue. Excluding this, revenue was CAD$6,682, including TerraSante sales’ impact. We estimated revenue of CAD$15,000. Net loss was CAD$1.7 million, or a loss of $0.03/sh, compared to a loss of CAD$1.9 million last year, or  $0.04/sh. We estimated a net loss of CAD$1.9 million or $0.04/sh.

Sales Revenue is Here. Notably, the quarter recognized product sales revenue for the TerraSante product for the first time. We expect TerraSante revenue to begin to impact revenue in a meaningful way in the latter half of 2025. As the Company receives more approvals from different states, we believe the opportunity to showcase TerraSante to farmers can expand, along with revenue.

Get the Full Report

Travelzoo (TZOO/$19.82 | Price Target: $25)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Joshua Zoepfel jzoepfel@noblefcm.com |
Raising Price Target
Rating: OUTPERFORM

Moving towards enhanced growth. We believe that the company’s strategic focus on developing a subscription model will accelerate revenue and cash flow growth in 2025 and beyond. We anticipate that even a modest 1% penetration of its 30+ million members will accelerate 2025 revenue and cash flow growth to 12% and roughly 15%, respectively. 

Providing revenue and cash flow stability. The subscription model is being launched Jan. 1, 2025 and is expected to offer a ballast to the company’s more cyclical advertising driven model. Notably, the company is not expected to abandon its 30 million plus members, but simply migrate a portion of those members to annual subscriptions, largely as those members seek to take advantage of the travel “deals”.

Get the Full Report

Traws Pharma (TRAW/$4.09 | Price Target: $6)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Antiviral Pipeline Makes Progress and Moves Forward
Rating: OUTPERFORM

Traws Has Made Significant Progress During 2024. In May 2024, Onconova and Transfynydd combined to form Traws Pharmaceuticals. The new company brought together the Transfynydd small molecules for respiratory viral diseases with the Onconova clinical-stage oncology pipeline. The company is planning Phase 2 clinical trials for its antivirals while looking for collaborations and/or partnerships for the oncology pipeline.

Phase 2 Trials Are Planned For Two Antivirals. Tivoxavir marboxil (TRX100) is a protease inhibitor of enzyme needed for the reproduction of the virus that causes seasonal and pandemic influenza. Ratutrelvir (TRX01) inhibits the protease Mpro (the main protease or 3CL), the main protease of SAR-CoV-2 (the COVID-19 virus), but does not require co-administration of a metabolic inhibitor. This avoids the risk of drug-drug interactions and potential side effects. Phase 2 studies for both drugs are expected to begin in 1H24.

Get the Full Report

Noble Capital Markets Research Report Tuesday, November 26, 2024

Companies contained in today’s report:

Aurania Resources (AUIAF)/OUTPERFORM – Increasing Financial Flexibility Ahead of the 2025 Exploration Program
FAT Brands (FAT)/OUTPERFORM – Another Step

Aurania Resources (AUIAF/$0.33 | Price Target: $0.65)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Increasing Financial Flexibility Ahead of the 2025 Exploration Program
Rating: OUTPERFORM

Private placement financing. Aurania intends to raise up to C$4.0 million in a private placement of up to ~8.9 million units at a price of C$0.45 per unit to fund exploration programs in France and Ecuador. Each unit will consist of one common share and one common share purchase warrant. Each warrant may be used to purchase one common share at an exercise price of C$0.75 for a period of 24 months following the closing of the offering. The private placement is expected to close in December and is contingent on the receipt of necessary approvals, including by the TSX Venture Exchange.

Concessions in Ecuador. Aurania reached an agreement with Ecuadorian authorities regarding the payment of its 2024 concession fees for its 42 mineral exploration concessions in Ecuador. Aurania has made a partial payment with the balance to be paid within the following six months, including interest associated with the outstanding amount. The concessions remain in good standing.

Get the Full Report

FAT Brands (FAT/$5.32 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Another Step
Rating: OUTPERFORM

Step 2. FAT Brands completed the second step in its anticipated planned listing of its Twin Hospitality unit as a standalone public company. FAT successfully completed the refinancing of the whole business securitization credit facility of its Twin Peaks and Smokey Bones restaurant brands.

Details. The aggregate principal balance of the new Series 2024-1 fixed rate notes is $416.7 million across four tranches with a weighted average annual interest rate of 9.5%.  The interest rate on the new notes is modestly higher than the rate on the previous securitization notes. However, the first anticipated call date goes from January 2025 to October 2027. We would point out that if the new notes are not repaid or refinanced by October 2027, additional interest equal to 5.0% per annum will accrue on each tranche of notes. The noteholders also are receiving warrants to acquire an aggregate of 5% of the Class A common stock of Twin Hospitality.

Get the Full Report

Noble Capital Markets Research Report Monday, November 25, 2024

Companies contained in today’s report:

Lifeway Foods (LWAY)/MARKET PERFORM – Another Rejection…And More

Lifeway Foods (LWAY/$24.26)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Another Rejection…And More
Rating: MARKET PERFORM

Rejected. Lifeway’s Board rejected Danone’s revised offer to acquire all of the LWAY shares it currently does not own for $27 per share. The Board stated the “revised proposal substantially undervalues Lifeway and is not in the best interests of the Company and its shareholders or other stakeholders.” Danone has yet to respond.

The Third Party. Following the rejection, Edward and Ludmila Smolyansky called for Lifeway’s Board to immediately establish an independent special committee to evaluate and negotiate a transaction with Danone or other potential buyers. In addition, Edward and Ludmila are seeking public disclosure of any valuation analysis done by Kroll when Kroll assisted the Board in June 2023 to explore strategic alternatives.

Get the Full Report

Noble Capital Markets Research Report Friday, November 22, 2024

Companies contained in today’s report:

Euroseas (ESEA)/OUTPERFORM – Third Quarter Financial Results Exceed Our Expectations; Outlook Remains Favorable
Haynes International (HAYN)/NOT RATED – Acerinox Completes the Acquisition of Haynes International
Hemisphere Energy (HMENF)/OUTPERFORM – Third Quarter Results Ahead of Expectations

Euroseas (ESEA/$39.45 | Price Target: $68)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Third Quarter Financial Results Exceed Our Expectations; Outlook Remains Favorable
Rating: OUTPERFORM

Third quarter results. Euroseas Ltd. reported adjusted EBITDA and earnings per share of $36.1 million and $3.92, respectively, exceeding our estimates of $35.1 million and $3.77. Net revenues increased 6.9% on a year-over-year basis, and total daily vessel operating expenses decreased on a per-day per-vessel basis from $7,692 to $7,249. The revenue growth is mainly driven by a larger fleet, while the decrease in daily operating expenses is due to the company’s newly built vessels requiring less maintenance.

Favorable outlook. Charter and freight rates have rebounded after a slight dip during the summer and are expected to remain elevated throughout 2024 and into 2025. Ongoing disruptions in the Red Sea continue to support rates. The supply of new vessels in 2025 is anticipated to be lower than in the previous two years but could still put downward pressure on rates. Potential regulations regarding vessel speeds to reduce emissions could be implemented in 2025, which may help alleviate the downward rate pressure from the increasing supply. Furthermore, charter rates for eco-friendly vessels are projected to rise as emission regulations become more stringent and market demand for these types of vessels increases. 

Get the Full Report

Haynes International (HAYN/$60.99)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Acerinox Completes the Acquisition of Haynes International
Rating: NOT RATED

Acquisition by North American Stainless. In February, Haynes International entered into an agreement to be acquired by North American Stainless, a wholly owned subsidiary of Acerinox. The transaction closed on November 21, 2024. We think the transaction is a positive outcome for Haynes’ various stakeholders.

Strategic benefits. Together, Haynes and VDM Metals will form Acerinox’s High-Performance Alloys Division. The integration of Haynes will support Acerinox’s strategic priorities, including the company’s focus on enhancing its operations in the U.S. market, high-performance alloys, and the aerospace sector. North American Stainless acquired all of the outstanding shares of Haynes for $61 per share in an all-cash transaction.

Get the Full Report

Hemisphere Energy (HMENF/$1.38 | Price Target: $2.2)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Third Quarter Results Ahead of Expectations
Rating: OUTPERFORM

Third quarter financial results. Hemisphere Energy reported third-quarter net income of C$8.6 million or C$0.09 per share compared to C$8.5 million or C$0.08 per share during the third quarter of 2023. We had projected net income of C$8.4 million or C$0.08 per share. Year-over-year, oil and natural gas revenue increased 9.6% to C$26.7 million, driven by an 18.5% increase in average daily production to 3,621 barrels of oil equivalent (BOE) compared to 3,056 during the prior year period and our estimate of 3,600. The average sales price per BOE declined to C$80.06 compared to C$86.57 in the third quarter of 2023. Adjusted funds flow from operations amounted to C$11.7 million or C$0.12 per diluted share compared to C$11.7 million or C$0.11 per diluted share during the prior year period.

Updating estimates. While our 2024 EPS estimate is unchanged at C$0.31, we have modestly lowered our adjusted funds flow estimate to C$43.5 million from C$43.8 million. We lowered our full year average daily production expectations to 3,456 barrels of oil equivalent from 3,534 to reflect down time in the fourth quarter associated with vessel inspections and maintenance. While our 2025 average daily production estimate of 3,625 barrels of oil equivalent is unchanged, we lowered our 2025 AFF and EPS estimates to C$38.0 million and C$0.27 per share from C$42.6 million and C$0.32 to reflect lower crude oil prices.

Get the Full Report

Noble Capital Markets Research Report Thursday, November 21, 2024

Companies contained in today’s report:

Century Lithium Corp. (CYDVF)/OUTPERFORM – Building on a Successful 2024
Codere Online (CDRO)/OUTPERFORM – Q3 Preview: Expecting a Strong Quarter

Century Lithium Corp. (CYDVF/$0.19 | Price Target: $2.35)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Building on a Successful 2024
Rating: OUTPERFORM

Closing out a productive year. Century Lithium had a productive year in 2024 with the two most significant achievements being completion of the feasibility study on the Angel Island lithium project and producing battery-grade lithium carbonate at its pilot plant. The feasibility study was released in April and while the economics were compelling, the company continues to focus on process optimization to improve potential returns by reducing the project’s estimated capital and operating costs. The use of a Chlor-alkali plant is unique and offers technical and environmental advantages by producing reagents for use onsite and producing surplus sodium hydroxide which can be sold to offset cash operating costs.

Environmental and regulatory permitting. On the environmental and permitting front, most of the required baseline studies have been completed and the company is editing a draft Plan of Operations and preparing key state permits for pollution and water quality compliance. Once the Plan of Operations is completed, the company may initiate the National Environmental Policy Act (NEPA) permitting process.

Get the Full Report

Codere Online (CDRO/$7.3 | Price Target: $14)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Q3 Preview: Expecting a Strong Quarter
Rating: OUTPERFORM

Positive upside. The company is expected to report Q3 results within the next 2 weeks. We are re-iterating our Q3 estimates of $50.0 million in revenue and $0.4 million in adj. EBITDA. Moreover, we believe there could be upside to our revenue estimate, which may be conservative.

Peso headwind. We expect solid results in Spain, bolstered by the rollback in marketing restrictions in the country. As for the company’s other core market, Mexico, trends appear to be strong. Weakness in the Peso, however, has presented a headwind for the company, which reports in Euros. Nonetheless, we expect a strong quarter, currency exchange concerns notwithstanding.

Get the Full Report

Noble Capital Markets Research Report Wednesday, November 20, 2024

Companies contained in today’s report:

EuroDry (EDRY)/OUTPERFORM – Third Quarter Performance Falls Short Amid a Weak Market
GeoVax Labs (GOVX)/OUTPERFORM – Interim Analysis Shows CM04S1 Outperforms mRNA Vaccines
Kelly Services (KELYA)/OUTPERFORM – Enhancing Education through Children’s Therapy Center Acquisition
Ocugen (OCGN)/OUTPERFORM – Interim Data From The Clinical Showcase Highlighted
QuoteMedia Inc. (QMCI)/OUTPERFORM – Working Through A Rough Patch

EuroDry (EDRY/$14.96 | Price Target: $20)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Third Quarter Performance Falls Short Amid a Weak Market
Rating: OUTPERFORM

Third quarter financial results.  Eurodry Ltd. reported an adjusted third-quarter net loss to controlling shareholders of $3.9 million or ($1.42) per share compared to an adjusted net loss of $675 thousand or ($0.24) per share during the prior year period. Adjusted EBITDA declined to $474 thousand compared to $3.1 million during the prior year period. The year-over-year decline was driven by a heavier-than-expected dry-docking quarter, a decline in charter rates due to a weakening Chinese economy and the reopening of trade routes.

Updating 2024 and 2025 estimates. We have lowered our 2024 adjusted EBITDA and earnings per share estimates to $14.7 million and $(2.46), respectively, from $23.0 million and ($0.85). Similarly, we have lowered our 2025 adjusted EBITDA and earnings per share to $30.8 million and $3.28, respectively, from $37.3 million and $5.65. Our revisions are primarily the result of a weak market outlook and corresponding rates.

Get the Full Report

GeoVax Labs (GOVX/$2.91 | Price Target: $12)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Interim Analysis Shows CM04S1 Outperforms mRNA Vaccines
Rating: OUTPERFORM

CM04S1 Continues In Phase 2 As DSMB Determines mRNA Vaccine Arm Failed Primary Endpoint. CM04S1 is in Phase 2 testing as a COVID-19 booster against an approved mRNA vaccine in patients with chronic lymphocytic leukemia (CLL). An interim analysis conducted by an independent Data Safety Monitoring and Review Board (DSMB) determined that the mRNA arm did not meet its specified primary endpoint, but the trial will continue with the CM04S1 arm.

Study Tests CM04S1 In Immunocompromised Patients. The Phase 2 study enrolled patients that are immunocompromised due to CLL and its therapies, which often leaves them unable to mount a sufficient immune response and vulnerable to COVID-19 infection. The trial was designed to determine the immune response with Pfizer’s mRNA vaccine as the control and comparator arm. Patients were randomized at 1:1 into two arms, receiving either two injections of CM04S1 three months apart or the mRNA vaccine. 

Get the Full Report

Kelly Services (KELYA/$14.16 | Price Target: $27)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Enhancing Education through Children’s Therapy Center Acquisition
Rating: OUTPERFORM

Adding On. Expanding on the Company’s Pediatric Therapy Services (PTS) portfolio in the Education segment, yesterday Kelly announced the acquisition of Children’s Therapy Center (CTC). Notably, the acquisition increases the current network’s scale of licensed therapists to Kelly, enabling practice flexibility between clinics and schools. The terms of the acquisition were not disclosed, but we do not believe it will impact fourth quarter results.

CTC Overview. Headquartered in Eagan, Minnesota, CTC specializes in occupational, physical, and speech therapy for children from birth to 18 years old. The company was founded in 1999 and has two office locations, one in Eagan and the other in Apple Valley, MN. Various disorders that are treated through CTC include motor or speech delays, sensory processing disorders, Cerebral Palsy, Autism Spectrum Disorders, and Attention Deficit Disorder.

Get the Full Report

Ocugen (OCGN/$0.8736 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Interim Data From The Clinical Showcase Highlighted
Rating: OUTPERFORM

Summary Of Data Announced For Products In Clinical Trials. Ocugen summarized some of the major points presented at its Clinical Showcase on November 12. As discussed in our Research Note on November 13, speakers reviewed the products’ mechanisms of action, reviewed OCU400 data from the Phase 1/2 trial, the design of the OCU400 Phase 3 liMeliGhT trial, and presented new interim data from the Phase 1/2 ArMaDa trial for OCU410.

Mechanism of Action For The Modifier Gene Therapy (MGT) Detailed. Ocugen is developing gene therapies for retinal diseases that deliver a regulatory gene to control other genes and regulate downstream pathways. Products in development are for inherited diseases that result from multiple gene mutations or conditions that result from several dysfunctional pathways.

Get the Full Report

QuoteMedia Inc. (QMCI/$0.2 | Price Target: $0.26)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Working Through A Rough Patch
Rating: OUTPERFORM

In-line results. The company reported Q3 revenue of $4.7 million, a decrease of 1.4% from the prior year period and largely in line with our estimate of $4.8 million. Q3 adj. EBITDA of $0.4 million, was modestly lighter than our estimate of $0.7 million, as illustrated in Figure #1 Q3 Results. The adj. EBITDA miss was driven by a modestly higher cost of revenue and increased sales headcount.

Lackluster near term outlook. Management indicated that Q4 revenue will be relatively flat compared to Q3 despite a solid business pipeline. Management highlighted that it lost a significant client and that some of its clients are experiencing financial hardship, leading to a lower volume and higher bad debt expenses. We believe the company should be able to offset lower volume and the loss of clients with its building business pipeline.

Get the Full Report

Noble Capital Markets Research Report Tuesday, November 19, 2024

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – Results Below Expectations, but Pipeline Being Realized
Comtech Telecommunications (CMTL)/MARKET PERFORM – Agreement Made with Dissident Former CEOs
GDEV Inc (GDEV)/OUTPERFORM – Raising Adj. EBITDA Estimates

Bit Digital (BTBT/$4.02 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Results Below Expectations, but Pipeline Being Realized
Rating: OUTPERFORM

3Q Results. Revenue of $22.7 million was lower than our and consensus estimate of $23.2 million and $25.9 million, respectively. The BTC halving resulted in lower revenue. Higher electricity costs, D&A, G&A, and a loss of $21.9 million on digital assets led to the reduced net loss of $38.8 million, or $0.26/sh, from our consensus estimate of a loss of $2.3 million, or $0.02/sh, and loss of $2.9 million, or $0.02/sh, respectively. Adjusted EBITDA was a negative $21.8 million compared to a negative $2.9 million last year.

Seizing Opportunity. After 3Q ended, Bit Digital entered into one term sheet agreement and two Master Services Agreements. Together, the three provide roughly $21 million in annual revenue once servers are fully deployed. Alongside this is the Boosteroid agreement, as management expects that to reach approximately 20% of the $700 million opportunity, or 10,000 GPUs, through the course of 2025, translating to $30 million of revenue annually.

Get the Full Report

Comtech Telecommunications (CMTL/$2.65)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Agreement Made with Dissident Former CEOs
Rating: MARKET PERFORM

Agreement Made. Yesterday, Comtech announced it entered into a cooperation agreement with former CEOs Michael Porcelain and Fred Kornberg, along with Oleg Timoshenko (the “Investor Group”), to appoint Michael Hildebrandt to the Board of Directors. Mr. Hildebrandt was one of the nominees chosen by the Investor Group to be appointed to the Board in a 13D filing through the SEC in September 2024.

Mr. Porcelain on as Advisor. Along with the appointment of Mr. Hildebrandt, Mr. Porcelain is authorized as an advisor to the Company. He will be entitled to periodically engage in discussions with the Company and provide advice or recommendations. We believe adding Mr. Porcelain as an advisor is a positive as the former CEO has a wealth of knowledge on the Company’s end markets and its processes.

Get the Full Report

GDEV Inc (GDEV/$25.86 | Price Target: $70)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Raising Adj. EBITDA Estimates
Rating: OUTPERFORM

Solid Q3 results. Total company revenue was $110.7 million, which beat our $103.0 million estimate by 7.4%, and adj. EBITDA of $16.9 million, substantially exceeded our estimate of $4.9 million. The adj. EBITDA beat was largely attributed to the revenue upside and modestly lower game operating and marketing expenses. The strong operating results also beat Street estimates, with consensus adj. EBITDA of $8.5 million.

Attractive outlook. While revenue outperformed our expectations, bookings were lower than expected. Management highlighted its focus on player retention and quality of play rather than short term monetization of its user base. Given that active users were down roughly 16% from the prior year period, we view the company’s focus on player retention and improving gameplay favorably.

Get the Full Report

Noble Capital Markets Research Report Monday, November 18, 2024

Companies contained in today’s report:

Haynes International (HAYN)/MARKET PERFORM – Acquisition by North American Stainless Expected to Close Shortly
Maple Gold Mines (MGMLF)/OUTPERFORM – Recent Private Placement Provides Flexibility to Pursue a Robust Exploration Program

Haynes International (HAYN/$60.93)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Acquisition by North American Stainless Expected to Close Shortly
Rating: MARKET PERFORM

Acquisition by North American Stainless. In February, Haynes International entered into an agreement to be acquired by North American Stainless, a wholly owned subsidiary of Acerinox. North American Stainless will acquire all the outstanding shares of Haynes for $61.00 per share. The merger is conditioned on, among other things, the receipt of the approvals, clearances, or expirations of waiting periods under certain regulatory laws.

Receipt of all regulatory approvals and clearances. With the Austria waiting period expiration on November 15, all regulatory approvals and clearances where the applicable authorities have asserted jurisdiction have been obtained, including in the United States and in the United Kingdom.

Get the Full Report

Maple Gold Mines (MGMLF/$0.04 | Price Target: $0.25)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Recent Private Placement Provides Flexibility to Pursue a Robust Exploration Program
Rating: OUTPERFORM

Private placement financing. On November 14, Maple Gold Mines closed a private placement of 32,695,384 non-flow-through (NFT) units at a price of C$0.065 per NFT unit and 35,935,000 flow-through (FT) common shares of the company at a price of C$0.08 per FT share for total gross proceeds of C$5 million. Each NFT unit consists of one common share and one-half of one common share purchase warrant. Each warrant entitles the holder to acquire one non-flow-through common share at a price per warrant share of C$0.10 until November 14, 2027.

Third quarter financial results. As an advanced exploration and development company, Maple Gold does not generate revenues and incurs expenses associated with advancing its projects. Maple Gold generated a third quarter loss of C$1.3 million or C$(0.00) per share compared to a loss of C$1.1 million or $(0.00) per share during the prior year period. We had anticipated a loss of C$1.5 million or C$(0.00) per share.

Get the Full Report

Noble Capital Markets Research Report Friday, November 15, 2024

Companies contained in today’s report:

Comtech Telecommunications (CMTL)/MARKET PERFORM – New Contract Awarded
Conduent Inc (CNDT)/OUTPERFORM – Lowering Forecast, Business Transformation Plan Still on Track
InPlay Oil (IPOOF)/OUTPERFORM – Expecting a Strong Finish in 2024; Outlook for 2025 Remains Positive
Lifeway Foods (LWAY)/MARKET PERFORM – Year-over-Year Growth, But Below Our Expectations
PDS Biotechnology (PDSB)/OUTPERFORM – 3Q24 Reported With Phase 3 VERSATILE-003 Trial Expected To Begin In 1Q25
ZyVersa Therapeutics, Inc. (ZVSA)/OUTPERFORM – Reported 3Q24 With Clinical Trials Beginning In 2025

Comtech Telecommunications (CMTL/$2.71)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
New Contract Awarded
Rating: MARKET PERFORM

New Navy Contract. Comtech has been awarded a sole source contract from the U.S. Navy Information Warfare Systems Command for the Company’s U.S sovereign software-defined SLM-5650B satellite communications (“SATCOM”) modems, upgrade kits, firmware options and technical support. The contract is for a four-year period and valued at $50 million with roughly $2 million of funded orders received to date.

Growing Market. Comtech’s new award is indicative of the growing satellite industry, as the satellite ground station market is projected to grow to $6.6 trillion by 2028, representing a 6.89% CAGR beginning in 2024. Various government departments, such as the Department of Defense are needing agile and distributed communications systems for keeping communication open and uninterrupted, producing demand for products such as Comtech’s SATCOM modems. Furthermore, budgets for next year show growth, with an example being the U.S. Space Force from $17 billion in 2022 to a projected $30 billion in 2025. With a growing industry over the next few years and potential growing budgets, we believe that Comtech has the capability of capturing additional contracts.

Get the Full Report

Conduent Inc (CNDT/$4.05 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Lowering Forecast, Business Transformation Plan Still on Track
Rating: OUTPERFORM

Q3 in line. The company reported a Q3 revenue of $807 million, largely in line with our estimate of $814 million. Adj. EBITDA was $36 million, better than our estimate of $24 million. Notably, it appears that there could be tailwinds developing in the company’s Commercial segment.

Positive trends in Commercial. Adj. revenue in the Commercial segment was down 3%, due to lower volumes. However, management indicated that new business signings helped to mitigate the weakness from lost business. Moreover, it appears that momentum from new business signings is beginning to outpace lost business that is rolling off.

Get the Full Report

InPlay Oil (IPOOF/$1.3 | Price Target: $5.25)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Expecting a Strong Finish in 2024; Outlook for 2025 Remains Positive
Rating: OUTPERFORM

Third quarter financial results. InPlay Oil generated third quarter net income of C$146 thousand or C$0.00 per share compared to C$9.2 million or C$0.08 per share during the prior year period. We had predicted net income in the amount of C$423 thousand or C$0.00 per share. Average quarterly production declined to 8,206 barrels of oil equivalents per day (boe/d) compared to 9,003 boe/d in the third quarter of 2023 and our estimate of 8,238 boe/d.

Corporate 2024 guidance. While InPlay has maintained its production guidance of 8,700 to 9,000 boe/d, commodity price expectations were lowered, and operating expenses are expected to be in the range of C$13.50 to C$15.50 per boe/d compared to prior guidance of C$13.00 to C$15.25 per boe/d. Capital expenditures are expected to total $63 million compared with prior guidance of C$64 million to C$67 million. Adjusted funds flow is expected to be in the range of C$70 million to C$73 million compared to previous expectations of C$80 million to C$85 million.

Get the Full Report

Lifeway Foods (LWAY/$22.39)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Year-over-Year Growth, But Below Our Expectations
Rating: MARKET PERFORM

Another Quarter of Y-o-Y Growth. For the 20th consecutive quarter, Lifeway reported y-o-y top line growth. Revenue for the quarter totaled $46.1 million, compared to the prior year’s $40.9 million, We were a little more aggressive in our forecast, projecting revenue of $51.5 million. Gross margin of 25.7% was below the prior year’s 27.2%. Net income was $3.0 million, or $0.19 per diluted share, compared to $3.4 million, or $0.23/sh, and our estimate of $4.2 million or $0.27/sh.

Expanded Distribution. Management noted that the Company expanded its kefir distribution to South Africa in September and recently announced that it is expanding into Dubai and the Emirates market. In South Africa, the products are available on shelves now, while product availability in the Emirates is expected in the fourth quarter. We believe the Company will continue to look for new potential markets to expand its presence in stores while also expanding on its advertising in these new markets to attract the attention of new consumers.

Get the Full Report

PDS Biotechnology (PDSB/$2.25 | Price Target: $17)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
3Q24 Reported With Phase 3 VERSATILE-003 Trial Expected To Begin In 1Q25
Rating: OUTPERFORM

Progress Toward Phase 3 With New Phase 2 VERSATILE-002 Data. PDS Biotech Reported 3Q24 loss of $10.7 million or $(0.29) per share, a slightly lower loss than we estimated. Earlier this week, modifications to the IND protocol for the Phase 3 VERSATILE-003 trial were submitted to the FDA. Approval is expected by mid-December, which would allow the trial to begin in early 2025. 

New Phase 2 VERSATILE-002 Data Analysis Shows Outcomes Were Maintained Or Improved. As additional patients complete their follow-up periods, further analysis of the data has shown improvements over the previous interim reports. The overall survival has been unchanged at 30.0 months, although the lower limit of the confidence interval has increased to 20 months. This compares with 17.9 months for published Keytruda studies. Overall response rate, complete response rate, and disease control rates have improved as well.

Get the Full Report

ZyVersa Therapeutics, Inc. (ZVSA/$1.13 | Price Target: $20)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Reported 3Q24 With Clinical Trials Beginning In 2025
Rating: OUTPERFORM

3Q24 Reported With Product Updates. ZyVersa reported a loss of $2.4 million or $(2.43) per share and updated its clinical trial plans for the two products in development. During the quarter, several scientific papers were published showing the role of inflammation in obesity, diabetes, and neurodegeneration. These studies all support previous work by the company and are consistent with the mechanism of action for IC 100.

VAR 200 To Start Phase 2a In Diabetic Kidney Disease. The Cholesterol Efflux Mediator™ VAR 200 has shown reductions in the initial damage that starts a cycle of damage and repair that leads to progressive scarring and loss of kidney function. A Phase 2a trial enrolling patients with diabetic kidney disease (DKD) is expected to begin in 1Q25 with initial data announcement around mid-2025.

Get the Full Report

Noble Capital Markets Research Report Thursday, November 14, 2024

Companies contained in today’s report:

Bitcoin Depot (BTM)/OUTPERFORM – Building Momentum Ahead of 2025
Cocrystal Pharma (COCP)/OUTPERFORM – 3Q24 Reported With Data Announcements Ahead
DLH Holdings (DLHC)/OUTPERFORM – A More Flexible Credit Facility
Snail (SNAL)/OUTPERFORM – Clearing Up The Noise
Unicycive Therapeutics (UNCY)/OUTPERFORM – 3Q24 Reported With Progress Driven By OLC

Bitcoin Depot (BTM/$2.48 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Building Momentum Ahead of 2025
Rating: OUTPERFORM

Q3 beat. The company reported solid Q3 results, beating our estimates on both revenue and adj. EBITDA. Q3 revenue was $135.3 million, better than our estimate of $130.6 million and adj. EBITDA was $9.2 million, better than our estimate of $7.8 million.

Kiosk re-deployment paying off. After focusing on re-deploying underperforming kiosks during 2023 and in the first half of 2024, the company’s kiosks appear to be gaining traction. This is evident in the median transaction size, which climbed from roughly $200 in the beginning of the year to $250 in Q3. Notably, it takes time for re-deployed kiosks to be discovered by potential users. As a result, newly deployed kiosks tend to have an initial drag on profitability.

Get the Full Report

Cocrystal Pharma (COCP/$1.77 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
3Q24 Reported With Data Announcements Ahead
Rating: OUTPERFORM

Two Trials Expected To Report Data Shortly. Cocrystal reported a 3Q24 loss of $4.9 million or $(0.49) per share. The company made progress in its clinical programs during the quarter, including CC42344, its oral PB2 inhibitor for seasonal and pandemic influenza. We see this an increasingly important product, given the spread of a new variant of the virus known as H5N1, or the avian flu. Data from its Phase 2a human challenge study is expected before year-end.

CC-42344 Could Be Effective Against The New Bird Flu. As discussed in our Research Note on June 21, a new virulent strain of influenza known as avian flu (H5N1) had been detected in dairy cattle. Earlier this year, the first infections in dairy workers showed the virus had mutated enough to begin infecting humans. Preclinical testing with CC-42344 showed it was able to inhibit the virus and has potential for human use against the strain.

Get the Full Report

DLH Holdings (DLHC/$8.76 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A More Flexible Credit Facility
Rating: OUTPERFORM

Credit Facility and CMOP Update. Yesterday, DLH announced the Company has amended its credit facility with lenders to modify the borrowing capacity of the facility itself and the financial covenants of the agreement. The credit facility’s maximum capacity is reduced from $70 million to $50 million with the amendment, although no changes were made to the maturity or pricing terms. We would point out that DLH also is expected to transition a portion of its CMOP locations to set-aside, small business contractors, although no further details were given.

Financial Covenants. As for the financial covenants of the agreement, the two that are specifically being changed are the Total Leverage ratio and Fixed Charge Coverage ratio. Importantly, the amendment increases the maximum threshold of the Total Leverage Ratio, with the most recent being to 4.5 to 1.0 in the first quarter next year from a prior 4.25 to 1.00. As for the Fixed Charge Coverage ratio, the minimum threshold is being lowered with the most recent staying the same at less than to 1.25 to 1.00 in the first quarter next year but lowering in subsequent quarters. While the reduction of the capacity of the facility is not ideal, we believe the changes to the covenants provides DLH flexibility in anticipation of the Company’s CMOP locations being moved to small businesses, impacting performance.

Get the Full Report

Snail (SNAL/$1.4 | Price Target: $4)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Clearing Up The Noise
Rating: OUTPERFORM

Q3 results. The company reported revenue of $22.5 million, largely in line with our estimate of $25.0 million, and Adj. EBITDA of $0.5 million, below our estimate of $4.0 million. Notably, results benefitted from the Aberration DLC release that was included in the sale of Ark: Survival Ascended (ASA), and part 2 of Bobs Tall Tales. Importantly, the adj. EBITDA miss was a largely a function of lower revenue, given the amount of fixed licensing expenses in its cost structure.

DLC release outlook. With the release of the Aberration DLC in September, there are three DLC packages that were included in the sale of ASA that have yet to be released. The next DLC is expected in Q4 and two more are expected in 2025. Importantly, as DLC packages included in ASA are released, the company will defer less revenue from ASA sales, which should provide investors with a clearer picture of company operating results. 

Get the Full Report

Unicycive Therapeutics (UNCY/$0.47 | Price Target: $7)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
3Q24 Reported With Progress Driven By OLC
Rating: OUTPERFORM

OLC Achieved Significant Milestones In 3Q24. Unicycive reported a 3Q24 loss of $4.1 million or $(0.05) per share. During the quarter, the NDA was submitted for approval of oxylanthanum carbonate (OLC), its phosphate binder for patients on renal dialysis. After the close of the quarter, the acceptance for filing was announced with a PDUFA date of June 28, 2025. The quarter ended with $32.3 million in cash, which we believe is sufficient to fund operations and launch of OLC in 2025-26.

NDA Submission Was Completed As Expected. In early September, Unicycive submitted the new drug application (NDA) for OLC, its phosphate binder for patients on renal dialysis. On November 11, the company announced FDA acceptance of the application for review and assigned a PDUFA date of June 28, 2025. This is the statutory date for the FDA to answer the application with Market Approval or a denial known as a Complete Response Letter (CRL).

Get the Full Report

Noble Capital Markets Research Report Wednesday, November 13, 2024

Companies contained in today’s report:

Aurania Resources (AUIAF)/OUTPERFORM – Black Sands Beach Project in Corsica is Taking Shape
Direct Digital Holdings (DRCT)/MARKET PERFORM – Building Back Better
FreightCar America (RAIL)/OUTPERFORM – Stock Price Decline May Offer an Attractive Entry Point for Investors
GeoVax Labs (GOVX)/OUTPERFORM – 3Q24 Reported With Continued Flow Of Good News
Ocugen (OCGN)/OUTPERFORM – Ocugen Clinical Showcase Highlights Fundamentals, Clinical Data, and Patient Stories
SKYX Platforms (SKYX)/OUTPERFORM – Seeding Future Revenue Growth
V2X (VVX)/OUTPERFORM – AIP Selling More Shares

Aurania Resources (AUIAF/$0.37 | Price Target: $0.65)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Black Sands Beach Project in Corsica is Taking Shape
Rating: OUTPERFORM

New assay results. Aurania received preliminary results from studies conducted by SGS Laboratories on a sample of magnetic sand taken from Nonza Beach, Corsica. The nickel-bearing mineral in the black magnetic sand is indeed awaruite, a natural nickel-iron alloy. SGS was able to isolate a nearly pure awaruite concentrate from the magnetic sand using a combination of grinding and flotation. New assays of awaruite flotation concentrate yielded 71.4% nickel, 0.98% cobalt, 0.65% copper, 0.58 grams of gold per tonne, 0.09 grams of platinum per tonne, and 0.39 grams of palladium per tonne. The flotation method recovered 83.8% of the nickel contained in the magnetic sand, which had a head grade of 6% nickel. Studies of identical sands at nearby Albo Beach are underway.

Extraction and processing. Aurania hired IHC Mining Advisory Services (IMAS) to identify the best means to extract and recover the black beach sands at Albo-Nonza. IHC proposed two different scenarios focused on the extraction of heavy minerals containing nickel and iron. The preferred scenario uses a floating suction and cutter-head dredge on floating pontoons. IMAS estimated the capital cost of the cutter suction dredger scenario to be €13 million, including €7.8 million for the dredging equipment and €5.2 million for a processing plant.

Get the Full Report

Direct Digital Holdings (DRCT/$2.64)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Building Back Better
Rating: MARKET PERFORM

Weak Q3 Results, likely the trough. Q3 revenues declined 85% to $9.1 million, with a decline in both its Buy-side and Sell-side businesses, down 12% and 96%, respectively. Adj. EBITDA was a negative $2.8 million. Management blamed the weak fundamentals on a business disruption caused by a “false and disproven” blog post by Adalytics, which it sued for defamation. Notably, the Q3 results puts the company back on track on its financial reporting under its new auditor BDO. 

Guidance anticipates a strong revenue rebuild. Management anticipates rebound in revenues as one of its largest clients rebuilds volume. We expect strong sequential Q4 revenue to $14.5 million, up from $9.1 million in Q3. Full year 2024 revenue is expected to be $67.7 million, with full year 2024 adj. EBITDA loss of $8.6 million. Management anticipates strong full year 2025 revenue growth to a range of $90 million to $110 million. 

Get the Full Report

FreightCar America (RAIL/$10.17 | Price Target: $14.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Stock Price Decline May Offer an Attractive Entry Point for Investors
Rating: OUTPERFORM

Third quarter financial results. FreightCar America generated third quarter adjusted net income to common stockholders of $2.455 million or $0.08 per share compared to $3.953 million or $0.13 per share during the prior year period. We had anticipated adjusted net income to common stockholders of $2.465 million or $0.07 per share. Average shares outstanding of 31.4 million were lower than our estimate of 34.5 million. Revenue and rail car deliveries increased to $113.3 million and 961, respectively, compared to $61.9 million and 503 during the third quarter of 2023. On a year-over-year basis, adjusted EBITDA increased to $10.9 million compared to $3.5 million during the prior year period and our estimate of $9.8 million. Free cash flow amounted to $5.7 million.

Full year 2024 corporate guidance. While guidance for revenue and rail car deliveries is unchanged, management narrowed its guidance range for EBITDA to $37.0 million to $39.0 million compared to previous expectations of $35.0 million to $39.0 million.

Get the Full Report

GeoVax Labs (GOVX/$3.25 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
3Q24 Reported With Continued Flow Of Good News
Rating: OUTPERFORM

3Q24 Report Reviews Progress During The Quarter. GeoVax reported a loss of $5.8 million or $(0.91) per share. The quarter included first revenues from its BARDA contract for the Project NextGen Phase 2b trial testing CM04S1 as a preventive vaccine for COVID-19. The company gave updates and data timeframes for clinical trials with CM04S1, MVA, and Gedeptin. During the quarter, it raised $13.5 million and ended with a cash balance of $8.6 million on September 30, 2024.

Gedeptin Trial Design Announced. GeoVax announced that the Phase 2 trial in head and neck squamous cell carcinoma (HNSCC) will test Gedeptin in combination with an immune checkpoint inhibitor (ICI) in recurrent patients before surgery. A single-cycle of Gedeptin will be given with a standard dose of Keytruda (pembrolizumab), followed by a second cycle of Keytruda alone, then surgery. Endpoints will include standard measures of response, tumor shrinkage, and survival that would make the data comparable to other treatments. The trial is expected to begin in 1H25.

Get the Full Report

Ocugen (OCGN/$1.02 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Ocugen Clinical Showcase Highlights Fundamentals, Clinical Data, and Patient Stories
Rating: OUTPERFORM

Ocugen Held A Meeting With Scientists, Doctors, and Patients. On November 12, Ocugen held a Clinical Showcase meeting to present the scientific basis of its Gene Modifier technology, interim data updates from its clinical trials, and allow patients to discuss their experiences with the treatments.

First OCU410 Data Shows Efficacy. The Phase 2 ArMaDa trial is testing OCU410 in Geographic Atrophy (GA), a lesion in patients with dry age-related macular degeneration that leads to blindness. The presentations included its four mechanisms of action and the clinical outcomes from the initial patient cohorts in the dose-escalation stage of the trial. These data at 6 months compare favorably to approved complement inhibitors for GA.

Get the Full Report

SKYX Platforms (SKYX/$1.26 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Seeding Future Revenue Growth
Rating: OUTPERFORM

Q3 results. The company reported Q3 revenue of $22.2 million and an adj. EBITDA loss of $2.6 million. While the revenue was slightly below our estimate of $24.1 million, the adj. EBITDA loss was milder than our estimate of $3.4 million.

Gaining traction with Home Depot. Since announcing the partnership in July, the company’s presence in Home Depot locations has expanded to 100 stores. Additionally, SKYX products are available on Home Depot’s website. We anticipate more SKUs to become available both online and in stores soon, as a wide variety of SKYX products are expected to arrive from the company’s manufacturing partner, Ruee Appliances.  

Get the Full Report

V2X (VVX/$67.69 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
AIP Selling More Shares
Rating: OUTPERFORM

Round 2. American Industrial Partners (AIP) is selling another trance of VVX shares, this time 2.5 million shares with up to an additional 375,000 shares to be sold. As we noted in AIP September’s stock sale, we had expected AIP eventually to begin to sell off its stake, so we are not surprised with this additional sale. V2X will not receive any proceeds from the sale. The additional float is a positive for investors, in our view.

Ownership. Upon the completion of this offering, investment funds affiliated with AIP will beneficially own approximately 44.9% of V2X’s outstanding common stock, or 14,167,286 shares (or approximately 43.7% if the underwriters exercise their option to purchase additional shares in full).

Get the Full Report

Noble Capital Markets Research Report Monday, November 11, 2024

Companies contained in today’s report:

Bowlero (BOWL)/OUTPERFORM – Developing More Legs To Its Growth Story
Graham Corp (GHM)/OUTPERFORM – Strong 2Q25 Results; Raising PT to $45
Gray Television (GTN)/OUTPERFORM – An Uncharacteristic Miss
Information Services Group (III)/OUTPERFORM – Building Up for Growth in 2025
Kratos Defense & Security (KTOS)/OUTPERFORM – Reports 3Q24 Results; Raising PT to $30
Ocugen (OCGN)/OUTPERFORM – 2Q24 Reported As We Look Forward To Clinical Showcase Data
The GEO Group (GEO)/MARKET PERFORM – Moving to Market Perform as Shares Skyrocket
Zomedica Corp. (ZOM)/OUTPERFORM – Improving Pet Health and Veterinary Practices – Initiating Coverage With An Outperform Rating

Bowlero (BOWL/$11.5 | Price Target: $17.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Developing More Legs To Its Growth Story
Rating: OUTPERFORM

Solid start. The company reported fiscal Q1 results that were better than expectations. Notably, revenue increased 14.4% from the prior year period to $260.2 million, and adj. EBITDA of $62.9 million grew 20.7% from the prior year period. The favorable results were driven by strategic initiatives in the Food & Beverage segment and the inclusion of Raging Waves operating results in the quarter. Furthermore, we believe the results are indicative of positive operating momentum, which could see enhanced growth prospects from M&A activity. 

Food & Beverage leads. The company’s Food & Beverage segment revenue increased by 17.5% from the prior year period and catalyzed the strong quarter. Notably, management highlighted that the increase in Food & Beverage revenue was due to its strategic efforts, not price increases. Furthermore, there appears to be room for growth through enhanced menu options.

Get the Full Report

Graham Corp (GHM/$39.07 | Price Target: $45)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Strong 2Q25 Results; Raising PT to $45
Rating: OUTPERFORM

2Q25 Results. Graham’s 2Q25 results exceeded expectations. The Company reported strong sales growth in its markets, along with exceptional execution throughout the business, which drove meaningful margin expansion. The balance sheet remained stellar with $32.3 million of cash and no debt. Graham raised full year gross margin and adjusted EBITDA estimates. GHM shares reacted favorably to the news, rising 17% to $39.07.

Financials. Record quarterly revenue of $53.6 million, up 19% y-o-y. Defense revenue was up 23%, Chemical/Petro sales were up 23%, and Space revenue was up 23%. Gross margin improved 790 basis points to 23.9%, fueled by sales growth and execution. Adjusted EBITDA rose 150% to $5.6 million. Adjusted net income up 353% to $3.4 million, or $0.31

Get the Full Report

Gray Television (GTN/$4.28 | Price Target: $20)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
An Uncharacteristic Miss
Rating: OUTPERFORM

Misses Q3 expectations. Q3 revenue of $950.0 million was below our $1.02 billion estimate, with the largest variance due to lower than expected Political advertising and weaker core advertising. Political was $173.0 million versus our $200.0 million estimate. Q3 adj. EBITDA of $322.0 million was lower than our $396.0 million estimate. Figure #1 Q3 Results illustrate our estimates versus reported results. 

Disappointing Political outlook. Management indicated that Q4 Political advertising will be in the range of $248 million to $253 million and in the range of $495 million to $500 million for the full year 2024, well below our $380 million and $652 million estimate, respectively. The shortfall appears to be due to a shift in spending for Senate and House races into more competitive markets which were outside of Gray’s footprint. 

Get the Full Report

Information Services Group (III/$3.35 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Building Up for Growth in 2025
Rating: OUTPERFORM

More Profitable. Topline performance at $61.3 million was lower sequentially, however, it was above management’s guidance of $60-$61 million and higher than our estimate of $61 million. Importantly, the quarter resulted in a record high utilization of 77%, leading towards a higher gross margin of 40.4% from 39.5% last quarter. The higher gross margin flowed through to higher adjusted EBITDA margin of 11.6% from 11.1% in the prior quarter.

Potential Growth in 2025. Management noted that the ISG Tango platform is continuing to see growth in its contract value, now at $5 billion compared to $4 billion last quarter, a 25% increase. Notably, the increase is an example of signs of increased demand in the U.S. and we believe the market will improve as the election uncertainty has passed and the macroeconomy continues to improve.

Get the Full Report

Kratos Defense & Security (KTOS/$25.97 | Price Target: $30)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Reports 3Q24 Results; Raising PT to $30
Rating: OUTPERFORM

Environment. The ongoing generational recapitalization of strategic weapon systems, including strategic satellites, air defense radar, and missile systems, continues to be a catalyst for Kratos. Current world events are driving demand for Kratos products, including target drones, which are used to exercise and test air defense systems.

Strong Engine. Kratos’ turbine technologies and engine business is generating record results, including having a record opportunity pipeline with hypersonic supersonic cruise missiles, loitering munitions drones, and space systems, all being expected future growth areas.  

Get the Full Report

Ocugen (OCGN/$0.9862 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
2Q24 Reported As We Look Forward To Clinical Showcase Data
Rating: OUTPERFORM

Clinical Trials Continued, Capital Was Raised, and New Data Expected. Ocugen reported a loss for 3Q24 of $13.0 million or $(0.05) per share. The company reported continued enrollment in all of its ongoing clinical trials and has scheduled a Clinical Showcase meeting in New York on Tuesday, November 12, 2024. We expect the meeting presentations to include data updates from the clinical trials. In August, Ocugen completed a stock offering that raised $35 million to end 3Q24 with $38.7 million in cash. After the quarter ended, the company added $30 million in debt funding. 

OCU400 in Retinitis Pigmentosa (RP) Is On Schedule. The company confirmed that the Phase 3 liMeliGhT (pronounced “Limelight”) trial continues to enroll patients and is on schedule to complete enrollment in 1H25. An approval by Health Canada will allow patient enrollment at up to 5 Canadian sites. The FDA has approved an expanded access program (EAP) to allow patients  to be treated outside of the clinical trials before OCU400 receives market approval.

Get the Full Report

The GEO Group (GEO/$25.36)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Moving to Market Perform as Shares Skyrocket
Rating: MARKET PERFORM

Below Expectations. The GEO Group reported third quarter 2024 results below management’s and our expectations. Results in the quarter were driven by lower-than-expected revenues in the Electronic Monitoring and Supervision Services segment, reflecting reduced participant count. ICE populations have remained relatively flat over the past three quarters, although they are up y-o-y.

3Q24. GEO reported total revenues for the third quarter 2024 of $603.1 million compared to $602.8 million last year. We forecasted $612 million. Adjusted EBITDA was $118.6 million, flat with 3Q23. We were at $128 million. Net income for 3Q24 totaled $26.3 million, or $0.19 per diluted share, compared to $24.5 million, or $0.16 per diluted share, for 3Q23. Adjusted EPS was $0.21 per diluted share compared to $0.19 per diluted share for 3Q23. We had projected $0.25 and $0.26, respectively.

Get the Full Report

Zomedica Corp. (ZOM/$0.12 | Price Target: $0.25)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Improving Pet Health and Veterinary Practices – Initiating Coverage With An Outperform Rating
Rating: OUTPERFORM

Initiating Coverage of Zomedica Corp. With An Outperform Rating. We are initiating coverage of Zomedica, a company that makes and sells veterinary therapeutic devices and diagnostics. These products are used to diagnose and treat animals ranging from horses to cats, dogs, and other pets. Veterinarians use these products to improve the outcome and quality of care for the pet as well as to streamline workflow and profitability of their practice.

Zomedica Has Made Several Acquisitions To Build Its Product Lines Zomedica has grown by acquiring complementary businesses that broaden its product line and leverage its existing infrastructure. It has five product lines in therapeutic devices and diagnostics, two fast-growing segments of the animal health market. These products are marketed by its own sales force and commercial partnerships. We expect near-term growth to come from the introduction of new internally-developed applications that increase uses and grow sales of existing products.

Get the Full Report

Noble Capital Markets Research Report Friday, November 8, 2024

Companies contained in today’s report:

Cadrenal Therapeutics (CVKD)/OUTPERFORM – Cadrenal Reports 3Q24 With Tecarfarin Progress Updates
CoreCivic, Inc. (CXW)/MARKET PERFORM – Another Solid Quarter
GoHealth, Inc. (GOCO)/OUTPERFORM – The Pieces are in Place; Poised for a Strong AEP
Information Services Group (III)/OUTPERFORM – A Look into the Third Quarter
Kelly Services (KELYA)/OUTPERFORM – Reports 3Q24 Results
Kratos Defense & Security (KTOS)/OUTPERFORM – First Look at 3Q24 Results
Lifeway Foods (LWAY)/MARKET PERFORM – In Danone’s Corner
Saga Communications (SGA)/OUTPERFORM – Resilient Amidst Economic Headwinds
Schwazze (SHWZ)/OUTPERFORM – Reports Preliminary 3Q24 Results
Townsquare Media (TSQ)/OUTPERFORM – Digital Revenue Gains Momentum

Cadrenal Therapeutics (CVKD/$16.29 | Price Target: $45)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Cadrenal Reports 3Q24 With Tecarfarin Progress Updates
Rating: OUTPERFORM

Financial Condition Improved In 3Q24. Cadrenal reported a loss of $2.4 million or $(2.18) per share, adjusted for the 1-for-15 reverse split on August 20, 2024. This loss was slightly less than our projections. Cash on September 30 was $4.4 million, excluding financing that brought in $9.8 million after the close of the quarter. The company reported that its current cash balance was approximately $11.3 million on November 7, 2024.

The Tecarfarin Made Progress In Its Next Indication. Cadrenal held a Type-B meeting with the FDA to discuss the planned Phase 3 trial for use of tecarfarin in patients with left ventricular assist devices. The company will use the guidance and comments from the meeting to design the pivotal trial. Cadrenal also continued to discuss collaborating with Abbott about a clinical trial with patients that have the Abbott HeartMate 3, the only LVAD available in the United States. Cadrenal has Orphan Drug designation for the LVAD indication, providing a strong incentive for collaborations.

Get the Full Report

CoreCivic, Inc. (CXW/$22.08)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Another Solid Quarter
Rating: MARKET PERFORM

3Q24 Results. CoreCivic’s financial results for the third quarter of 2024 demonstrated the Company’s continued strong operating momentum. Increased occupancy and higher per diems drove the increased revenue in the quarter. While ICE populations were relatively stable in the quarter, management did note populations have increased by 5% since the beginning of October. Operating margin increased compared with the prior-year quarter through continued cost management and strong demand for CXW’s services.

Opportunity. Obviously, with the coming change in the President, most industry observers expect to see a step change in the use of services provided by the industry. There also is significant opportunity at the state and local levels being driven by increasing jail populations, forecasts for prison population’s to rise over the next five years, ongoing staffing issues, and an aging physical stock.

Get the Full Report

GoHealth, Inc. (GOCO/$11.78 | Price Target: $22)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
The Pieces are in Place; Poised for a Strong AEP
Rating: OUTPERFORM

Q3 beat. The company reported Q3 revenue of $118.3 million and an adj. EBITDA loss of $12.1 million, better than our estimates of $104.0 million and a loss of $14.1 million, respectively. Notably, the company benefited from improved efficiency with declines in direct costs of policy submissions and strong agent productivity.

Prepared for AEP. In our view, the company is well positioned heading onto this year’s Annual Enrolment Period (AEP) with several technological enhancements that drive favorable customer experiences and agent productivity. Using AI based tools, such as Plan GPT, the company has reduced its average call time from 90 minutes to 67 minutes. We believe the company could make additional incremental efficiency enhancements in Q4 and beyond, which could lead to more volume and margin improvement.   

Get the Full Report

Information Services Group (III/$3.33 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
A Look into the Third Quarter
Rating: OUTPERFORM

Hitting the Top of Revised Guidance. ISG reported revenue and net income at the top end of the Company’s revised guidance and in-line with our estimates. Revenue for the quarter was $61.3 million, which while down 15% from last year, was slightly above our estimate of $61 million. Net income was $1.1 million, or EPS of $0.02, beating out our estimate of $0.2 million or flat EPS.

Rising Client Demand. Management noted that ISG Tango now includes over $5 billion of contract value, up from $4 billion in the previous earnings release. Management is seeing signs that client demand in the U.S. is on the rise, translating to higher spending. We believe that the rise in contract value offers a sign towards higher spending on projects.

Get the Full Report

Kelly Services (KELYA/$18.14 | Price Target: $27)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Reports 3Q24 Results
Rating: OUTPERFORM

Challenges. In the third quarter, Kelly remained focused on what it could control, but the uncertain economic environment persisted, impacting consolidated results. On an organic basis, revenue rose in two of the business units, while gross profit rate fell in three of the four units. Integration costs related to the MRP acquisition of $6.1 million also impacted results. Investors reacted negatively to the results, sending the shares down 18% to $18.14.

3Q24 Results. Revenue of $1.038 billion, down 7.1% y-o-y, but essentially flat on an organic basis. We were at $1.075 billion, the same as the consensus. Adjusted EBITDA of $26.2 million, up 2.7% y-o-y, but below our $34 million estimate and consensus $33 million. Net income of $0.8 million, or $0.02/sh and adjusted EPS of $0.21, compared to $0.18 and $0.50 in 3Q23. 

Get the Full Report

Kratos Defense & Security (KTOS/$23.82 | Price Target: $26)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
First Look at 3Q24 Results
Rating: OUTPERFORM

Solid Quarter. Kratos reported a solid quarter, with Unmanned Systems reporting 8.7% organic revenue growth. Turbine Technologies, Microwave Products, C5ISR, Defense  Rocket Support, and Training Solutions businesses also all reported organic revenue growth. This was offset by the previously reported and expected decline of approximately  $24.2 million in the Space and Satellite business, primarily resulting from the industry related impact from OEM delays.

3Q24 Results. Kratos reported revenue of $275.9 million, flat with the same period last year. We had estimated $280 million. Adjusted EBITDA was $24.6 million, compared to $27.7 million last year and our $21 million estimate. Reported net income was $3.2 million, or $0.02/sh, up from a $1.6 million loss, or a loss of $0.01/sh in 3Q23. Adjusted EPS was $0.11 compared to $0.12 last year. We were at $0.01 and $0.06, respectively.

Get the Full Report

Lifeway Foods (LWAY/$25)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
In Danone’s Corner
Rating: MARKET PERFORM

Support for Danone. In response to Lifeway’s rejection of the Danone offer to acquire the Company, yesterday, Edward and Ludmila Smolyansky released a statement stating, among other things, “we strongly support Danone’s offer, which represents a substantial premium over Lifeway’s recent share price and reflects their confidence in the growing U.S. kefir market…” They go on to say, “As we approach one of most significant and closely watched earnings releases in Lifeway’s history, we remain optimistic about the company’s potential and believe that Danone’s proposal presents a unique opportunity to enhance value for all shareholders.”

Ownership. According to their most recent amended 13D filing dated August 14th, Edward and Ludmila may be deemed to be the beneficial owners of an aggregate of 4,332,451 shares of common stock, representing approximately 29.3% of the outstanding shares of common stock. This includes 500,000 shares (3.3% of the outstanding) held in a trust of which Edward and Julie each own 50%. Danone owns 3,454,756 shares representing 23.4% of the outstanding. Together, Danone and the Smolyansky’s control over 50% of the outstanding, even if we split the 500,000 trust shares equally. 

Get the Full Report

Saga Communications (SGA/$13.9 | Price Target: $24)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Resilient Amidst Economic Headwinds
Rating: OUTPERFORM

Q3 results. The company reported Q3 revenue of $28.1 million and adj. EBITDA of $3.6 million, both of which were in line with our estimates of $28.7 million and $3.6 million, respectively. Notably, the company ended an unprofitable relationship with a digital services provider, which contributed to digital revenue growth slowing to 3.2% in Q3. While we anticipate this will make year-over-year digital revenue comparisons difficult in the short term, we believe the company’s digital segment offers a favorable growth outlook.

Q4 outlook. Management indicated that Q4 revenue is pacing down low to mid-single digits, highlighting a difficult advertising market that is feeling the effects of the high interest rate environment. Furthermore, operating expenses on a same station basis are guided to increase in the range of 3% – 5% over the prior year period. We anticipate this increase will largely be attributed to investments in the company’s digital growth initiatives.

Get the Full Report

Schwazze (SHWZ/$0.15 | Price Target: $4)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Reports Preliminary 3Q24 Results
Rating: OUTPERFORM

Preliminary 3Q24 Results. Last night, Schwazze reported preliminary 3Q24 results. We believe the ongoing audit of past results is likely causing a delay in reporting results. According to the release, 3Q24 revenue is expected to be approximately $42 million, and adjusted EBITDA is expected to be approximately $11 million. In 3Q23, Schwazze reported revenue of $46.7 million and adjusted EBITDA of $14.1 million. We had estimated revenue of $44.5 million and adjusted EBITDA of $10.3 million.

Making Progress. In spite of the challenging operating environment, Schwazze continued to generate momentum from its retail growth and optimization initiatives in the quarter, reflected by the Company once again outpacing two highly competitive markets while generating sequential improvements in profitability and positive cash flow from operations. Management noted increased store traffic in both Colorado and New Mexico.

Get the Full Report

Townsquare Media (TSQ/$10.15 | Price Target: $21)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Digital Revenue Gains Momentum
Rating: OUTPERFORM

In line quarter. Total company revenues of $115.3 million was roughly flat with the year earlier period and in line with our $115.0 million estimate. Q3 adj. EBITDA was $25.5 million versus our $26.5 million estimate. Notably, the results were in line with the company’s previous guidance. 

Digital revenue accelerates. Total digital revenue swung positive in the latest quarter, up 1.1%, the first time since q2 2023. The revenue improvement was led by its Ignite business (up 4.7%) and a significant moderation in the revenue decline at Townsquare Ignite (down 5.8%, much better than down 12.9% in Q2). Management indicated that Ignite’s Q4 revenue growth should triple to near 15% and Interactive should swing positive. 

Get the Full Report

Noble Capital Markets Research Report Thursday, November 7, 2024

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – Steady Production in October
Conduent Inc (CNDT)/OUTPERFORM – Q3 in Line: More Divestitures to Come?
CoreCivic, Inc. (CXW)/MARKET PERFORM – Solid 3Q24 Results – A First Look
Seanergy Maritime (SHIP)/OUTPERFORM – Third Quarter Financial Results Exceed Our Estimates
The ODP Corporation (ODP)/OUTPERFORM – Accelerating B2B Pivot

Bit Digital (BTBT/$4.1 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Steady Production in October
Rating: OUTPERFORM

AI Revenue In-line. As of October 31, Bit Digital had 256 servers actively generating revenue and earned approximately $4.3 million of unaudited revenue during the month, in-line with the prior month. With the recent agreement signed with Boosteroid, we expect an uptick in revenue in the coming months.

Mining Business. The Company produced 52.2 BTC in the month, a 1.4% increase from 51.5 BTC in September. The active hash rate was 2.43 EH/s, flat with the prior month. In our view, management is continuing to take an opportunistic approach to mining, with additional miner acquisitions based on appropriate returns on invested capital.

Get the Full Report

Conduent Inc (CNDT/$4.13 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Q3 in Line: More Divestitures to Come?
Rating: OUTPERFORM

Q3 in line. The company reported a solid Q3 with revenue that was largely in line with our estimate and adj. EBITDA that was better than expected. Revenue of $807 million compared with our estimate of $814 million and adj. EBITDA of $36 million compared with our estimate of $24 million, illustrated in Figure #1 Q3 Results.

Revenue trends should improve. Adj. revenue, which excludes divested business units, was down in each of the 3 segments and down roughly 8% overall. In the company’s largest segment, Commercial, adj. revenue was down 3%, due to lower volumes. Importantly though, new business signings helped to mitigate the weakness and new business momentum is expected to continue for the remainder of the year.

Get the Full Report

CoreCivic, Inc. (CXW/$17.58)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Solid 3Q24 Results – A First Look
Rating: MARKET PERFORM

Solid Results and a Favorable Reaction. CoreCivic reported above expected 3Q24 results, driven by higher compensated occupancy and continued cost management. Notably, the results were achieved even with the headwinds of CalCity and South Texas, which resulted in ICE revenue declining 3.4% y-o-y. Excluding the South Texas facility, ICE revenue rose 10.9% y-o-y. CXW shares reacted favorably to the election results, rising nearly 30% to close at $17.58 yesterday.

Third Quarter Detail. Total revenue was at $491.6 million (including $5.7 million of deferred revenue related to South Texas), above our forecast of $479.5 million and above last year’s $483.7 million. Occupancy rates increased to 75.2% from 72.0% in the prior year. Operating margin improved 130 basis points y-o-y, reflecting the increased top line and cost control. Adjusted EBITDA was $83.3 million, up from $75.2 million. Net income was $21.1 million, or $0.19 per diluted share, compared to $13.9 million or $0.12 last year. Adjusted EPS was $0.20 versus $0.14 last year. We estimated net income of $10 million or $0.09 per diluted share.

Get the Full Report

Seanergy Maritime (SHIP/$9.42 | Price Target: $12)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Third Quarter Financial Results Exceed Our Estimates
Rating: OUTPERFORM

Third quarter financial results. The company reported third quarter adjusted EBITDA and earnings per share (EPS) of $26.8 million and $0.69, respectively, exceeding our estimates of $25.5 million and $0.61. Revenue was $1.1 million above our estimate, while expenses were only modestly higher. The variance to our net revenue estimate is attributed to lower commissions and greater fees from related parties. Operating income was $17.7 million compared to our estimate of $17.0 million. 

Updating estimates. We are lowering our 2024 adjusted EBITDA and EPS estimates to $101.7 million and $2.52, respectively, from our previous estimates of $102.1 million and $2.56. Additionally, we are lowering our 2025 adjusted EBITDA and EPS estimates to $93.7 million and $1.93, respectively, from $102.0 million and $2.39. The revisions are mainly due to lower time charter equivalent (TCE) rates and more dry-docking days in 2025, resulting in lower operating days and net revenue than previously estimated.

Get the Full Report

The ODP Corporation (ODP/$27.57 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Accelerating B2B Pivot
Rating: OUTPERFORM

3Q24 Results. Weak macroeconomic and business conditions resulted in challenging performance in the quarter. Third quarter revenue of $1.78 billion declined 11% y-o-y. Adjusted operating income was $41 million, down from $112 million in 3Q23. Adjusted EBITDA fell to $62 million from $138 million. ODP reported adjusted net income from continuing operations of $24 million, or EPS of $0.71, versus $85 million, or EPS of $2.17, in the same period last time.

Accelerating the Pivot. Given the recent operating challenges, ODP is accelerating its B2B pivot. The Company is leveraging its differentiated core strengths to pivot towards higher growth B2B opportunities. Recent contract wins, including a 10-year $1.5 billion contract with a reseller organization and a new contract with one of the world’s largest social media-focused e-commerce companies, are reflective of these efforts.

Get the Full Report

Noble Capital Markets Research Report Wednesday, November 6, 2024

Companies contained in today’s report:

Commercial Vehicle Group (CVGI)/OUTPERFORM – Post 3Q Call Commentary
DLH Holdings (DLHC)/OUTPERFORM – New Contract Award
Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Strong Results Continue
Lifeway Foods (LWAY)/MARKET PERFORM – Rejects Danone; Implements Poison Pill

Commercial Vehicle Group (CVGI/$2.4 | Price Target: $8)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Post 3Q Call Commentary
Rating: OUTPERFORM

Cost Reduction Efforts. CVG has eliminated approximately 1,200 roles or roughly 15% of the organization’s workforce from continuing operations compared to the prior year through both restructuring and ongoing continuous improvement efforts. We believe these actions will create a lower cost, more efficient, and agile company positioned for future success.

Markets Remain Challenged. Both Class 8 truck sales and the Ag/Construction end markets remain soft. In 2025, current forecasts call for a relatively flat Ag/Construction market, while the Class 8 market will likely begin to turn up in the second half of the year.

Get the Full Report

DLH Holdings (DLHC/$8.69 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
New Contract Award
Rating: OUTPERFORM

New Award. DLH has been awarded a contract to support the Naval Information Warfare Center Atlantic’s (“NIWC Atlantic”) Tactical Networks. NIWC Atlantic conducts research, development, and engineering to bolster integrated information warfare capabilities, with an emphasis on Enterprise IT systems.

Details. The award has a total value of approximately $76 million, comprised of $61 million in initial firm value and $15 million in optional services. The contract term includes up to a five-year period of performance. As the prime contractor, DLH will perform In-Service Engineering Agent and Integrated Logistics Support services. DLH’s work will support the missions of several C5ISR program offices and systems including PEO-C4I, PMW-160, NAVWAR, NAVSEA, and others.

Get the Full Report

Great Lakes Dredge & Dock (GLDD/$11.61 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Strong Results Continue
Rating: OUTPERFORM

Strong Results. Revenue for the quarter was up $74 million from last year to $191.2 million, beating our estimate of $185 million. Continued strong results from the Company’s capital and coastal protection projects contributed to the growth. Gross margin improved from 7.7% to 19.0%. Net income totaled $8.9 million, or EPS of $0.13, from a net loss of $6.2 million or $0.09/sh last year. Adjusted EBITDA increased to $27 million from $5.3 million last year.

Net Income. We would note reported net income was negatively impacted by two events we, and we believe other analysts had not included in their estimates. First, the Company moved forward a dry docking into the third quarter to take advantage of the recent strong awards and second, the impact of incentive comp taken in the quarter. Together, these two items increased expenses by an estimated $5-$6 million in the quarter.

Get the Full Report

Lifeway Foods (LWAY/$24.84)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Rejects Danone; Implements Poison Pill
Rating: MARKET PERFORM

Rejects Danone. Yesterday, Lifeway Foods announced its Board of Directors rejected the unsolicited proposal made by Danone North America PBC to acquire all the shares of Lifeway that it does not already own for $25.00 per share. According to the Board, Danone’s proposal substantially undervalues Lifeway. Lifeway shares rose on the news, indicating investors may believe an improved offer may materialize.

Adopts Poison Pill. In addition, the Company adopted a Rights Plan that becomes exercisable if an entity, person, or group acquires beneficial ownership of 20% or more of the outstanding shares of Lifeway common stock in a transaction not approved by the Board or if an entity, person or group that currently beneficially owns 20% or more of the outstanding shares of Lifeway common stock acquires any additional shares. Unless earlier redeemed, terminated, or exchanged pursuant to the Rights Plan, the rights will expire on November 4, 2025.

Get the Full Report

Noble Capital Markets Research Report Tuesday, November 5, 2024

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – Agreement Signed with Boosteroid
Bowlero (BOWL)/OUTPERFORM – Keeping The Ball Rolling
Commercial Vehicle Group (CVGI)/OUTPERFORM – Reports 3Q24 Results
E.W. Scripps (SSP)/OUTPERFORM – Debt Overshadows Record Quarter
FAT Brands (FAT)/OUTPERFORM – Files Form 10-12b Registration Statement for Planned Listing of Twin Hospitality Group
MAIA Biotechnology (MAIA)/OUTPERFORM – SITC Late Breaking Presentation To Update Phase 2 THIO Data
SelectQuote (SLQT)/OUTPERFORM – Tailwinds Appear Underway
V2X (VVX)/OUTPERFORM – Record Quarterly Results

Bit Digital (BTBT/$3.37 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Agreement Signed with Boosteroid
Rating: OUTPERFORM

MSA Signed. Yesterday, Bit Digital announced that the Company executed its Master Service Agreement (MSA) with Boosteroid Inc. This follows the previously signed binding term sheet with Boosteroid in August 2024. Importantly, the MSA is a five-year term and the Company has placed an initial purchase order of 300 GPUs for its servers.

Performance Impact. The purchase order translates to approximately $4.6 million over five years, or $0.9 million annualized. Management noted that the GPUs are expected to be delivered and begin earning revenue by the end of November. The GPUs will be installed in U.S. datacenters, with management noting there are another 600 GPUs in the pipeline for European datacenters. With the Enovum datacenter fully leased, the machines will go into third party locations, at least in the short-term.

Get the Full Report

Bowlero (BOWL/$10.38 | Price Target: $17.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Keeping The Ball Rolling
Rating: OUTPERFORM

Off to a good start. Fiscal Q1 end Sept. results were better than expectations. Revenues were $260.2 million versus our $240.0 million estimate. Adj. EBITDA was $62.9 million versus our $59.0 million estimate. The key revenue upside driver was a solid performance in Food & Beverage, up a strong 17.3% y-o-y and beating our estimate by a solid 10.7%. Figure #1 Q1 Results highlight the quarter versus our estimates. 

Raises low end of fiscal 2025 guidance. Management increased its total revenue guidance for fiscal 2025 by $10 million on the low end of its previous guidance range of $1.22 billion to $1.28 billion, now $1.23 billion to $1.28 billion. The guidance implies attractive mid-single digit to 10% plus year over year revenue growth. Adj. EBITDA margins are expected to be 32% to 34%, or adj. EBITDA between $390 million to $430 million. 

Get the Full Report

Commercial Vehicle Group (CVGI/$3.08 | Price Target: $8)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Reports 3Q24 Results
Rating: OUTPERFORM

Another Challenging Quarter. Third quarter revenue decreased 15.3% to $171.8 million from $202.9 million in the prior year. Operating loss was $1.1 million and adjusted operating loss was $0.4 million, down from operating and adjusted operating income of $8.9 million last year. Net loss was $0.9 million, or $0.03/sh, and adjusted net loss totaled $0.4 million, or $0.01/sh, compared to net income of $4.7 million, or $0.14/sh. Adjusted EBITDA was $4.3 million, down 64.8%. Note: results from the sold Cab Structures and Industrial Automation businesses have been reclassified to discontinued operations.

Soft Customer Demand. Continuing from the second quarter, the agricultural and construction end markets have had softer demand, impacting the Electrical Systems segment. The Vehicle Solutions and Aftermarket & Accessories segments also experienced decreased customer demand, alongside a lower margin business phase out and a reduced backlog, respectively. 

Get the Full Report

E.W. Scripps (SSP/$2.27 | Price Target: $10)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Debt Overshadows Record Quarter
Rating: OUTPERFORM

Solid Q3 results. The company reported revenue of $646.3 million and adj. EBITDA of $176.8 million, both of which were record highs. Notably, the quarter was driven by strong political revenue of $125.2 million, which exceeded expectations. Furthermore, the company was able to capitalize on the influx of high-margin political revenue and pay down $115 million of debt in the quarter.

Record political advertising. The company generated $125.2 million in political revenue for Q3, a record high, and increased its full year political revenue guidance from $270 million – $290 million to a minimum of $340 million. The company’s increased 2024 political revenue guidance reflects a roughly 30% increase over its highest political advertising year, 2020.

Get the Full Report

FAT Brands (FAT/$5.32 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Files Form 10-12b Registration Statement for Planned Listing of Twin Hospitality Group
Rating: OUTPERFORM

Form 10-12b. FAT Brands filed a Form 10-12b with the SEC. The Form 10-12b contains a preliminary information statement about the planned distribution to FAT Brands’ common shareholders of approximately 5% of the Class A Common Stock of Twin Hospitality Group and its planned listing on Nasdaq as an independent publicly traded company.

Unlocking Value. The filing of the Form 10 Registration Statement is an important milestone in unlocking value and growth opportunities for Twin Hospitality Group and the Twin Peaks brand, while continuing to generate long-term value for FAT Brands shareholders, in our view. The Company expects to complete the separation later this year.

Get the Full Report

MAIA Biotechnology (MAIA/$2.88 | Price Target: $14)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
SITC Late Breaking Presentation To Update Phase 2 THIO Data
Rating: OUTPERFORM

Interim Update From Phase 2 Trial Scheduled For SITC. MAIA is scheduled to present a data update from the ongoing THIO-001 trial at a Late-Breaker session of the STIC (Society For The Immunotherapy of Cancer) Annual meeting on Saturday, November 9. The presentation could include data on endpoints and measures of efficacy such as disease control rate, overall survival, and median survival with additional patients and longer treatment times.

Trial Treats Patients With THIO and A Checkpoint Inhibitor. The THIO-001 trial enrolled advanced non-small cell lung cancer (NSCLC) patients that had progressive disease and no longer responded after two or more standard-of-care therapy regimens. Patients were treated with the combination of 3-week cycles of THIO and the standard dose of cemiplimab (350 mg Libtayo, an anti-PD-1 checkpoint inhibitor from Regeneron). Patient enrollment was completed in February 2024.

Get the Full Report

SelectQuote (SLQT/$2.03 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Tailwinds Appear Underway
Rating: OUTPERFORM

Solid FY Q1 results. The company reported fiscal Q1 revenue growth of 26% to $292.3 million, better than our estimate of $275.1 million. Margins were also better than we anticipated; an adj. EBITDA loss of $1.7 million was significantly better than our estimate of a loss of $6.6 million.  

Agents performing well. The company has a high concentration of tenured agents, who performed well in the quarter. A combination of efficient marketing and strong close rates primarily led to the better-than-expected revenue and profitability. Importantly, we believe the demonstrated strength of the company’s tenured agent force and strong consumer engagement this Annual Enrollment Period (AEP) could result in an impressive upcoming fiscal Q2 for the Senior segment.

Get the Full Report

V2X (VVX/$61.91 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Record Quarterly Results
Rating: OUTPERFORM

A Record Quarter. Record revenue, net income, and adjusted EBITDA were driven by the Company’s alignment to well funded, critical missions. V2X’s full spectrum capabilities across the mission lifecycle continue to serve as a differentiator. We believe there remains additional opportunity for V2X through further optimization of the business, including enhancing the breadth and depth of the pipeline.

3Q24 Results. Revenue rose 8% to $1.08 billion, with continued double digit growth in the Indo-Pacific and Middle East areas. Reported operating income was $49.9 million and adjusted operating income totaled $76.9 million, versus $21.0 million and $59.5 million, respectively, last year. Adjusted EBITDA rose to $82.7 million from $64.7 million. V2X reported EPS was $0.47 and adjusted EPS was $1.29, compared to a loss of $0.21/sh and EPS of $0.73, respectively, in the third quarter last year.

Get the Full Report

Noble Capital Markets Research Report Monday, November 4, 2024

Companies contained in today’s report:

ACCO Brands (ACCO)/OUTPERFORM – 3Q Post Call Commentary
Aurania Resources (AUIAF)/OUTPERFORM – Setting Up for the 2025 Drilling Program
Century Lithium Corp. (CYDVF)/OUTPERFORM – Focus and Execution
Comtech Telecommunications (CMTL)/MARKET PERFORM – Releases Full Year Results; Removes “Interim” Tag From CEO
Cumulus Media (CMLS)/MARKET PERFORM – Revenue Visibility Still Murky

ACCO Brands (ACCO/$5.26 | Price Target: $12)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
3Q Post Call Commentary
Rating: OUTPERFORM

Green Shoots. In the third quarter, ACCO experienced growth across each of its segments. This was the second consecutive quarter of growth in computer accessories, which can be attributed to an improving demand environment as well as new product launches in gaming accessories. Growth was fueled by the successful rollout of new products as well as international expansion efforts.

Cash Flow. Following the historic pattern, ACCO generated significant cash flow in the quarter. CFFO in the quarter totaled $95.5 million, with CFFO for the nine month period totaling $96 million. On a year-to-date basis, CFFO is up $25 million. Free cash flow for the quarter totaled $89 million and is $87 million year-to-date. Free cash flow is up $26 million from the same period last year, reflecting improved working capital. Management continues to project full year free to be approximately $130 million.

Get the Full Report

Aurania Resources (AUIAF/$0.5 | Price Target: $0.65)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Setting Up for the 2025 Drilling Program
Rating: OUTPERFORM

Kuri-Yawi geophysical survey. Aurania commenced an induced polarization (IP) geophysical survey over its Kuri-Yawi gold target where the discovery of numerous sinters in 2018 revealed the area to be highly prospective for epithermal gold mineralization. Kuri-Yawi is the most advanced epithermal target at the company’s Lost Cities-Cutucu project in southeastern Ecuador and may represent the quickest path for a successful outcome based on work that has already been completed, along with easy access. In 2020 and 2021, nine scout holes were drilled that indicated a vector to mineralization toward the northeast which is the focus of the IP survey.

Preparing for the 2025 drilling program. The IP survey is designed to identify deep conductors that could correspond to gold mineralization, and to target drill holes for the planned program in 2025. The IP survey is expected to be completed by mid-December 2024, with results expected in early 2025 following a review and interpretation of the data.

Get the Full Report

Century Lithium Corp. (CYDVF/$0.38 | Price Target: $2.35)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Focus and Execution
Rating: OUTPERFORM

Lithium carbonate production at the pilot plant. Century Lithium has successfully produced battery-quality lithium carbonate at its Angel Island lithium project pilot plant and demonstrated it has an end-to-end process to produce lithium carbonate. The pilot plant utilizes the Company’s patent-pending process for chloride leaching combined with direct lithium extraction (DLE). Management is now focused on process optimization to reduce the project’s estimated capital and operating costs, along with advancing environmental studies, permitting, and project funding.

Progress on the environmental and permitting front. Century Lithium has completed a draft hydrological model and a draft Plan of Operations Additionally, Century has identified potential alternative locations for water supply closer to the project within its water rights permit to optimize resource usage.

Get the Full Report

Comtech Telecommunications (CMTL/$2.91)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Joshua Zoepfel jzoepfel@noblefcm.com |
Releases Full Year Results; Removes “Interim” Tag From CEO
Rating: MARKET PERFORM

4Q24 Results. Revenue totaled $126.2 million, down sequentially and down from $148.8 million in 4Q23. We were at $130 million. Gross margin fell to 21.5% from 32.6% a year ago and was below our 30.8% estimate. Adjusted EBITDA was $0.3 million versus $18.9 million in 4Q23. Driven by $64 million of impairment charges, Comtech reported a 4Q24 net loss of $100.6 million, or a loss of $3.48/sh versus a loss of $5.3 million, or $0.19/sh in 4Q23.

Going Concern Still. Although we were hopeful the “Going Concern” designation would go away following the refinancing, it remains. According to the 10-K, “the Company has suffered recurring losses and negative cash outflows from operations, and may be unable to maintain compliance with financial covenants required by its credit agreement that raise substantial doubt about its ability to continue as a going concern.”

Get the Full Report

Cumulus Media (CMLS/$0.94)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Joshua Zoepfel jzoepfel@noblefcm.com |
Revenue Visibility Still Murky
Rating: MARKET PERFORM

In-line Q3 results. The company reported revenue of $203.6 million and adj. EBITDA of $24.1 million, in-line with our estimates of $203.3 million and $24.8 million, respectively. Its digital businesses, now 20% of total revenues, was the highlight of the quarter, up 7.5% from the prior year. Political advertising was a little softer than expected, $4.4 million versus our $5.5 million estimate. 

National/Network remains lackluster. National advertising is over 50% of total company revenues and carries very high margins. A recovery in National/Network will be key toward improved company fundamentals. Management indicated that National advertisers appear to be hesitant to spend, possibly

Get the Full Report

Noble Financial Group and Channelchek are pleased to present the NobleCon20 VIP Giveaway. This contest was open exclusively to registered, verified Channelchek members.

Contest is now closed.  The winner will be announced on November 18, 2024. The winner was notified via email on November 15.

Learn more about NobleCon20 @ www.nobleconference.com